Skip to main content
Antibiotics logoLink to Antibiotics
. 2026 Apr 1;15(4):359. doi: 10.3390/antibiotics15040359

Carbapenem-Resistant Serratia marcescens: Genomic Plasticity, Virulence Architecture, and the Expanding Threat of Multidrug Resistance

Theodoros Karampatakis 1, Katerina Tsergouli 1, Payam Behzadi 2,*
Editor: Michael J McConnell
PMCID: PMC13113151  PMID: 42041322

Abstract

Serratia marcescens is a highly adaptable Gammaproteobacterium with broad ecological distribution and growing clinical importance. Advances in whole-genome sequencing (WGS) and pangenome analysis reveal extensive genomic plasticity, driven by mobile genetic elements (MGEs) such as plasmids, transposons, integrons, prophages, and extracellular vesicles, which collectively accelerate virulence and antimicrobial resistance (AMR) evolution. S. marcescens displays a dynamic accessory genome enriched in resistance and virulence determinants, supporting persistence in diverse environments, including hospital water systems. Clinically, S. marcescens is an emerging opportunistic pathogen associated with severe healthcare-associated infections, ICU outbreaks, and multidrug-resistant “superbug” phenotypes. Its resistome includes intrinsic AmpC β-lactamase, broad efflux systems, and chromosomal determinants conferring resistance to β-lactams, polymyxins, and multiple additional drug classes, while acquired ESBLs and carbapenemases urther limit therapeutic options. Integrating genomic, evolutionary, and clinical insights underscores the urgent need for improved surveillance, mechanistic understanding, and targeted interventions against carbapenem-resistant S. marcescens (CRSM).

Keywords: Serratia marcescens, pangenome, virulence factors, bacterial drug resistance, carbapenem resistance, horizontal gene transfer

1. Introduction

Serratia marcescens is a rod-shaped, ubiquitous Gram-negative bacterium known for producing the red pigment prodigiosin, which can resemble blood on starchy substrates [1,2,3,4,5,6]. This striking feature historically led to cultural and religious interpretations, such as the 1263 Mass in Bolsena, later explained by Bartholomeo Bizio as microbial in origin in the nineteenth century [3,4,5,6]. Although the term “miracle bacterium” is now obsolete, the pigmentation of S. marcescens remains a notable example of the intersection between microbiology and cultural perception [3,4,5,6].

1.1. Taxonomy

In accordance with the List of Prokaryotic names with Standing in Nomenclature (https://lpsn.dsmz.de/genus/serratia (accessed on 12 February 2026)), the genus Serratia comprises 24 validly published species, among which S. marcescens is a recognised member [7]. According to LPSN and NCBI/Taxonomy [https://www.ncbi.nlm.nih.gov/datasets/taxonomy/tree/ (accessed on 12 February 2026)], Serratia belongs to kingdom Pseudomonadati, phylum Pseudomonadota, class Gammaproteobacteria, order Enterobacterales, and family Yersiniaceae (https://www.ncbi.nlm.nih.gov/datasets/taxonomy/615/ (accessed on 12 February 2026) [8].

Since 2016, Enterobacterales has been reorganised into eight valid families—Budviciaceae, Enterobacteriaceae, Erwiniaceae, Gallaecimonadaceae, Hafniaceae, Morganellaceae, Pectobacteriaceae, and Yersiniaceae. Under this revised taxonomy, genera such as Serratia (Yersiniaceae), Edwardsiella and Hafnia (Hafniaceae), Morganella, Proteus, and Providencia (Morganellaceae), and Yersinia (Yersiniaceae) have been removed from the traditional Enterobacteriaceae family [8,9,10].

Enterobacterales are Gram-negative, rod-shaped, non-spore-forming facultative anaerobes whose evolutionary distinction is defined by five conserved insertion–deletion mutations in genes encoding L-arabinose isomerase, an EF-P-like protein (YeiP), a hypothetical protein, a peptide ABC transporter permease, and pyrophosphatase [8]. Hypothetical proteins are in silico predictions produced in dry labs using bioinformatic software tools but lack confirmation through wet lab experiments. Computational analyses, including Basic Local Alignment Search Tool [BLAST, https://blast.ncbi.nlm.nih.gov/Blast.cgi, v. 2.17.0 (accessed on 10 February 2026)] and structural modelling, help infer their potential functions and underscore their evolutionary and therapeutic importance. BLAST identifies regions of sequence similarity to support such predictions [11,12,13,14,15,16,17,18,19].

Notably, Serratia has also been traditionally placed within Enterobacteriaceae due to its phenotypic characteristics [2]. Although the genus comprises several species, research has largely focused on the type species S. marcescens because of its value as a model organism and its growing relevance in healthcare-associated infections (HAIs) [1,2].

S. marcescens has been central to studies on motility and secretion systems and is increasingly recognised as a clinically important opportunistic pathogen, marked by rising multidrug resistance and challenging nosocomial infection profiles [2,20,21,22].

1.2. Carbapenem-Resistant Serratia marcescens (CRSM)

S. marcescens is a highly adaptable bacterium capable of surviving in a wide range of environments, from natural habitats to healthcare settings [20,23]. Its remarkable stress tolerance enables colonisation of medical surfaces, facilitating healthcare-associated transmission. This opportunistic pathogen causes diverse infections, including arthritis, endocarditis, pneumonia, meningitis, osteomyelitis, and skin infections, urinary tract infections, keratitis, wound infections, peritonitis, sepsis and bacteremia, posing significant risks to immunologically vulnerable patients, particularly those in intensive care units (ICUs) [23,24,25,26,27,28,29,30,31]. S. marcescens contributes to ICU outbreaks and the spread of carbapenem-resistance, leading to the emergence of carbapenem-resistant S. marcescens (CRSM) [32]. As an ESCPM group member (including Enterobacter, Serratia, Citrobacter, Providencia, and Morganella), it harbours a chromosomal AmpC β-lactamase conferring intrinsic β-lactam resistance, which can be amplified during therapy [32,33,34]. The emergence of plasmid-mediated Extended Spectrum β-lactamases (ESBLs) and carbapenem resistance has further limited treatment options [32]. ESBLs, which have evolved from standard β-lactamases via mutation, are mostly classified as Ambler class A β-lactamases (e.g., CTX-M/TEM/SHV). Although they are derivatives, the ESBL phenotype can also be seen with some class D OXA variants. These enzymes are structurally characterised by a serine residue at their active site. Accordingly, they are referred to as serine-based β-lactamases (SBLs) [35,36,37].

Multidrug-resistant (MDR) S. marcescens and CRSM strains cause severe healthcare-associated infections, particularly in pediatric and ICU patients [32,34,38]. AMR is classified by its extent: MDR (strains are resistant to at least one drug in three or more antimicrobial categories); extensively drug-resistant (XDR) (strains retain susceptibility to only one or two categories); and pan drug-resistant (PDR) (strains are resistant to all available antimicrobial agents) [37,39,40,41,42,43,44]. The emergence of MDR bacteria, or “superbugs”, poses a critical global health threat [45,46,47]. Given the multifaceted significance of S. marcescens and CRSM, this study aims to investigate CRSM-specific mobilome, resistome, and virulome synthesis, high-risk genes and mobile genetic elements (MGEs).

2. Genomic Pool, Pangenome and Genomic Plasticity of Serratia marcescens

Advances in genomic sequencing have shifted bacterial classification from phenotypic criteria to genotype-based approaches [48]. High-throughput technologies and whole-genome sequencing (WGS) allow comprehensive characterisation of microbial genomes, while pangenome analysis provides a framework for interpreting genomic diversity [48]. A species’ pangenome generally consists of three components: the core (or persistent) genome shared by nearly all strains; the accessory (or adaptive/flexible/dispensable) genome present in many but not all strains and contributing to phylogroup-specific variation; and the rare (or unique/singleton/cloud) genome comprising genes found in only one or a few strains [40,43,44,48,49,50]. The core—or persistent—genome predominantly comprises housekeeping and metabolic genes, along with a small proportion of transposable elements (TEs) and genes of unknown function. In contrast, the adaptive genome includes a diverse set of genes with broad functional roles, as well as both characterised and uncharacterized mobile genetic elements (MGEs), or the mobilome, such as plasmids, integrons, transposons, and insertion sequences (ISs) [40,43,44,48,50,51]. The cloud genome is enriched in TEs (e.g., transposons, ISs, Integrons), which serve as vehicles for passenger or cargo or jumping genes. In this context, horizontal gene transfer (HGT) —through conjugation, transformation, transduction, and vesiduction—plays a central role in the movement of genomic elements (GEs) and genomic islands (GIs) [40,43,44,48,50,51]. Conjugation is a major leading power of plasmid-mediated ARG dissemination in some bacterial groups like Enterobacterales. Plasmids in Gram-negative bacteria fall into 27 well-established incompatibility groups, with IncA/C, F, H, L/M, and P widely distributed and commonly ARG-bearing [52,53]. Yet clinically important genes—including ESBLs, carbapenemases, 16S methyltransferases, and mcr—are not restricted to specific plasmid groups [52,53]. Moreover, the mobility of plasmids across microbial species creates a dynamic, moving target that significantly complicates the tracking and management of drug-resistant bacteria [53].

Natural transformation occurs in two stages: a type IV pilus captures environmental DNA (e-DNA), which binds surface proteins such as ComEA. One strand enters through ComEC while the other is degraded, and the resulting ssDNA, potentially resistant to restriction, integrates via RecA-mediated homologous recombination [53]. Godeux et al. [53,54] showed that Gram-negative bacteria, including A. baumannii, use transformation to transfer large GEs, such as AbaR4 carrying blaOXA-23 and AbaR1, which harbours multiple resistance genes, including aac(3), aph(3′), aad variants, cat, tetA, blaOXA-10, and blaPRE-1 [53,54].

Transduction transfers DNA between bacteria via bacteriophages, occurring as generalised or specialised. In addition to phage genes, ARGs—including blaTEM-1, armA, aac, aph, aad, mph, and tetA—and intrinsic resistance determinants like gyrA (S81L) can be mobilised, often along with up to 35 kb of adjacent genomic DNA [53,55,56,57,58]. Phages carrying ARGs, including blaTEM and blaCTX-M, are found in hospital effluents, wastewater, and rivers, and can transfer these genes to E. coli, demonstrating transduction’s environmental role in spreading AMR [53,59,60,61].

AMR can spread via the fourth HGT mechanism of vesiculation, where extracellular vesicles (EVs) transfer plasmids and resistance genes between bacteria, rapidly disseminating β-lactamase and carbapenemase genes (e.g., blaCTX-M, blaKPC, blaOXA, blaNDM) across species like ESBL-producing E. coli and carbapenem-resistant K. pneumoniae (CRKP) [43,44,58,62,63,64,65,66,67,68,69,70]. Antibiotic exposure further enhances EV-mediated transfer, accelerating AMR spread in clinical and environmental settings. EVs also carry proteins, lipids, nucleic acids, and pathogenic virulence factors, highlighting their broad role in bacterial adaptation and pathogenicity [43,44,62,63,64,65,66,67,68,69].

Previous studies have shown that members of the Tn3 family are highly effective transposons involved in the dissemination of AMR features, particularly carbapenemase genes and colistin resistance genes, among Enterobacteriaceae [51,71,72]. Genomic analyses of S. marcescens reveal well-defined phylogenetic lineages, many of which correlate with specific infection sources. These associations suggest niche-adapted evolutionary trajectories, further supported by the distinctive accessory genome profiles characterising each lineage [1,2,31,73,74].

According to the NCBI Genome database, 3864 genomes from various S. marcescens isolates are currently available (https://www.ncbi.nlm.nih.gov/datasets/genome/?taxon=615 (accessed on 12 February 2026)).

Among these, ASM3029173v1 is designated as the reference genome (RefSeq). This genome has a total size of 5.2 Mb and consists of two circular replicons: a plasmid (pELP1.10) measuring 129,237 bp and a chromosome measuring 5,031,539 bp. The assembly contains 4906 genes, including 4752 protein-coding genes and coding sequences (CDSs). The genomic GC content is 59.5%. This strain was isolated from soil in Telegraph Bay, Hong Kong [https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_030291735.1/ (accessed on 12 February 2026)].

Among Serratia species, genome sizes vary considerably [https://www.ncbi.nlm.nih.gov/datasets/genome/?taxon=613 (accessed on 12 February 2026)]. S. fonticola possesses the largest genome, approximately 6.0 Mb with a single chromosome and 5440 predicted genes [https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_001006005.1/ (accessed on 12 February 2026)], whereas S. microhaemolytica has the smallest genome at about 3.3 Mb, comprising 2889 genes [https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_004011885.1/ (accessed on 12 February 2026)].

Nuncio-García et al. [75] described the genome of S. marcescens CH31, isolated from Periplaneta americana (American cockroach) near a tertiary hospital in Mexico. The strain carries a single chromosome and one plasmid, totalling 5.63 Mb with a GC content of 58.96% [75]. These features exemplify the genus’s notable genomic plasticity, which underpins its pathogenicity potential and capacity for AMR gene dissemination [76,77,78].

A bacterial pangenome encompasses all genes within a species, though strain-to-strain diversity can be substantial. Some taxa exhibit highly fluid genomes enriched in accessory genes associated with traits such as virulence or AMR, whereas others retain a more conserved core genome. Evidence suggests that an ecological lifestyle is a major determinant of this variability [79]. Dewar et al. [79] further showed that host-associated bacteria, including pathogens, less-motile forms, intracellular species, and obligate symbionts, display significantly lower pangenome fluidity than free-living bacteria, a pattern driven by lifestyle rather than effective population size. Thus, Dewar et al. [79] demonstrated that bacterial lifestyle shapes both overall genome architecture and the inter-strain diversity that underlie pangenome structure. Serratia species are highly adaptable and occupy diverse environments, with aquatic habitats (both in nature and hospital water systems) being especially common [2,20,80]. While S. rubidaea and S. liquefaciens are occasionally associated with HAIs [78,81], many Serratia species are entomopathogenic, including S. proteamaculans and S. marcescens [25,82]. Notably, S. marcescens bridges ecological and clinical relevance and dominates available genomic datasets, including those from metagenomic studies of preterm infants and hospital environments [73]. Furthermore, S. ficaria participates in the fig wasp mutualism, highlighting the genus’s ecological breadth. Although it can be isolated from various clinical specimens, it rarely causes severe disease, and most infections remain mild [83,84,85,86].

As proposed by Ramdass and Rampersad [77], the metabolic plasticity of S. marcescens represents an adaptive evolutionary response to persistent environmental pressures.

Ono et al. [31] updated the S. marcescens complex by analysing more than 200 newly sequenced isolates, resolving 14 phylogenetic clades shaped by MGEs acquisition, e.g., plasmids, prophages and integrase genes. MDR strains were restricted to clades 1 and 2, dominated by hospital-associated isolates carrying diverse ARGs, including ESBL-encoding genes, carbapenemase genes, and fluoroquinolone resistance (FQR) mutations [31]. These findings reported by Ono et al. [31] re-evaluate the species’ evolutionary structure and pinpoint the clades of greatest clinical concern.

Sanchez-Perez et al. [87] showed that three pigmented S. marcescens isolates (HU1848, HU2225, HU2228), though phylogenetically aligned with environmental strains, carry multiple virulence factors and ARGs to chloramphenicol, fosfomycin, and tetracycline, yet remain susceptible to aminoglycosides and fluoroquinolones. Methyl gallate affected pigment production and motility, and the absence of N-Acyl Homoserine Lactone (AHL) biosynthetic genes contradicted the assumed quorum-sensing (QS) control of prodigiosin synthesis [87]. In Serratia spp., AHLs regulate diverse phenotypes, including virulence factors (e.g., production of enzymes, antibiotics, and prodigiosin), motility, pathogenicity, biosurfactant production, biofilm formation, and 2,3-butanediol fermentation [88,89,90]. Sanchez-Perez et al. [87] indicated that environmental lineages can persist in clinical settings and may contribute to HAIs.

Abreo and Altier [74] assessed genotype–source associations in S. marcescens by analysing 45 strains within a pangenome framework. Their 19,469-gene pangenome comprised 84% flexible or cloud genes and only 16% core genes, highlighting the species’ substantial accessory repertoire and well-documented ecological adaptability [74].

Robust methodologies and reliable pangenome analyses support a shift from traditional and classical Darwinian evolutionary perspectives to a Woeseian, a term denoting the model introduced by Carl Richard Woese, the HGT-driven model of microbial evolution, thereby improving diagnostic accuracy and treatment selection [48].

As noted above, the pronounced genomic fluidity and plasticity of Serratia spp., including S. marcescens, endow this species with a broad and dynamic repertoire of virulence determinants (virulome) and ARGs (resistome).

3. Virulence Factors and Strategies

S. marcescens is a major contributor to HAIs and is routinely identified among the most concerning hospital pathogens. Its pathogenic capacity stems from a diverse suite of virulence determinants, such as flagella, proteases, and hemolysins, along with an unusual ability to withstand medical solutions and disinfectants, facilitating persistent contamination and recurrent clinical outbreaks [91,92,93,94,95,96,97]. To persist in diverse environments and host tissues, S. marcescens deploys adhesion factors and multiple secretion systems that enable tissue invasion and immune evasion. The cooperative action of these mechanisms greatly amplifies its pathogenic potential. The virulome of S. marcescens (Figure 1) is composed of a wide range of pathogenic strategies including adhesion [adhesion-like curli-like fibers, type 1 fibers [98], capsule and outer membrane proteins (OMPs)], hemolysis (e.g., hemolysins and cytotoxins), extracellular enzymes (such as nucleases and DNases, proteases (including serralysin), lipases and phospholipases), prodigiosin pigment production, secretion systems, iron acquisition systems (such as siderophores, QS and regulation.

Figure 1.

Figure 1

Serratia marcescens and its virulome and resistome.

  • Curli-like fibers: Research on S. marcescens pili and fimbriae remains limited. Campos et al. [99] reported thin fibrillar surface structures, and Boldeanu et al. [20] proposed an adhesive role, though mechanisms were not defined. In contrast, curli fimbriae (amyloid fibres produced via a dedicated assembly pathway) are well characterised in Enterobacteriaceae (e.g., E. coli) and are known to mediate surface adhesion and promote robust biofilm formation [42,100]. Indeed, curli fibres are produced via a nucleation–precipitation pathway, which is classified as the Type VIII secretion system (T8SS) [101].

  • Type 1 fibers: Chaperone–Usher (CU) fimbriae, key adhesion and biofilm mediators in Enterobacteriaceae, are poorly characterised in S. marcescens [42,98,100,102,103,104,105,106,107,108]. Readily metabolised carbon sources activate cAMP–CRP-dependent catabolite repression, which suppresses Type 1 fimbrial expression in S. marcescens and Vibrio cholerae, thereby reducing biofilm formation. In contrast, the same regulatory system can enhance biofilm development in other species, including E. coli and P. aeruginosa [109,110]. Gonzalez-Montalvo et al. [98] identified 421 fimbrial usher proteins (FUPs) across 39 S. marcescens genomes, defining 20 CU operons, six forming the core fimbriome (Fgov, Fgfo, Fgft, Fpo, Fps, and Fso; detected among ≥94% of the S. marcescens strains). Three core operons (fgov, fpo, fps) are primarily expressed and act as major adhesins, with Fgov (former Fim) mediating yeast agglutination, human corneal epithelial (HCE) cell adhesion, and biofilm formation [98,111,112]. Core fimbriae provide general adhesion (known as housekeeping adhesins), while the strain-specific repertoire drives niche adaptation, phenotypic diversity, and genomic plasticity [74,77,79,98].

  • Capsule: Capsule production is a conserved virulence trait among Enterobacteriaceae, providing effective protection against host immune clearance. In S. marcescens, the capsule is composed of acidic polysaccharides, with its chemical composition varying across clinical isolates. Notably, capsule expression is considered essential for the establishment of bloodstream infections. Thus, the polysaccharide capsule is known as a virulence factor in S. marcescens [113,114,115,116,117].

Acidic polysaccharides constitute the S. marcescens capsule, although their composition varies among isolates [114]. A defining feature of S. marcescens is the absence of wzi from its capsule locus, though a distant homolog exists. As an outer membrane anchor, wzi differentiates cell-associated CPS loci from secreted exopolysaccharides like colanic acid [113,118,119]. Biochemical analyses further separate neutral O antigens from acidic CPS, the latter consistently containing glucuronic and galacturonic acids across K serotypes but absent from O-antigen structures [114,115,116]. Anderson et al. [114] identified the genes regulating CPS biosynthesis and export, showing that disruption of capsule formation diminishes bacterial survival in host environments and heightens serum susceptibility. Capsule locus (KL) analyses of bloodstream isolates further revealed notable genetic diversity, consistent with previous observations [76,120], and classical biochemical and serological studies have distinguished at least 14 CPS antigens [115,116,120]. More recently, Anderson et al. [73] demonstrated that KL variation drives functional differences in virulence: sialylated KL1 and KL2 capsules enhance resistance to macrophage uptake, and KL types differ in organ colonisation during bacteremia, highlighting capsule-type-dependent adaptation among circulating lineages [73].

  • Outer membrane (OM): The OM is central to Gram-negative biology, supporting adhesion, environmental sensing, host interaction, and cell-to-cell communication [69,100,121,122,123,124,125,126,127,128,129,130,131]. Its defining feature, however, is its permeability barrier, which excludes large or hydrophobic antibiotics and underlies the intrinsic drug resistance of Gram-negative pathogens, an obstacle that continues to impede antibiotic development and drive MDR [41,47,121,127,132,133,134,135].

Among these OMPs, porins facilitate passive uptake of hydrophilic molecules and are broadly classified as specific porins or non-specific porins according to substrate selectivity [136,137,138,139,140,141,142].

Choi and Lee [140] proposed a functional classification of porins into three categories. The first comprises specific uptake channels, such as LamB and YddB. The second includes non-specific porins that predominantly contribute to membrane stability, e.g., OmpA. The third category consists of non-specific porins, including OmpC and OmpF, which perform dual roles by facilitating transport while maintaining membrane integrity.

Hutsul and Worobec reported the identification of OmpC and OmpF orthologues in a clinical isolate of S. marcescens (UOC-51) in 1994. These proteins demonstrate approximately 70% sequence identity to their E. coli homologs [143,144].

Porin expression is orchestrated by a multifaceted regulatory network involving XylS/AraC-family transcription factors, extracytoplasmic function (ECF) sigma factors, and key two-component systems (EnvZ–OmpR, PhoB/PhoR, CpxAR, PhoPQ, PmrAB, Rcs) [139,144,145,146,147,148].

In S. marcescens, OmpF and OmpC expression is governed by the EnvZ–OmpR two-component system (TCS) and the micF small RNA [144,149].

PhoE PhoE, structurally similar to OmpC and OmpF, but differs functionally by exhibiting anion selectivity and a marked preference for phosphate-containing substrates [144,150,151]. Unlike OmpC and OmpF, PhoE is activated by the PhoB/PhoR system, but, like OmpF, it is post-transcriptionally repressed by micF sRNA [144,148,151]. Like OmpC, OmpF, and PhoE, S. marcescens LamB forms a homotrimer. However, its structural features are specialised for carbohydrate transport [144,152,153].

S. marcescens LamB, which is 78% identical to canonical maltoporin, acts as a broad sugar transporter. Its expression is controlled by the malEFG and malK-lamB-malM operons, coordinating LamB with ABC transporter-mediated maltodextrin uptake [144,153].

These pathways fine-tune outer-membrane permeability through direct regulation or hierarchical cascades. LPS alterations, envelope stress, and biofilm-associated physiological shifts further influence porin insertion, stability, and overall abundance [139,145,146,147]. Porins such as OmpC, OmpF, OmpN, LamB, and PhoE significantly influence antibiotic susceptibility and frequently act synergistically with enzymatic resistance, target-site alterations, and efflux systems [145,146,154,155].

In this regard, OmpA, OmpC, and OmpF collectively influence outer-membrane integrity and antibiotic permeability, but their roles differ. OmpA functions primarily as a structural anchor through its peptidoglycan-binding C-terminal domain [140,156,157,158,159,160,161,162,163,164,165,166,167,168]. OmpF serves mainly as a high-conductance β-lactam porin with minimal impact on membrane stability. In contrast, OmpC contributes to both β-lactam influx and envelope maintenance by interacting with MlaA in the Mla pathway to remove mislocalized phospholipids, thereby sustaining lipid asymmetry and outer-membrane stability [140,156,157,158,159,160,161,162,163,164,165,166,167,168]. OmpX is a conserved outer membrane protein (first described in S. marcescens by Guasch et al. in 1995) that enhances bacterial adhesion, virulence, and adaptability [144,169,170,171].

OmpW, a small Omp family protein, facilitates the transport of hydrophobic compounds, contributing to reduced antimicrobial efficacy [136,172,173]. OmpW mediates host attachment and elicits immune responses to intestinal pathogens. It is immunogenic in Salmonella-induced reactive arthritis, celiac disease, pediatric Crohn’s, and oral pathogen-associated inflammatory bowel disease, suggesting a role in mucosal inflammation [172,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191]. OmpW is highly conserved among facultative anaerobes, including major pathogens, suggesting roles in adaptation or virulence [192,193]. Phage LC53 exploits this conservation by using OmpW as its receptor across diverse hosts, and Mahler et al. [194] confirmed OmpW as essential for phage attachment.

  • Extracellular enzymes: S. marcescens employs a broad spectrum of exoenzymes [e.g., proteases, phospholipases, lipases, and nucleases (such as DNases)] to breach host barriers and establish infection. Pathogenic bacteria, including S. marcescens, secrete non-cytotoxic extracellular nucleases that play multifaceted roles in disease progression. These enzymes contribute to nutrient acquisition, facilitate immune evasion, modulate biofilm architecture, and enhance HGT [195]. Indeed, nucleases are multifunctional enzymes present across bacterial pathogens like S. marcescens, contributing to nutrient acquisition, DNA uptake, and biofilm remodelling. They also promote host invasion through tissue damage, degrade the DNA backbone of neutrophil extracellular traps (NETs) to evade immune clearance, and modulate host immune responses [196].

Proteases, particularly Serralysin (PrtS), are well-recognised for inducing cytotoxicity and inflammation in localised infections such as keratitis [197,198,199,200,201,202,203,204]. Importantly, González et al. [197] reported that isolates from wounds and respiratory sites produce markedly higher protease levels than bloodstream isolates, indicating that protease expression is modulated by the tissue microenvironment to enhance bacterial invasiveness.

The pore-forming hemolysin ShlA is critical to S. marcescens pathogenicity. By physically damaging host membranes, ShlA undermines vascular stability, triggers immune responses, and facilitates bacterial entry into tissues. This cascade results in severe localised infections, and the overproduction of ShlA is specifically linked to the emergence of a hypervirulent phenotype [197,198,199,200,201,202,203,204].

The shlA and shlB loci encode the hemolysin ShlA and its outer-membrane accessory protein ShlB, which together operate through type Vb secretion system (T5bSS) similar to that described in Yersinia pestis [201,205]. Indeed, ShlB functions dually as both the secretion system and the activator of the pore-forming toxin ShlA. In the absence of shlB, shlA accumulates in the periplasm in an inactive, non-hemolytic state, indicating that ShlB is essential for its maturation and functional activation [206].

A distinguishing feature of the Serratia system is its activation mechanism: ShlB requires phosphatidylethanolamine (PE) as a cofactor to activate ShlA through a defined conformational shift. ShlA mediates erythrocyte lysis via pore formation, yet at sub-lytic concentrations it induces apoptosis, vacuolization, and cytoskeletal alterations, contributing to tissue damage under physiological conditions [201,205].

Prodigiosin pigment production: Prodigiosin, the red secondary metabolite of S. marcescens, has shifted from being viewed as a metabolic byproduct to a molecule with notable ecological and biomedical relevance [207,208]. Although not required for virulence, it contributes to stress resilience, particularly by mitigating oxidative damage, and can act as a competitive factor in polymicrobial settings through its antimicrobial activity [209,210]. Beyond its ecological functions, prodigiosin exhibits broad bioactivity, including potent anticancer, antifungal, antimalarial, and larvicidal effects, along with pronounced immunomodulatory and immunosuppressive properties [208,211]. Prodigiosin, a red tripyrrole pigment produced by Serratia, Vibrio, and Streptomyces, is encoded in Serratia spp. by the pigA–pigN biosynthetic cluster [212,213]. Its expression is regulated by a complex network integrating quorum sensing (QS) and two-component systems (TCS), including the SmaI/SmaR and SpnI/SpnR QS circuits and the PigQ/PigW, PhoB/PhoR, RssB/RssA, and EepR/EepS TCS modules [212,213,214,215,216,217]. Additional transcriptional regulators act as activators (PigP, PigT, PigS, PigR, PigV) or repressors (PigX, HexS). Recent genetic studies, including Tn5 transposon mutagenesis, have further expanded this network, identifying rcsA, slyA, and rpoS as important contributors to pigment production, alongside the CpxA/CpxR and EnvZ/OmpR systems as additional positive regulators [212,216,218,219,220,221,222,223]. The results of previous studies show that, disruption of multiple cellular systems strongly impaired prodigiosin synthesis. Insertions in acrB and tolC, components of the AcrAB–TolC efflux pump, reduced pigment production, and mutations in the Tol-Pal genes tolR and pal similarly diminished output. Loss of Tai4, a structural element of the type VI secretion system, caused an even greater decline. Additional disruptions in central metabolic genes further highlight the strong linkage between core metabolism and prodigiosin biosynthesis [212].

Lin et al. [205] investigated the role of metalloendopeptidase pitrilysin, encoded by the ptrA gene, in S. marcescens. Their study demonstrated that the ptrA gene not only regulates prodigiosin biosynthesis by activating the pig gene cluster but also broadly controls motility (both types of swarming and swimming), biofilm formation, hemolytic activity, and stress tolerance, coordinating key metabolic and virulence traits.

  • Secretion systems (SSs): The Sec and Tat pathways are the primary conserved routes for protein export across the bacterial cytoplasmic membrane, operating via distinct mechanisms [224,225,226,227]. The Sec pathway transports unfolded proteins through the SecYEG translocase, often with accessory factors in Gram-positive bacteria, and is responsible for secreting many virulence factors [224,226]. In contrast, the Tat pathway exports folded, frequently cofactor-containing proteins via the TatA–TatB–TatC complex (with TatA/B fused in some Gram-positive species). In Gram-positive bacteria, substrates are released extracellularly, whereas in Gram-negative species they remain in the periplasm or are further exported via the type II secretion system (T2SS). The Tat pathway is critical for virulence in several pathogens, including phospholipase C–producing bacteria [227,228,229,230,231,232].

Bacteria use specialised nanomachines to secrete molecules critical for adhesion, virulence, and survival. In Gram-negative species, secretion systems span both membranes (T1SS, T2SS, T3SS, T4SS, T6SS) or only the outer membrane (T5SS, pili, curli). Transport occurs via one-step (cytoplasm to exterior) or two-step (via periplasm) mechanisms. Most systems export unfolded proteins, whereas T2SS, T6SS, and chaperone–usher pathways can secrete folded substrates [42,100,232,233,234,235,236].

  • Type I secretion system (T1SS) and RND pumps are tripartite, double-membrane systems. T1SS secrete key virulence and nutrient-acquisition factors, including toxins, adhesins, bacteriocins, and enzymes that support bacterial survival and pathogenicity, while RND pumps export small molecules, including antibiotics. Both use a one-step mechanism, with T1SS relying on an ABC transporter in the inner membrane [233,237,238,239,240,241,242]. Previous studies indicate that S. marcescens secretes the hemophore HasA through a T1SS-dependent pathway [224,243]. The Swr QS system in S. liquefaciens MG1/S. marcescens MG1 regulates both swarming motility and the Lip T1SS, which secretes lipases, metalloproteases, and S-layer proteins [244,245,246].

  • Type II secretion systems (T2SSs) in Gram-negative bacteria export folded proteins from the periplasm, receiving substrates delivered by Sec or Tat. They secrete diverse enzymes, e.g., proteases, phospholipases, and toxins, many linked to virulence, and their pseudopilus is evolutionarily related to type IV pili and competence systems [224,247,248,249,250]. The T2SS is widely distributed among Gammaproteobacteria and has been documented in at least 15 genera, including Serratia, Klebsiella, Yersinia, Acinetobacter, etc. [20,251].

  • Type III secretion (T3SS) systems are multi-component nanomachines that deliver effectors to host cells via a pilus-like structure and a translocon. T3S structural components are encoded in pathogenicity islands (PAIs) within chromosomal or plasmid gene clusters likely acquired through HGT [224,233,252,253,254]. The term also includes flagellar T3SSs, which mainly export structural proteins but can additionally secrete virulence factors. Many bacteria, including Serratia, possess multiple T3S systems, including flagellar and translocation-associated types, which function at distinct infection stages [20,224,233,252,253,254]. Translocation-associated systems, while mainly pathogenic, can also support symbiosis and feature appendages—pili in plant pathogens or needles in animal pathogens for protein delivery [224,233,252,255]. Thus, effector proteins are delivered into host cells via the T3SS [20].

  • Type IV secretion systems (T4SSs) are the only secretion systems that transfer both DNA and proteins, underpinning plasmid conjugation and contributing to pathogen–host interactions [224,233,256,257]. Widespread “minimised” T4SSs, streamlined derivatives of ancestral conjugative modules, occur across Gram-positive and select Gram-negative bacteria, often linked to MGEs and surface-associated virulence traits [256,257,258,259,260]. Tn916-like Integrative and conjugative elements (ICEs), including Tn6009 identified in Klebsiella, Pseudomonas, and Serratia encode a reduced VirB/VirD4 set yet retain broad host-range mobility. Despite structural variation, most Gram-negative T4SSs conserve a VirB/VirD4 core that mediates conjugation, DNA exchange, and effector translocation [256,257,259,260,261,262]. All in all, T4SS mediates HGT, driving the spread of resistance genes across bacterial populations. It also performs effector delivery and interbacterial antagonism. T4SS has key roles in bacterial pathogenesis and host–pathogen interactions [20,241,263,264].

  • Type V secretion systems [(Va–Ve); Va (classical Autotransporters (ATs); Vb (two-partner Secretion); Vc (trimeric AT Adhesins); Vd (a hybrid form of types Va and Vb systems); Ve (inverse ATs)] share a hallmark design in which a single polypeptide encodes both the β-barrel pore and its passenger [265,266,267,268]. This minimalist architecture underlies their self-contained export mechanism, giving rise to the term “autotransporters,” especially for Va, Vc, and Ve [265,266,267,268]. Type Vf represents a recently defined AT subclass restricted to Helicobacter pylori, with BapA as its prototypical member [257,268,269,270].

Type Va passengers exhibit considerable functional diversity, particularly in protease activity, and are grouped into three classes: non-serine protease ATs of Enterobacteriacea (SPATE) proteases, SPATE-like proteases, and canonical SPATEs [268,271,272]. Comparative studies highlight this breadth; S. marcescens encodes the non-SPATE proteases Ssph1/2 (T5aSS) and the ShlA/ShlB cyto-/hemolysin (T5bSS) [267,268,273,274,275,276]; while in S. liquefaciens, the lipolytic autotransporter EstA (T5aSS) supports cellular signalling by generating lipids required for second-messenger synthesis [268,277].

  • Type VI secretion system (T6SS) is a widespread contractile apparatus in Gram-negative bacteria that underpins interbacterial antagonism, host interactions, and environmental adaptation [278,279]. In Serratia, it is key to competitive fitness. Jiang et al. further demonstrated that its broad protein diversity and frequent HGT confer strong evolutionary adaptability [278,279]. Beyond their standard roles, T3SS and T6SS broadly modulate microbial ecology: T3SS can influence microbiota composition, whereas T6SS mediates antifungal activity, metal scavenging, and DNase-dependent interactions in biofilms [280,281,282,283,284,285].

Cummins et al. [286] report that Serratia genomes contain three conserved “hotspots” that act as multifunctional defence islands, integrating anti-phage systems, antibacterial elements, and virulence factors. Their analysis revealed four distinct anti-phage strategies, including a newly described TIR-domain system and two loci that repurpose T6SS-associated proteins for defensive roles, underscoring the organism’s modular genomic architecture [286].

  • The Type VII secretion system (T7SS), first characterised in Bacillus spp., has since been identified in several Pseudomonas strains. Unlike typical Gram-negative systems, T7SS (T7SSa/b) in Actinobacteria and Firmicutes mediates virulence, modulates membrane permeability, nutrient (e.g., iron) acquisition, competition, development and niche colonisation [287,288,289,290].

  • Type VIII secretion system (T8SS) is known as a Gram-negative bacterial two-step transporter [241]. As aforementioned in the curli-like fibres section, constitution, assembling, and secretion of curli fibres occur via a nucleation–precipitation pathway, recognised as T8SS [42,100,101,108,291,292,293]. As curli-like fibres have been detected in Serratia species like S. marcescens [20], it seems that T8SSs are detectable in their bacterial cell [101]. In other words, curli biogenesis, classified as the T8SS, is governed by two divergently transcribed operons, csgBAC and csgDEFG [101].

  • Type IX secretion system (T9SS) is unique to Bacteroidetes. T9SS exports virulence factors, degradative enzymes, and motility adhesins—supporting pathogenesis in Porphyromonas gingivalis and gliding in Flavobacterium johnsoniae. Recent structural studies have clarified its translocon and motor machinery [294,295,296].

  • The Type X secretion system (T10SS), originally identified in Gram-negative bacteria, is homologous to phage lysis cassettes and consists of a minimal holin–hydrolase module that mediates controlled protein release [297,298,299,300]. In S. marcescens DB10, it enables chitinase export through a pathway distinct from the T2SS. T10SS function requires coordinated holin–hydrolase activity and proceeds through at least two stages, with a possible third step yet to be defined [297,298,299,300].

  • The Type XI secretion system (T11SS) is a conserved proteobacterial pathway (e.g., E. coli, A. baumannii), which functions as a transport channel that moves soluble proteins and lipoproteins across the outer membrane via a dedicated protein complex [301,302,303,304]. The specific molecules it exports are determined by the system’s genetic makeup; known effectors include proteins that interact with transferrin, lactoferrin, factor H, and heme [301,302,303,304].

  • Iron acquisition systems: For pathogenicity and survival, bacteria require iron acquisition. S. marcescens utilises two distinct mechanisms to retrieve iron from heme: the Hem system, which directly extracts the metal, and the Has system, which relies on a hemophore protein to aid in the extraction and transport processes [117,305,306,307].

S. marcescens employs two coordinated heme-acquisition pathways adapted to iron limitation. At relatively high heme levels (≥10−6 M), uptake is mediated by the TonB-dependent Hem system. Under stringent iron deprivation, the Has pathway is induced, using a secreted haemophore and the dedicated HasR receptor, which operates exclusively with HasB. Together, these systems enable efficient haem scavenging across a wide range of environmental conditions [307].

Pathogens such as S. marcescens and P. aeruginosa utilize the ATP-independent HasA hemophore system for heme uptake, involving the HasA hemophore, the HasR outer-membrane receptor, and the TonB-like protein HasB [308,309,310,311,312,313,314,315,316]. Unlike TonB, HasB is dedicated exclusively to HasR, reflecting the high receptor specificity of this system and its adaptation for efficient heme scavenging in Gram-negative bacteria [308,309,310,311,312,313,314,315,316]. In S. marcescens, iron uptake is driven by the ExbB–ExbD–TonB complex. ExbB interacts with HasB via its periplasmic extension, while membrane residues coordinate interactions with both TonB and HasB, collectively supporting inner-membrane iron acquisition [317].

Genomic studies confirm that S. marcescens and S. plymuthica produce two iron-chelating siderophores: serratiochelin (a hybrid compound composed of enterobactin and vibriobactin) and chrysobactin (a low-affinity siderophore). When iron is scarce, these molecules bind to Fe3+ ions and transport them into the cell, a process essential for the bacteria’s survival and growth in low-iron environments [306,318,319,320,321].

  • Quorum sensing (QS) and regulation: In contrast to eukaryotes, which rely on hormone-mediated signalling, prokaryotic communication is largely governed by QS mechanisms [322]. Bacteria display coordinated social behaviours via QS, a cell-to-cell communication mechanism. QS relies on autoinducers (AIs) (chemical signals produced by pathogens) that trigger collective procedures once a threshold concentration is reached, enabling bacteria to perform tasks unattainable by individual cells [323,324]. AHLs/AIs constitute the principal QS signals in Gram-negative bacteria, regulating density-dependent gene expression and collective behaviours, including biofilm formation [20,323,324,325,326]. Although primarily involved in intra-species communication, they can also facilitate interspecies signalling. The best-characterised framework for AHL-dependent QS is the Vibrio cholerae, V. harveyi, V. fischeri and Myxococcus xanthus LuxI/LuxR system. LuxI produces the autoinducer, which binds to the cytoplasmic receptor LuxR. This interaction induces a conformational change in LuxR, allowing it to bind DNA and regulate target gene expression [20,323,327].

Serratia species exhibit unusually diverse QS systems despite the broad conservation of LuxI/LuxR homologues. In Serratia, multiple LuxI/LuxR-type systems have been identified. Examples include SmaI/SmaR (Serratia sp. ATCC 39006), SpnI/SpnR (S. marcescens SS-1), SwrI/SwrR (S. liquefaciens MG1/S. marcesens MG1 [246]), and SprI/SprR (S. proteamaculans) [214,325,328,329,330,331,332].

In Serratia spp. ATCC 39006, the SmaI/SmaR system is involved in the production of carbapenem and prodigiosin [88,330]. In S. marcescens strain 12, the SmaI/SmaR QS system governs multiple coordinated procedures, including swarming motility, hemolytic activity, and biofilm development, among other virulence-associated traits [88,333]. The SwrI/SwrR QS system in S. liquefaciens MG1/S. marcescens MG1 [246] has been shown to coordinate several key phenotypes. This regulatory pair promotes swarming motility, drives the production of serrawettin, extracellular proteases, and S-layer proteins, and enhances both biofilm formation and 2,3-butanediol fermentation [88,329].

In S. marcescens SS-1, SpnI produces four AHLs, and SpnR—a repressor relieved by 3OC6-HSL—controls sliding motility, the production of biosurfactant, prodigiosin, rhamnolipid, and nuclease. The spnI/spnR module, located on a mobile Tn3 transposon, confers AI production and substantially alters its metabolic profile [88,214,325,328,329,330,331,332].

As aforementioned, QS regulates the expression of genes associated with biofilm formation, biosurfactant synthesis, virulence factor production, pathogenicity, infection, and antibiotic resistance in S. marcescens [90,325,334,335]. The resilience of S. marcescens stems primarily from its dual defence strategies. β-lactamase production provides an effective enzymatic barrier against β-lactam antibiotics, while robust biofilm formation supplies a physical refuge. The biofilm’s extracellular polymeric substance (EPS) creates a protected niche that facilitates cell-to-cell communication, genetic exchange, and coordinated behaviour, all while limiting access by host immune factors [336,337,338]. Normally, the composition of EPS comprises protein molecules, polysaccharides, or extracellular/environmental DNA (eDNA). The EPS matrix functions as a structural and protective biopolymer, shielding cells from antimicrobial agents and host immunity while promoting aggregation [336,337,338]. It also enhances desiccation resistance, aids nutrient retention, and serves as a carbon source. Together, these mechanisms underscore the pathogen’s sophisticated adaptive capacity and clinical persistence [336,337,338]. Evidence suggests that QS is a key mechanism facilitating communication within the gut microbiota and between microbiota and host cells [129,183,184,257,322,325,339,340,341].

While QS regulates biosurfactant production, biosurfactants in turn modulate QS signalling and QS-dependent processes, including biofilm formation, motility, and pathogenicity [90,342,343,344]. Originating from bacteria, fungi, and yeasts, biosurfactants are secondary metabolites that function either within the cell membrane or as secreted extracellular substances. They facilitate cellular attachment and dispersal by creating thin films, while also orchestrating critical biological processes such as motility, antagonism, and intercellular signalling [90]. Biosurfactants are classified by composition and molecular weight, the low-mass types and the high-mass types [90].

QS inhibition offers a novel antibacterial approach by disrupting microbial communication and virulence without imposing strong selective pressure [345,346]. QS inhibition limits resistance development and attenuates bacterial virulence by targeting communication instead of essential processes [345,347].

4. Antimicrobial Resistance (AMR) Mechanisms in CRSM

Serratia spp. carry a broad set of resistance determinants against multiple antibiotic classes. These arise from intrinsic, chromosome-encoded mechanisms as well as acquired mutations or HGT, mobilised by plasmids, integrons, ISs, transposons, and GIs that facilitate rapid dissemination of resistance [43,91,348]. The diversity, mobility, and mechanisms of many MGEs remain largely unknown [349]. Over half of plasmids lack the machinery for autonomous transfer and likely depend on alternate routes such as transduction, transformation, conjugation, vesiduction or helper plasmids [43,349,350,351,352,353]. Most putative genomic insertions also remain uncharacterized, highlighting major gaps in understanding how MGEs originate, spread, and shape microbial evolution [43,349,350,351,352,353]. MGEs disseminate resistance by inserting into bacterial chromosomes, where they may become permanently fixed or remain excisable and mobile. This dynamic is regulated by integrases encoded by the element itself, or supplied by the host, which mediate precise excision from the genome and thereby enable subsequent HGT [348,354].

Bacteria are evolving into “superbugs” that survive standard treatments by using four main mechanisms: preventing drug entry, modifying drug targets, neutralising drugs chemically, or expelling them via efflux pumps [37,43,45,46,91,348]. The main factor of this procedure is HGT, a process that allows bacteria to rapidly share resistance genes, often clustered together across different species. This enables bacteria to receive ARGs in a single event, making these resilient strains incredibly difficult to eliminate [348,355,356].

The overuse/misuse/self-medication of antibiotics has triggered a global health emergency known as AMR. Indeed, the escalation of the AMR phenomenon is driven by intertwined pressures, including antibiotic overuse/misuse/self-medication and inadequate sanitation in human settings, extensive antibiotic application in agriculture and aquaculture, environmental contamination, and ecological disruptions that promote wildlife-associated transmission [348,355,356,357].

Serratia species display pronounced AMR driven by the combined action of intrinsic, acquired, and adaptive mechanisms [26].

Serratia spp. exhibit strong intrinsic resistance, widely via efflux pumps, against β-lactams, polypeptides, macrolides and quinolones. Yet, they typically remain susceptible to trimethoprim and sulfonamides, likely because resistance to these agents imposes a high fitness cost or has been rarely selected [33,36,91,238,358,359,360,361]. Although plasmid-mediated resistance occurs sporadically, it remains uncommon. Targeting efflux regulation may offer a strategy for next-generation treatments, while advances in genome sequencing accelerate the detection of resistance determinants [33,36,91,238,358,359,360,361]. Multidrug-resistance is widespread in Serratia, largely due to its extensive efflux pump repertoire, complicating treatment. However, tailoring treatment to the strain’s genomic and resistance profile enables clinicians to avoid ineffective agents and improve therapeutic outcomes [91,238].

Efflux pumps are transmembrane transporters that expel toxic compounds (including antibiotics, detergents, and heavy metals) from the bacterial cytoplasm, thereby supporting intrinsic tolerance to diverse stressors. Mutational changes can further modify pump activity or specificity, contributing to acquired resistance [26,362,363,364,365,366]. Although efflux pumps are widely recognised for their role in antibiotic export, their functional scope is considerably broader. They participate in key normal processes, including the removal of endogenous metabolites, transport of siderophores, and regulation of QS signals [366,367,368,369,370]. Bacterial antimicrobial efflux systems are categorized into six major superfamilies, defined by their amino acid sequences, topologies, structures and energetic requirements, including: (a) the ATP-Binding Cassette (ABC) and (b) Major Facilitator Superfamilies (MFS), as well as (c) the Resistance–Nodulation–Cell Division (RND), (d) Drug/Metabolite Transporter (DMT), e.g., Small Multidrug Resistance (SMR) family, (e) Multidrug and Toxic Compound Extrusion (MATE), (f) Proteobacterial Antimicrobial Compound Efflux (PACE), and an additional family, the p-Aminobenzoyl-glutamate Transporter (AbgT) [26,44,367,371].

Genomic analysis of S. marcescens has identified efflux pumps from five of the seven major families (ABC, MATE, MFS, SMR, and RND), with the PACE family being the only one absent. While pumps from the ABC, RND, DMT (SMR), and MFS families are known to contribute to multidrug-resistance, the specific function of the MATE family homologs in this species remains uncharacterized [26,76,91,371].

The DMT superfamily, present in all life forms, includes over 30 families that transport metabolites and drugs. While some are compact four-helix pumps, others evolved into complex ten-helix systems. The SMR family exemplifies this diversity, comprising small four-helix pumps that function independently [371,372,373,374,375].

ABC transporters form a universally conserved superfamily and represent the most prevalent transport systems across all life domains [371,376,377,378]. Encompassing nearly 100 families, they translocate a broad spectrum of substrates, including nutrients, ions, drugs, and xenobiotics. In bacteria, they function primarily in substrate uptake, while efflux activity is widely conserved in both prokaryotes and eukaryotes [371,376,377,378].

In S. marcescens, the MacAB efflux pump is vital for bacterial viability. Although its removal does not alter resistance to macrolides, it significantly heightens sensitivity to colistin and aminoglycosides [26,367,371,379]. Furthermore, MacAB is required for oxidative stress response, motility, and biofilm formation. Therefore, inhibiting this pump offers a viable approach to reduce both the virulence and antibiotic resistance of the organism [26,367,371,379].

In S. marcescens, RND pumps drive key multidrug resistance. SdeXY mediates intrinsic resistance, especially to tetracyclines and fluoroquinolones. SdeAB adds broader MDR, while SdeCDE is limited to novobiocin [26,363,371,380,381,382,383,384]. In strain Db10, SdeGH and SdePQ-OmsA export diverse substrates, whereas SdeIJ is specific for benzalkonium chloride. Collectively, these systems equip the bacterium to withstand multiple antimicrobials [26,363,371,380,381,382,383,384].

In S. marcescens, SMR transporters are small four-helix dimers that route toxins to the periplasm, yet their role in antibiotic resistance remains unclear [26,371,385,386,387]. SsmE expels ethidium bromide, acriflavine, and norfloxacin, whereas the newer pumps SsmD and SsmK show no clear link to resistance, leaving their functional relevance unresolved [26,371,385,386,387].

In S. marcescens, MFS transporters—typically 12–14-helix exporters—support AMR by removing diverse toxic compounds [371,388,389,390,391]. SmfY expels norfloxacin and cationic agents, SmvA confers resistance to biocides such as chlorhexidine, and TetA mediates tetracycline resistance under TetR control. Additional uncharacterized MFS members likely broaden the species’ multidrug resistance capacity [371,388,389,390,391].

Aminoglycoside resistance is mainly conferred due to modifying enzymes, but low gene expression generally preserves clinical susceptibility [26,34,36,91,392,393,394,395,396,397,398,399,400].

Fluoroquinolone resistance can arise through two primary mechanisms: mutations in DNA gyrase or topoisomerase IV, or the acquisition of plasmid-mediated determinants like qnr, qepA, aac(6′)-Ib-cr, and oqxAB. The aac(6′)-Ib-cr variant is particularly common in strains resistant to both fluoroquinolones and aminoglycosides, a pattern consistent with prior studies connecting the gene to reduced susceptibility in both antibiotic families [40,43,395,401,402,403].

S. marcescens exhibits intrinsic resistance to macrolides and cationic antimicrobial peptides (CAPs) such as polymyxins, driven by low outer-membrane permeability and arnBCADTEF-mediated LPS modifications, although polymyxins serve as a key last-resort treatment option against Gram-negative superbugs [26,34,45,91,404,405,406]. The PhoP/PhoQ and PmrA/PmrB systems—modulated by MgrB—induce arn expression in response to environmental cues, promote polymyxin and colistin resistance across Serratia species [26,34,91,404,405,406,407]. Beyond CAPs, Serratia spp. shows broad intrinsic resistance, frequently carrying bacA (bacitracin), hslJ (novobiocin), fosA (fosfomycin), cat (chloramphenicol), and occasionally vanX (vancomycin) on the chromosome [26,91,408,409].

B-Lactam resistance in S. marcescens is largely mediated by β-lactamases, including AmpC enzymes, ESBLs, and carbapenemases. The chromosomal AmpC is universally present and inducible, conferring resistance to penicillins and third-generation cephalosporins; carbapenem resistance can emerge when AmpC overproduction coincides with porin loss [26,34,36,91,392,393,394,395,396,397,398,399,400]. Derepression is less frequent in S. marcescens than in other Enterobacterales, though mutations can expand AmpC activity. Carbapenem resistance may also arise from the rare, chromosomal SME carbapenemase [26,34,36,91,392,393,394,395,396,397,398,399,400]. As mentioned, S. marcescens resistance is largely driven by a broad repertoire of β-lactamases, including acquired ESBLs and carbapenemases as well as their intrinsic, inducible AmpC cephalosporinase. Class A enzymes (such as SME and KPC) and class B MBLs are widely reported globally, while class D variants (like OXA), though still less prevalent, are becoming increasingly detected [410,411,412,413,414]. S. marcescens is particularly concerning because it is intrinsically resistant to colistin. Once it acquires carbapenem resistance, it becomes impervious to both major last-line treatments, effectively eliminating viable treatment options. This dual resistance is associated with markedly elevated treatment failure. Mortality rates approaching 55% have been reported in critically ill patients with CRSM and dual resistance mechanisms in observational studies and case reports, although these estimates vary depending on patient population and study design [415,416,417,418,419].

5. CRSM and the Impact of Transposable Elements (TEs)

Managing the ‘CES’ pathogens (Citrobacter spp., Enterobacter spp., and Serratia spp.) is challenging because they carry intrinsic resistance to penicillins, cephamycins, and early-generation cephalosporins via AmpC β-lactamases [38,420,421,422,423,424,425]. Serratia spp. add inherent resistance to nitrofurantoin, doxycycline, colistin, macrolides and most of the aminoglycosides. Although classified under the ‘SPICE’ group for their clinical relevance, rising MDR strains with plasmid-borne ESBLs or carbapenemases further constrain treatment, often necessitating expensive last-line antimicrobial agents such as tigecycline, ceftazidime–avibactam, meropenem-vaborbactam or imipenem-relebactam. ‘SPICE’ term is an acronym for Serratia, Pseudomonas, indole-positive Proteus, Citrobacter, and Enterobacter [38,47,91,135,420,421,422,423,424,425,426,427,428,429,430]. Furthermore, as mentioned before, Serratia spp., similar to other ESCPM organisms, is intrinsically resistant to many β-lactams via chromosomal AmpC. The rise in plasmid-borne ESBLs and carbapenemases has compounded this, as these SBLs further limit effective therapy [32,33,34,35,36,37,47,135].

Although carbapenemase-production is the primary factor of resistance in Gram-negative bacteria like Enterobacteriaceae, decreased OMP permeability combined with the overexpression of AmpC or ESBL enzymes can also lead to reduced susceptibility [431]. Carbapenemases—classified as Class A (e.g., KPC), Class B (e.g., VIM, NDM, IMP), and Class D (e.g., OXA variants such as OXA-48)—function by hydrolysing carbapenems and other β-lactams [36,37,40,41,43,394,415,432,433,434]. Their rapid dissemination is facilitated by large conjugative plasmids. Conversely, resistance arising from OMP loss and AmpC/ESBL overproduction is not plasmid-borne; rather, it spreads primarily through clonal expansion [431,433,434,435].

Plasmid-mediated β-lactamases spread readily in S. marcescens through HGT, with Amber’s Class A ESBLs, KPCs (e.g., CTX-M, SHV) and Class D OXA variants (e.g., OXA-48) underpinning most clinically relevant resistance [36,43,395,415,431,436,437,438,439].

KPC-producing strains, often acquired in hospital settings, are now globally distributed (such as Brazil, China, Greece, Italy, United States), spreading through different types of plasmids, including IncX6-like and IncX8 plasmids [401,417,440,441,442,443,444,445,446,447].

Bolourchi et al. [415] identified the blaOXA-48a gene as the cause of carbapenem resistance in four Iranian S. marcescens isolates. Their investigation revealed that the gene was plasmid-borne, residing on an IncMCR incompatibility group plasmid [415].

Pérez-Viso et al. [448] investigated carbapenemase-producing S. marcescens in a Madrid hospital (2016–2018). Most isolates carried VIM-1, fewer produced OXA-48, and they found out seven lineages dominated by two clones [448]. Nearly all strains possessed an IncL plasmid related to IncL-pOXA-48a, with two variants identified: IncL-pVIM-1, containing an MDR integron, and IncL-pOXA-48, encoding only blaOXA-48Tn1999 [448]. The results obtained by Pérez-Viso et al. indicate ongoing CPSM transmission across care settings and emphasise the role of S. marcescens in local carbapenemase-producing Enterobacterales (CPE) spread beyond the usual Enterobacterales reservoirs [448].

Pangenome analyses reveal lineage-specific patterns: Sm7 typically carries blaKPC-2, Sm3 shows high plasmid diversity, and lineages Sm9 and Sm12 harbour the mcr-9 colistin-resistance gene [1,26]. The blaKPC-2 gene is typically flanked by a Tn3 resolvase and ISKpn27 upstream, and an inverted sequence downstream [1,442]. A study classifying S. marcescens into 12 distinct lineages reveals significant differences in their distribution and resistance profiles [1]. While environmental samples are concentrated in the Sm1, Sm4, and Sm10 groups, the Sm5, Sm6, and Sm7 groups are exclusively human-associated and show signs of niche specialisation [1]. The most concerning resistance profiles are found in Sm7 and Sm9; Sm7 is linked to plasmids carrying the blaKPC-2 gene, while the human-restricted Sm9 displays the highest plasmid diversity and burden, including blaNDM-1 [1]. These findings highlight the urgent need for genomic surveillance to monitor carbapenemase-producing S. marcescens [1].

Matteoli et al. showed that the broad global distribution of most S. marcescens lineages reflects deep evolutionary roots, whereas the regional restriction of Sm2 in Asia and Sm6 in Europe suggests more recent emergence. The predominance of the most divergent lineages (Sm1 and Sm10) in environmental sources further supports an evolutionary shift from a natural reservoir to a human-associated pathogen [1].

In 2011, a neonatal ward in Argentina reported its first documented nosocomial outbreak of MBL-producing Enterobacteriaceae [449]. Nastro et al. [449] identified seven MDR S. marcescens isolates, all belonging to a single clone and harbouring a class I integron carrying blaVIM-16.

Carbapenem resistance in S. marcescens is uncommon, arising mainly from porin loss or MBLs. Chromosomal class A carbapenemases (SME, NMC-A, IMI-1) are clavulanate-susceptible, while plasmid-borne class B MBLs (IMP, VIM, NDM) represent the greatest clinical threat, hydrolysing most β-lactams, evading modern inhibitors, and spreading via integrons [410,420,450,451,452]. IMP-1, the first transferable carbapenemase identified in S. marcescens, isolated from a Japanese urinary tract infection case in 1991, illustrates the remarkable mobility of these resistance determinants [410,420,450,451,452]. Although VIM enzymes are largely restricted to Pseudomonas, plasmid-mediated MBLs have caused outbreaks worldwide, with recent isolates co-carrying blaIMP and mcr-9 on conjugative plasmids, highlighting the expanding dissemination and clinical impact of mobile resistance in this species [1,47,135,450,451,453].

Zhong et al. [454] reported that S. marcescens YL4 carries chromosomal resistance genes (blaSRT-1, aac(6′)-Ic, tet(41)) and plasmid-borne determinants, including mcr-9, which can reduce colistin susceptibility and potentially spread to other bacteria via HGT. The megaplasmid pYL4.1 (IncHI2/2A) shares high similarity with blaIMP-26-harbouring plasmids from E. cloacae [455] and E. hormaechei [456], suggesting evolutionary links [454]. IS26 and Tn3 mediate plasmid rearrangements and gene amplification, while class I integrons facilitate mobilisation of resistance cassettes [43,457]. These MGEs drive dissemination of multidrug and carbapenem resistance among Enterobacterales, posing significant clinical challenges [454].

The IS26 family—which includes elements such as IS257/IS431, ISSau10, IS1216, IS1006, and IS1008—plays a major role in disseminating antibiotic resistance across diverse pathogens, yet IS26 remains the best-characterised and most intensively studied member [457]. In Gram-negative bacteria, IS26 is a dominant MGE that accelerates the spread of resistance by assembling and mobilising gene clusters on plasmids [457]. It forms pseudo-compound transposon and translocatable units, enabling targeted cointegration events that restructure plasmids and amplify AMR loci [457]. IS26-family elements also modulate adjacent gene activity and promote extensive plasmid remodelling [457]. These dynamics are central to resistance dissemination in diverse species, including S. marcescens, where IS26-driven rearrangements enhance plasmid adaptability and transfer [457]. Due to this knowledge, several ISs and transposons—most notably ISEcp1, IS26, IS903, IS1380, and Tn3—play central roles in capturing and mobilising ESBL-associated genes [458].

Huang et al. characterised an IMP-4–producing, CRSM (S378) from an asymptomatic UTI in Sichuan, China. WGS identified five resistance genes—blaIMP-4, blaSRT-2, aac(6′)-Ic, qnrS1, and tet(41). Conjugation assays confirmed transfer of the blaIMP-4 plasmid pS378P, an IncN replicon (GC 50%) nearly identical to pP378-IMP [459].

Ghaith et al. [460] reported a NICU outbreak of S. marcescens at Cairo University Hospital over a five-month period in 2015. The predominant MBL determinants were blaIMP-4 (42.5%) and blaVIM-2 (37.5%) [460]. This investigation provided the first evidence of IMP-4– and VIM-2–producing S. marcescens causing bacteremia in this ICU [459,460].

BlaIMP-4, the most frequently reported IMP variant, is commonly embedded within class I integrons and disseminated via several types of vehicles, including IncHI2, IncL/M, IncA/C, and IncN plasmids [419,461].

As aforementioned, carbapenem resistance in Enterobacterales is primarily mediated by five major carbapenemase families—KPC (Class A); IMP, NDM, and VIM (Class B); and OXA-48-like (Class D). Because these enzymes are usually encoded on mobile vehicles of plasmids, they disseminate efficiently through HGT. Such plasmids often harbour additional resistance determinants, including those conferring aminoglycoside and quinolone resistance, further limiting therapeutic options for CPE [419,462,463,464]. Several plasmid families are pivotal in carbapenemase dissemination within Enterobacteriaceae, with IncF, IncL/M, IncA/C, and IncX being the most prevalent. In this regard, IncF plasmids are globally widespread and commonly carry KPC, NDM, and ESBLs such as CTX-M-15; whereas IncX plasmids, particularly IncX3, are major vectors for NDM spread. In addition, IncL/M plasmids primarily transmit NDM and OXA-48, while IncA/C plasmids facilitate the dissemination of NDM, VIM, KPC, and CMY-type cephalosporinases [419,465,466].

Formerly grouped together, IncL and IncM plasmids are now recognised as distinct. IncL plasmids drive the global dissemination of OXA-48, whereas IncM2 plasmids transmit NDM-1 and carry multiple resistance genes conferring broad resistance to cephalosporins, carbapenems, aminoglycosides, trimethoprim, sulfonamides, and fosfomycin [467,468].

Sabtcheva et al. [419] analysed carbapenemases in the ESCPM bacterial group, including S. marcescens, finding VIM-4 chromosomally encoded in S. marcescens. Furthermore, VIM predominated in bacterial strains of Providencia stuartii and S. marcescens [419]. Furthermore, they found that among Bulgarian CP-ESCPM isolates, S. marcescens carried plasmid-borne carbapenemases: OXA-48 on IncL, NDM-1 on IncM2 and IncX3, and VIM-4 on IncM2, underscoring its role as a reservoir of transferable resistance [419].

MGEs drive plasmid and bacterial evolution by reshaping plasmid architecture through transposons and ISs, sometimes improving host compatibility, as seen with IS26-mediated deletions in E. coli. IS26 spreads resistance via IS26-flanked cointegrates or translocatable units, while Tn3 transposons mobilise resistance genes through a copy-and-paste mechanism, promoting interbacterial transfer [40,41,43,44,454,469,470].

Zhu et al. [437] analysed 3769 Serratia genomes, enrolled between 1823 and 2024 from 65 countries, expanding the genus’ diversity with 14 new species and 809 additional sequence types (STs). S. sarumanii, S. nevei, and S. marcescens were most common, with ST367 and ST324 dominating [437]. Moreover, carbapenem resistance appeared in 26.6% of isolates and was driven by 34 genes, mainly blaKPC-2, blaSPR-1, and blaKPC-3. Resistance emerged after 2011 and now spans 46 countries [437]. Zhu et al. [437] identified 94 putative transmission clusters, including major ST324 spread in the USA. MDR was widespread (61.6%), supported by numerous mobile elements—248 IS types and 61 plasmid replicons—highlighting their central role in disseminating resistance determinants [437]. Zhu et al. [437] reported that carbapenemase-producing Serratia carried 248 ISs (ISSen4, IS26, IS903B) and 61 plasmids (ColRNAI_1, Col440II_1, IncFIB(K)_1_Kpn3), displaying gene-specific MGE patterns: ISs showed gene-specific correlations: ISEc33/ISEc36 negatively correlated with blaIMP-1, IS1 × 3/ISPa26 positively with blaIMP-13; ISAba125 negatively with blaNDM-1, while other ISs linked positively to NDM, OXA, and VIM variants. They [437] indicated that key plasmids were associated with blaIMP, blaKPC, blaNDM, blaOXA, and blaVIM. No IS or transposons correlated with blaSME, underscoring a complex, element-specific mobilome underpinning resistance [437].

Aracil-Gisbert et al. [32] analysed ICU sinks (2019–2021) and clinical (2003–2019) Serratia isolates with 165 genomes, identifying six clades: 1A (S. nematodiphila), 1B (S. marcescens), 2A (S. bockelmannii), 2B (S. ureilytica), 3 (S. marcescens/S. nevei), and 4A–4B (S. nevei), with clades 3–4 predominating. Aracil-Gisbert et al. [32] showed that persistent sink lineages—4A (ST92, ST490) and 4B (ST424) were clonally linked to outbreak strains carrying blaVIM-1 or blaOXA-48 on IncL/pB77-CPsm plasmids [448], highlighting sinks as reservoirs for carbapenemase plasmids and their transmission into patients. Among 190 plasmids, 142 clustered into 10 plasmid groups: PG1 (IncL/L-M), PG2, PG3, PG9, PG11, PG12 (Col), PG4 (IncI1, clinical only), PG7–PG8 (IncF-like), and PG10/others (untyped) [32]. PG1 included IncL plasmids with a class I integron, found in Serratia clades 3–4 and in K. pneumoniae, K. variicola, C. cronae, and E. roggenkampii; variants included a truncated IncL and an IncM1 tetA/tetR plasmid in sinks. PG8 comprised IncF-like plasmids in sinks and patients (subclade 2B, clade 3, subclade 4B) resembling p87710 and carrying fimbrial genes, PG7 matched clinical pE28_003, multiple Col PGs occurred in clades 3–4, and PG4/IncI1 plasmids were confined to clinical isolates [32].

In another study, Mauffrey et al. [471] documented two CPE outbreaks involving patients and contaminated sink traps. Among 57 K. pneumoniae and S. marcescens isolates, genomic analysis revealed 22 plasmid clusters including blaNDM-1 and blaKPC-2, shared between clinical and environmental sources [471]. Their findings highlight sink traps as reservoirs enabling plasmid-mediated resistance spread beyond clonal transmission [471].

Although IncU and IncX3 plasmids play a pivotal role in spreading the blaKPC and blaNDM resistance genes across various Serratia species [472,473,474], the specific relationships between plasmid types, antibiotic resistance genes, and their bacterial hosts remain poorly characterised [474].

Liu et al. [474] analysed 2632 S. marcescens genomes from 49 regions and found 350 (13.3%) carrying blaKPC and/or blaNDM, predominantly clinical isolates. Prevalence reached 100% in Ecuador, Chile, Ethiopia, and Iraq, with notable rates in Romania (70%), Bangladesh (52.38%), and Colombia (50%) [474]. The USA (20.78%) and China (45.45%) contributed the largest numbers. Overall, 284 strains carried blaKPC, 64 blaNDM, and two strains carried both genes, with KPC-2 and NDM-1 the most common [474]. Phylogenomics revealed five species and 126 ARGs, enriched in wastewater isolates. Species-specific distributions of Tn4401/NTEKPC and plasmid types—including IncL/M, IncU, and IncX3—highlighted distinct mobility patterns [474]. Moreover, in the study conducted by Liu et al. [474], multiple ESBL genes were detected, and 283 strains carried both ESBLs and carbapenemase genes (blaKPC and/or blaNDM). A species-layered pattern emerged [474]: S. nevei showed the broadest resistance profile, dominated by blaKPC-2, blaTEM-1, blaOXA-9, and blaSHV-30. S. sarumanii was characterised by prominent blaOXA-1, blaCTX-M-14, and blaTEM-1, supplemented by blaKPC-2 and blaKPC-3. In contrast, S. ureilytica carried fewer determinants overall but consistently retained key genes such as blaTEM-1 [474].

In a study performed by Xu et al. [475], they showed that CRSM posed major clinical challenges. In 14 isolates, whole-genome and expression analyses revealed three resistance pathways: acquisition of blaKPC, enhanced blaKPC expression, or loss of an outer-membrane protein with elevated blaCTX-M-14 [475]. These findings indicate diverse in vivo evolutionary routes (e.g., transformation) rather than clonal replacement [475].

Zheng et al. [476] found that, beyond blaKPC-2, 121 S. marcescens genomes carried 52 additional resistance genes across 10 antimicrobial classes. Among 14 newly sequenced isolates, key determinants included aac(3)-IId, aac(6′)-Ic, blaLAP-2, blaSRT-1, and tet(41). Resistance patterns varied by cluster: β-lactam and aminoglycoside genes were most diverse, with aac(6′)-Ic (99.2%), blaSRT-1 (79.3%), and qnrS1 (72.7%) predominating [476]. blaLAP-2 and blaCTX-M-14 were geographically restricted to Chinese isolates. Three strains carried both blaKPC-2 and blaNDM-1 [476]. Plasmid typing revealed IncFIIK, IncFII, IncM, and IncR groups, while K17 and K1030 lacked known plasmids. Due to this knowledge, Zheng et al. [476] identified a novel plasmid lineage, pK17-KPC/pK1030-KPC, carrying blaKPC-2 and enabling HGT, providing crucial evidence for controlling CRSM.

Wang et al. [477] performed a genomic analysis of a S. marcescens isolate (L4843) from a faecal sample in China, which harboured both blaKPC-2 and blaCTX-M-14 resistance genes. WGS and conjugation assays revealed that blaKPC-2 was located on a transferable plasmid characterised by complex ISs and transposons [477]. This study marks the first report of a faecal isolate in China carrying both resistance genes, underscoring the critical need for enhanced surveillance of MGEs [477].

6. Conclusions

S. marcescens has transitioned from a historically intriguing microorganism to a clinically significant opportunistic pathogen shaped by remarkable genomic plasticity and an expansive accessory genome. Its ability to acquire and disseminate mobile genetic elements—including plasmids, integrons, transposons, bacteriophages, and extracellular vesicles—drives the rapid evolution of its resistome and virulome. The convergence of intrinsic resistance, potent efflux systems, and the escalating spread of ESBLs and carbapenemases has positioned S. marcescens among the most challenging Gram-negative threats, particularly in ICU settings. Phylogenomic studies reveal distinct lineages with niche-specific adaptations, underscoring the dynamic evolutionary pathways that complicate surveillance and outbreak control.

Given the organism’s increasing multidrug- and occasionally pan-drug-resistance, effective containment will require integrated genomic surveillance, high-resolution epidemiology, and targeted antimicrobial stewardship. A deeper understanding of its mobile genetic landscape and regulatory networks is essential for developing future treatment and infection control strategies.

Acknowledgments

AI tools were employed to polish the language and correct spelling and grammatical errors in the manuscript.

Author Contributions

T.K., K.T. and P.B. have equally contributed to the conception and design of the work and have approved the submitted version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analysed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding Statement

This research received no external funding.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Matteoli F.P., Pedrosa-Silva F., Dutra-Silva L., Giachini A.J. The global population structure and beta-lactamase repertoire of the opportunistic pathogen Serratia marcescens. Genomics. 2021;113:3523–3532. doi: 10.1016/j.ygeno.2021.08.009. [DOI] [PubMed] [Google Scholar]
  • 2.Williams D.J., Grimont P.A., Cazares A., Grimont F., Ageron E., Pettigrew K.A., Cazares D., Njamkepo E., Weill F.-X., Heinz E. The genus Serratia revisited by genomics. Nat. Commun. 2022;13:5195. doi: 10.1038/s41467-022-32929-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gillen A.L., Gibbs R. Serratia marcescens: The miracle bacillus. Fac. Publ. Present. 2012;138 [Google Scholar]
  • 4.Ball A., McGhie D., Geddes A. Serratia marcescens in a general hospital. QJM Int. J. Med. 1977;46:63–71. [PubMed] [Google Scholar]
  • 5.Virgolini I., Zelger B., Zelger B., Kenner L. Reality or fiction of the “real presence” of Jesus Christ in the holy eucharist. Ann. Clin. Med. Case Rep. 2023;11:1–10. [Google Scholar]
  • 6.Grzybowski T., Wrzosek M., Wołyniec W., Hałoń A., Chmielik E., Gorzkiewicz M., Woźniak M., Mikucka A., Lebioda A., Jonkisz A. Methodology for the analysis of biological impurities associated with peri-eucharistic phenomena. Appl. Microbiol. Biotechnol. 2025;109:58. doi: 10.1007/s00253-025-13439-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Göker M., Christensen H., Fingerle V., Kostovski M., Margos G., Moore E.R., Oren A., Patrick S., Reischl U., Vázquez-Boland J.A. List of Recommended Names for bacteria of medical importance: Report of the Ad Hoc Committee on Mitigating Changes in Prokaryotic Nomenclature. Int. J. Syst. Evol. Microbiol. 2025;75:006943. doi: 10.1099/ijsem.0.006943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Adeolu M., Alnajar S., Naushad S., Gupta R.S. Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: Proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Int. J. Syst. Evol. Microbiol. 2016;66:5575–5599. doi: 10.1099/ijsem.0.001485. [DOI] [PubMed] [Google Scholar]
  • 9.Janda J.M., Abbott S.L. The changing face of the family Enterobacteriaceae (Order:“Enterobacterales”): New members, taxonomic issues, geographic expansion, and new diseases and disease syndromes. Clin. Microbiol. Rev. 2021;34:e00174-20. doi: 10.1128/CMR.00174-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chuvochina M., Mussig A.J., Chaumeil P.-A., Skarshewski A., Rinke C., Parks D.H., Hugenholtz P. Proposal of names for 329 higher rank taxa defined in the Genome Taxonomy Database under two prokaryotic codes. FEMS Microbiol. Lett. 2023;370:fnad071. doi: 10.1093/femsle/fnad071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Martins P.A., Pacheco T.F., de Camargo B.R., De Marco J.L., Salum T.F.C. Solid-state fermentation production and characterization of an alkaline lipase from a newly isolated Burkholderia gladioli strain. Prep. Biochem. Biotechnol. 2022;52:70–79. doi: 10.1080/10826068.2021.1910959. [DOI] [PubMed] [Google Scholar]
  • 12.Rout R.K., Maity S.P., Daya Sagar B.S., Hassan S.S. Fractal and mathematical morphology in intricate comparison between tertiary protein structures. Comput. Methods Biomech. Biomed. Eng. Imaging Vis. 2018;6:192–203. doi: 10.1080/21681163.2016.1214850. [DOI] [Google Scholar]
  • 13.Behzadi P., Ranjbar R. DNA microarray technology and bioinformatic web services. Acta Microbiol. Immunol. Hung. 2019;66:19–30. doi: 10.1556/030.65.2018.028. [DOI] [PubMed] [Google Scholar]
  • 14.Behzadi P., Gajdács M. Writing a strong scientific paper in medicine and the biomedical sciences: A checklist and recommendations for early career researchers. Biol. Futur. 2021;72:395–407. doi: 10.1007/s42977-021-00095-z. [DOI] [PubMed] [Google Scholar]
  • 15.Ranjbar R., Behzadi P., Najafi A., Roudi R. DNA microarray for rapid detection and identification of food and water borne bacteria: From dry to wet lab. Open Microbiol. J. 2017;11:330–338. doi: 10.2174/1874285801711010330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Behzadi P., Najafi A., Behzadi E., Ranjbar R. Microarray long oligo probe designing for Escherichia coli: An in-silico DNA marker extraction. Cent. Eur. J. Urol. 2016;69:105–111. doi: 10.5173/ceju.2016.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Behzadi P., Ranjbar R., Alavian S.M. Nucleic acid-based approaches for detection of viral hepatitis. Jundishapur. J. Microbiol. 2014;8:e17449. doi: 10.5812/jjm.17449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Behzadi P., Gajdács M. Worldwide Protein Data Bank (wwPDB): A virtual treasure for research in biotechnology. Eur. J. Microbiol. Immunol. 2022;11:77–86. doi: 10.1556/1886.2021.00020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ranjbar R., Behzadi P., Mammina C. Respiratory tularemia: Francisella tularensis and microarray probe designing. Open Microbiol. J. 2016;10:176–182. doi: 10.2174/1874285801610010176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Boldeanu L., Boldeanu M.V., Novac M.B., Assani M.-Z., Radu L. Serratia marcescens: A Versatile Opportunistic Pathogen with Emerging Clinical and Biotechnological Significance. Int. J. Mol. Sci. 2025;26:11479. doi: 10.3390/ijms262311479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Li X., Zhuang X., Dong H., Qin R., Ran T., Xu D., Wang W. The NtrB/C two-component system positively regulates the motility in Serratia marcescens FS14. Int. J. Biol. Macromol. 2025;328:147689. doi: 10.1016/j.ijbiomac.2025.147689. [DOI] [PubMed] [Google Scholar]
  • 22.Miller J., Murray P.J. Space and time on the membrane: Modelling Type VI secretion system dynamics as a state-dependent random walk. R. Soc. Open Sci. 2023;10:230284. doi: 10.1098/rsos.230284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Cosimato I., Santella B., Rufolo S., Sabatini P., Galdiero M., Capunzo M., Boccia G., Folliero V., Franci G. Current epidemiological status and antibiotic resistance profile of Serratia marcescens. Antibiotics. 2024;13:323. doi: 10.3390/antibiotics13040323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zhu H., Li F., Cao X., Zhang Y., Liu C., Chen Y., Shen H. Epidemiology, resistance profiles, and risk factors of multidrug-and carbapenem-resistant Serratia marcescens infections: A retrospective study of 242 cases. BMC Infect. Dis. 2025;25:1105. doi: 10.1186/s12879-025-11569-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Akhtar M.R., Younas M., Xia X. Pathogenicity of Serratia marcescens strains as biological control agent: Implications for sustainable pest management. Insect Sci. 2025;33:13–32. doi: 10.1111/1744-7917.13489. [DOI] [PubMed] [Google Scholar]
  • 26.Tavares-Carreon F., De Anda-Mora K., Rojas-Barrera I.C., Andrade A. Serratia marcescens antibiotic resistance mechanisms of an opportunistic pathogen: A literature review. PeerJ. 2023;11:e14399. doi: 10.7717/peerj.14399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Vollset S.E., Ababneh H.S., Abate Y.H., Abbafati C., Abbasgholizadeh R., Abbasian M., Abbastabar H., Abd Al Magied A.H., Abd ElHafeez S., Abdelkader A. Burden of disease scenarios for 204 countries and territories, 2022–2050: A forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2204–2256. doi: 10.1016/S0140-6736(24)00685-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Oh J., Kim S., Kim M.S., Abate Y.H., Abd ElHafeez S., Abdelkader A., Abdi P., Abdulah D.M., Aboagye R.G., Abolhassani H. Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Respir. Med. 2025;13:425–446. doi: 10.1016/S2213-2600(25)00003-7. [DOI] [PubMed] [Google Scholar]
  • 29.Schumacher A.E., Zheng P., Barber R.M., Aalipour M.A., Aalruz H., Ababneh H.S., Abaraogu U.O., Abbafati C., Abbas N., Abbasifard M. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: A demographic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406:1731–1810. doi: 10.1016/S0140-6736(25)01330-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Monardo R., Park L.P., Ruffin F., Cox P., Dinh A.Q., Korn R.E., Farahani P., Ripa M., Castagna A., Hanson B.M., et al. Clinical and Genomic Characterization of Serratia Bloodstream Infections. CMI Commun. 2025;2:105128. doi: 10.1016/j.cmicom.2025.105128. [DOI] [Google Scholar]
  • 31.Ono T., Taniguchi I., Nakamura K., Nagano D.S., Nishida R., Gotoh Y., Ogura Y., Sato M.P., Iguchi A., Murase K. Global population structure of the Serratia marcescens complex and identification of hospital-adapted lineages in the complex. Microb. Genom. 2022;8:000793. doi: 10.1099/mgen.0.000793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Aracil-Gisbert S., Fernández-De-Bobadilla M.D., Guerra-Pinto N., Serrano-Calleja S., Pérez-Cobas A.E., Soriano C., de Pablo R., Lanza V.F., Pérez-Viso B., Reuters S. The ICU environment contributes to the endemicity of the “Serratia marcescens complex” in the hospital setting. Mbio. 2024;15:e03054-23. doi: 10.1128/mbio.03054-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Jacoby G.A. AmpC β-lactamases. Clin. Microbiol. Rev. 2009;22:161–182. doi: 10.1128/CMR.00036-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Tamma P.D., Aitken S.L., Bonomo R.A., Mathers A.J., Van Duin D., Clancy C.J. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin. Infect. Dis. 2022;74:2089–2114. doi: 10.1093/cid/ciab1013. [DOI] [PubMed] [Google Scholar]
  • 35.Husna A., Rahman M.M., Badruzzaman A., Sikder M.H., Islam M.R., Rahman M.T., Alam J., Ashour H.M. Extended-spectrum β-lactamases (ESBL): Challenges and opportunities. Biomedicines. 2023;11:2937. doi: 10.3390/biomedicines11112937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Behzadi P., García-Perdomo H.A., Karpiński T.M., Issakhanian L. Metallo-ß-lactamases: A review. Mol. Biol. Rep. 2020;47:6281–6294. doi: 10.1007/s11033-020-05651-9. [DOI] [PubMed] [Google Scholar]
  • 37.Ahmadi S., Foroohi F., Shirzadian M., Vosoughi A.F., Golpasand T., Behzadi P. Distribution of acquired carbapenemase genes among uropathogenic Escherichia coli. Naunyn-Schmiedeberg's Arch. Pharmacol. 2025;399:3477–3494. doi: 10.1007/s00210-025-04643-5. [DOI] [PubMed] [Google Scholar]
  • 38.Moradigaravand D., Boinett C.J., Martin V., Peacock S.J., Parkhill J. Recent independent emergence of multiple multidrug-resistant Serratia marcescens clones within the United Kingdom and Ireland. Genome Res. 2016;26:1101–1109. doi: 10.1101/gr.205245.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Magiorakos A.-P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M., Giske C., Harbarth S., Hindler J., Kahlmeter G., Olsson-Liljequist B. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. doi: 10.1111/j.1469-0691.2011.03570.x. [DOI] [PubMed] [Google Scholar]
  • 40.Karampatakis T., Tsergouli K., Behzadi P. Carbapenem-Resistant Acinetobacter baumannii: Virulence factors, molecular epidemiology, and latest updates in treatment options. Microorganisms. 2025;13:1983. doi: 10.3390/microorganisms13091983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Kebriaee A.N., Behzadi P., Mohammadian T., Imani Fooladi A.A., Hosseini M.S. Distribution of antimicrobial resistance genes and virulence genes in different genotypes of Acinetobacter baumannii. BMC Infect. Dis. 2025;25:1230. doi: 10.1186/s12879-025-11632-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Golpasand T., Keshvari M., Behzadi P. Distribution of chaperone-usher fimbriae and curli fimbriae among uropathogenic Escherichia coli. BMC Microbiol. 2024;24:344. doi: 10.1186/s12866-024-03472-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Karampatakis T., Tsergouli K., Behzadi P. Carbapenem-resistant Pseudomonas aeruginosa’s resistome: Pan-genomic plasticity, the impact of transposable elements and jumping genes. Antibiotics. 2025;14:353. doi: 10.3390/antibiotics14040353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Karampatakis T., Tsergouli K., Behzadi P. Pan-genome plasticity and virulence factors: A natural treasure trove for Acinetobacter baumannii. Antibiotics. 2024;13:257. doi: 10.3390/antibiotics13030257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Algammal A., Hetta H.F., Mabrok M., Behzadi P. Emerging multidrug-resistant bacterial pathogens “superbugs”: A rising public health threat. Front. Microbiol. 2023;14:1135614. doi: 10.3389/fmicb.2023.1135614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Algammal A.M., Behzadi P. Antimicrobial resistance: A global public health concern that needs perspective combating strategies and new talented antibiotics. Discov. Med. 2024;36:1911–1913. doi: 10.24976/Discov.Med.202436188.177. [DOI] [PubMed] [Google Scholar]
  • 47.Behzadi P., Gajdács M., Pallós P., Ónodi B., Stájer A., Matusovits D., Kárpáti K., Burián K., Battah B., Ferrari M. Relationship between biofilm-formation, phenotypic virulence factors and antibiotic resistance in environmental Pseudomonas aeruginosa. Pathogens. 2022;11:1015. doi: 10.3390/pathogens11091015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Chauhan S.M., Ardalani O., Hyun J.C., Monk J.M., Phaneuf P.V., Palsson B.O. Decomposition of the pangenome matrix reveals a structure in gene distribution in the Escherichia coli species. mSphere. 2025;10:e00532-24. doi: 10.1128/msphere.00532-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Hyun J.C., Monk J.M., Palsson B.O. Comparative pangenomics: Analysis of 12 microbial pathogen pangenomes reveals conserved global structures of genetic and functional diversity. BMC Genom. 2022;23:7. doi: 10.1186/s12864-021-08223-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Karampatakis T., Tsergouli K., Behzadi P. Carbapenem-resistant Klebsiella pneumoniae: Virulence factors, molecular epidemiology and latest updates in treatment options. Antibiotics. 2023;12:234. doi: 10.3390/antibiotics12020234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Mitra S., Naha S., Chakraborty J., De S., Kaur H., Majumdar T., Basu S. Diversity of mobile genetic elements in carbapenem-resistant Enterobacterales isolated from the intensive care units of a tertiary care hospital in Northeast India. Front. Microbiol. 2025;16:1543427. doi: 10.3389/fmicb.2025.1543427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Fang L., Chen R., Li C., Sun J., Liu R., Shen Y., Guo X. The association between the genetic structures of commonly incompatible plasmids in Gram-negative bacteria, their distribution and the resistance genes. Front. Cell. Infect. Microbiol. 2024;14:1472876. doi: 10.3389/fcimb.2024.1472876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Wachino J.I. Horizontal Gene Transfer Systems for Spread of Antibiotic Resistance in Gram-Negative Bacteria. Microbiol. Immunol. 2025;69:367–376. doi: 10.1111/1348-0421.13222. [DOI] [PubMed] [Google Scholar]
  • 54.Godeux A.-S., Svedholm E., Barreto S., Potron A., Venner S., Charpentier X., Laaberki M.-H. Interbacterial transfer of carbapenem resistance and large antibiotic resistance islands by natural transformation in pathogenic Acinetobacter. MBio. 2022;13:e02631-21. doi: 10.1128/mbio.02631-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Chiang Y.N., Penadés J.R., Chen J. Genetic transduction by phages and chromosomal islands: The new and noncanonical. PLoS Pathog. 2019;15:e1007878. doi: 10.1371/journal.ppat.1007878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Borodovich T., Shkoporov A.N., Ross R.P., Hill C. Phage-mediated horizontal gene transfer and its implications for the human gut microbiome. Gastroenterol. Rep. 2022;10:goac012. doi: 10.1093/gastro/goac012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Wachino J.-I., Jin W., Kimura K., Arakawa Y. Intercellular transfer of chromosomal antimicrobial resistance genes between Acinetobacter baumannii strains mediated by prophages. Antimicrob. Agents Chemother. 2019;63:e00334-19. doi: 10.1128/AAC.00334-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Ahmadi Z., Noormohammadi Z., Behzadi P., Ranjbar R. Molecular detection of gyrA mutation in clinical strains of Klebsiella pneumoniae. Iran. J. Public Health. 2022;51:2334. doi: 10.18502/ijph.v51i10.10992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Gunathilaka G.U., Tahlan V., Mafiz A.I., Polur M., Zhang Y. Phages in urban wastewater have the potential to disseminate antibiotic resistance. Int. J. Antimicrob. Agents. 2017;50:678–683. doi: 10.1016/j.ijantimicag.2017.08.013. [DOI] [PubMed] [Google Scholar]
  • 60.Pires J., Santos R., Monteiro S. Antibiotic resistance genes in bacteriophages from wastewater treatment plant and hospital wastewaters. Sci. Total Environ. 2023;892:164708. doi: 10.1016/j.scitotenv.2023.164708. [DOI] [PubMed] [Google Scholar]
  • 61.Quirós P., Colomer-Lluch M., Martínez-Castillo A., Miró E., Argente M., Jofre J., Navarro F., Muniesa M. Antibiotic resistance genes in the bacteriophage DNA fraction of human fecal samples. Antimicrob. Agents Chemother. 2014;58:606–609. doi: 10.1128/AAC.01684-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Rima M., Dakramanji M., El Hayek E., El Khoury T., Fajloun Z., Rima M. Unveiling the wonders of bacteria-derived extracellular vesicles: From fundamental functions to beneficial applications. Heliyon. 2025;11:e42509. doi: 10.1016/j.heliyon.2025.e42509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Chen L.-J., Jing X.-P., Meng D.-L., Wu T.-T., Zhou H., Sun R.-L., Min X.-C., Liu R., Zeng J. Newly Detected Transmission of bla KPC-2 by Outer Membrane Vesicles in Klebsiella Pneumoniae. Curr. Med. Sci. 2023;43:80–85. doi: 10.1007/s11596-022-2680-7. [DOI] [PubMed] [Google Scholar]
  • 64.Tang B., Yang A., Liu P., Wang Z., Jian Z., Chen X., Yan Q., Liang X., Liu W. Outer membrane vesicles transmitting bla NDM-1 mediate the emergence of carbapenem-resistant hypervirulent Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2023;67:e01444-22. doi: 10.1128/aac.01444-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Zhu S., Yang B., Wang Z., Liu Y. Augmented dissemination of antibiotic resistance elicited by non-antibiotic factors. Ecotoxicol. Environ. Saf. 2023;262:115124. doi: 10.1016/j.ecoenv.2023.115124. [DOI] [PubMed] [Google Scholar]
  • 66.Barathan M., Ng S.-L., Lokanathan Y., Ng M.H., Law J.X. Unseen weapons: Bacterial extracellular vesicles and the spread of antibiotic resistance in aquatic environments. Int. J. Mol. Sci. 2024;25:3080. doi: 10.3390/ijms25063080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Briaud P., Carroll R.K. Extracellular vesicle biogenesis and functions in gram-positive bacteria. Infect. Immun. 2020;88:e00433-20. doi: 10.1128/IAI.00433-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Fan F., Chen G., Deng S., Wei L. Proteomic analysis of meropenem-induced outer membrane vesicles released by carbapenem-resistant Klebsiella pneumoniae. Microbiol. Spectr. 2024;12:e02917–e02923. doi: 10.1128/spectrum.02917-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Sarshar M., Scribano D., Behzadi P., Masotti A., Ambrosi C. Outer membrane vesicles are the powerful cell-to-cell communication vehicles that allow bacteria to monitor extracellular milieu. ExRNA. 2022;4:25. doi: 10.21037/exrna-22-18. [DOI] [Google Scholar]
  • 70.Ahmadi Z., Noormohammadi Z., Ranjbar R., Behzadi P. Prevalence of tetracycline resistance genes tet (A, B, C, 39) in Klebsiella pneumoniae isolated from Tehran, Iran. Iran. J. Med. Microbiol. 2022;16:141–147. doi: 10.30699/ijmm.16.2.141. [DOI] [Google Scholar]
  • 71.Tian D., Zhao M., Zheng S., Jiang X., Zhang B. Involvement of Tn3 transposon in formation and transmission of hypervirulent and carbapenem-resistant Klebsiella pneumoniae. Microbiol. Spectr. 2023;11:e03038-23. doi: 10.1128/spectrum.03038-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Talat A., Khan F., Khan A.U. Genome analyses of colistin-resistant high-risk bla NDM-5 producing Klebsiella pneumoniae ST147 and Pseudomonas aeruginosa ST235 and ST357 in clinical settings. BMC Microbiol. 2024;24:174. doi: 10.1186/s12866-024-03306-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Anderson M.T., Himpsl S.D., Kingsley L.G., Smith S.N., Bachman M.A., Mobley H.L. Infection characteristics among Serratia marcescens capsule lineages. Mbio. 2025;16:e00559-25. doi: 10.1128/mbio.00559-25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Abreo E., Altier N. Pangenome of Serratia marcescens strains from nosocomial and environmental origins reveals different populations and the links between them. Sci. Rep. 2019;9:46. doi: 10.1038/s41598-018-37118-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Nuncio-García L.A., Sánchez-Pérez M., Andrade A., Dávila-Barboza J.A., Tavares-Carreón F. Complete genome sequence of Serratia marcescens strain CH31 isolated from a Periplaneta americana associated with a tertiary hospital setting. Microbiol. Resour. Announc. 2025;14:e00611-25. doi: 10.1128/mra.00611-25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Iguchi A., Nagaya Y., Pradel E., Ooka T., Ogura Y., Katsura K., Kurokawa K., Oshima K., Hattori M., Parkhill J. Genome evolution and plasticity of Serratia marcescens, an important multidrug-resistant nosocomial pathogen. Genome Biol. Evol. 2014;6:2096–2110. doi: 10.1093/gbe/evu160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Ramdass A.C., Rampersad S.N. Genome-resolved analysis of Serratia marcescens strain SMTT infers niche specialization as a hydrocarbon-degrader. DNA Res. 2025;32:dsaf001. doi: 10.1093/dnares/dsaf001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Zhu W., Chen X., Shen H., Wei M., Yang C., Gu L. Genomic diversity, antimicrobial resistance and dissemination of Serratia marcescens complex in patients admitted to ICUs. Front. Cell. Infect. Microbiol. 2025;15:1672468. doi: 10.3389/fcimb.2025.1672468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Dewar A.E., Hao C., Belcher L.J., Ghoul M., West S.A. Bacterial lifestyle shapes pangenomes. Proc. Natl. Acad. Sci. USA. 2024;121:e2320170121. doi: 10.1073/pnas.2320170121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Komorowski A.S., Surette M.G., Rossi L., Tertigas D., Gaskin M., Shekarriz S., McArthur A.G., Smieja M., Mertz D. Molecular Epidemiology of Clinical Infections Caused by Serratia marcescens Complex in a Tertiary Care Hospital System: Insights From Whole-Genome Sequencing. J. Infect. Dis. 2025;232:e589–e600. doi: 10.1093/infdis/jiaf392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Singh P., Pandey A. Community-acquired lower respiratory tract infection due to Serratia rubidaea: A rare and opportunistic pathogen. MRIMS J. Health Sci. 2025;13:35–38. doi: 10.4103/mjhs.mjhs_61_24. [DOI] [Google Scholar]
  • 82.Hurst M.R., O’Callaghan M., Glare T.R., Jackson T.A. Serratia spp. bacteria evolved in Aotearoa-New Zealand for infection of endemic scarab beetles. N. Z. J. Zool. 2025;52:121–143. doi: 10.1080/03014223.2023.2243225. [DOI] [Google Scholar]
  • 83.Lucchi G., Gibiino G., Binda C., Sbrancia M., Coluccio C., Gatti G., Taddei F., Sambri V., Fabbri C., Cricca M. First Italian case of Serratia ficaria infection in a woman with obstructive pancreatitis and review of the literature. Access Microbiol. 2024 doi: 10.1099/acmi.0.000789.v1.3. [DOI] [Google Scholar]
  • 84.Dalamaga M., Pantelaki M., Karmaniolas K., Matekovits A., Daskalopoulou K. Cutaneous abscess and bacteremia due to Serratia ficaria. J. Eur. Acad. Dermatol. Venereol. 2008;22:1388–1389. doi: 10.1111/j.1468-3083.2008.02652.x. [DOI] [PubMed] [Google Scholar]
  • 85.Badenoch P.R., Thom A.L., Coster D.J. Serratia ficaria endophthalmitis. J. Clin. Microbiol. 2002;40:1563–1564. doi: 10.1128/JCM.40.4.1563-1564.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Hashemi L. A case of subhepatic abscess with Serratia ficaria after emergent laparoscopic cholecystectomy. Proc. UCLA Health. 2016;20 [Google Scholar]
  • 87.Sánchez-Pérez M., Andrade A., Flores-Maldonado O., de Anda-Mora K., García-Contreras R., Maeda T., Becerril-García M.A., Tavares-Carreón F. Genomic insights into pigmented Serratia marcescens strains isolated from patients in northeast Mexico. Microb. Pathog. 2025;203:107456. doi: 10.1016/j.micpath.2025.107456. [DOI] [PubMed] [Google Scholar]
  • 88.Van Houdt R., Givskov M., Michiels C.W. Quorum sensing in Serratia. FEMS Microbiol. Rev. 2007;31:407–424. doi: 10.1111/j.1574-6976.2007.00071.x. [DOI] [PubMed] [Google Scholar]
  • 89.Pang Y., Liu X., Ma Y., Chernin L., Berg G., Gao K. Induction of systemic resistance, root colonisation and biocontrol activities of the rhizospheric strain of Serratia plymuthica are dependent on N-acyl homoserine lactones. Eur. J. Plant Pathol. 2009;124:261–268. doi: 10.1007/s10658-008-9411-1. [DOI] [Google Scholar]
  • 90.Sharma J., Sundar D., Srivastava P. Biosurfactants: Potential agents for controlling cellular communication, motility, and antagonism. Front. Mol. Biosci. 2021;8:727070. doi: 10.3389/fmolb.2021.727070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Sandner-Miranda L., Vinuesa P., Cravioto A., Morales-Espinosa R. The genomic basis of intrinsic and acquired antibiotic resistance in the genus Serratia. Front. Microbiol. 2018;9:828. doi: 10.3389/fmicb.2018.00828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Mahlen S.D. Serratia infections: From military experiments to current practice. Clin. Microbiol. Rev. 2011;24:755–791. doi: 10.1128/CMR.00017-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Bertrand X., Dowzicky M.J. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin. Ther. 2012;34:124–137. doi: 10.1016/j.clinthera.2011.11.023. [DOI] [PubMed] [Google Scholar]
  • 94.Morillo Á., González V., Aguayo J., Carreño C., Torres M.J., Jarana D., Artacho M.J., Jiménez F., Conde M., Aznar J. A six-month Serratia marcescens outbreak in a neonatal intensive care unit. Enfermedades Infecc. Microbiol. Clin. 2016;34:645–651. doi: 10.1016/j.eimc.2016.01.006. [DOI] [PubMed] [Google Scholar]
  • 95.Dawczynski K., Proquitté H., Roedel J., Edel B., Pfeifer Y., Hoyer H., Dobermann H., Hagel S., Pletz M.W. Intensified colonisation screening according to the recommendations of the German Commission for Hospital Hygiene and Infectious Diseases Prevention (KRINKO): Identification and containment of a Serratia marcescens outbreak in the neonatal intensive care unit, Jena, Germany, 2013–2014. Infection. 2016;44:739–746. doi: 10.1007/s15010-016-0922-y. [DOI] [PubMed] [Google Scholar]
  • 96.Merkier A.K., Rodríguez M.C., Togneri A., Brengi S., Osuna C., Pichel M., Cassini M.H., Group S.M.A.C., Centrón D. Outbreak of a cluster with epidemic behavior due to Serratia marcescens after colistin administration in a hospital setting. J. Clin. Microbiol. 2013;51:2295–2302. doi: 10.1128/JCM.03280-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Hervé B., Chomali M., Gutiérrez C., Luna M., Rivas J., Blamey R., Espinoza R., Cabezas C., Alvarez C., de la Fuente S. Brote de infección nosocomial por Serratia marcescens asociado a contaminación intrínseca de clorhexidina acuosa. Rev. Chil. Infectol. 2015;32:517–522. doi: 10.4067/S0716-10182015000600004. [DOI] [PubMed] [Google Scholar]
  • 98.Gonzalez-Montalvo M.A., Tavares-Carreon F., González G.M., Villanueva-Lozano H., Garcia-Romero I., Zomosa-Signoret V.C., Valvano M.A., Andrade A. Defining chaperone-usher fimbriae repertoire in Serratia marcescens. Microb. Pathog. 2021;154:104857. doi: 10.1016/j.micpath.2021.104857. [DOI] [PubMed] [Google Scholar]
  • 99.Campos V., Moraga R., Fernández Í., Yáñez F., Valenzuela A., Mondaca M.-A. Reducción de cromo hexavalente, por Serratia marcecens inmobilizada en carbon activado y su potencial uso en biorremediacion. Gayana (Concepción) 2013;77:61–63. doi: 10.4067/S0717-65382013000100008. [DOI] [Google Scholar]
  • 100.Behzadi P. Classical chaperone-usher (CU) adhesive fimbriome: Uropathogenic Escherichia coli (UPEC) and urinary tract infections (UTIs) Folia Microbiol. 2020;65:45–65. doi: 10.1007/s12223-019-00719-x. [DOI] [PubMed] [Google Scholar]
  • 101.Bhoite S., Van Gerven N., Chapman M.R., Remaut H. Curli biogenesis: Bacterial amyloid assembly by the type VIII secretion pathway. EcoSal Plus. 2019;8:10.1128/ecosalplus.ESP-0037-2018. doi: 10.1128/ecosalplus.esp-0037-2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Behzadi P., Behzadi E. The microbial agents of urinary tract infections at central laboratory of Dr. Shariati Hospital, Tehran, Iran. Turk. Klin. Tip. Bilim. 2008;28:445. [Google Scholar]
  • 103.Sarshar M., Behzadi P., Ambrosi C., Zagaglia C., Palamara A.T., Scribano D. FimH and anti-adhesive therapeutics: A disarming strategy against uropathogens. Antibiotics. 2020;9:397. doi: 10.3390/antibiotics9070397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Khonsari M.S., Behzadi P., Foroohi F. The prevalence of type 3 fimbriae in Uropathogenic Escherichia coli isolated from clinical urine samples. Meta Gene. 2021;28:100881. doi: 10.1016/j.mgene.2021.100881. [DOI] [Google Scholar]
  • 105.Behzadi P., García-Perdomo H.A., Autrán Gómez A.M., Pinheiro M., Sarshar M. Uropathogens, urinary tract infections, the host-pathogen interactions and treatment. Front. Microbiol. 2023;14:1183236. doi: 10.3389/fmicb.2023.1183236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Jahandeh N., Ranjbar R., Behzadi P., Behzadi E. Uropathogenic Escherichia coli virulence genes: Invaluable approaches for designing DNA microarray probes. Cent. Eur. J. Urol. 2015;68:452. doi: 10.5173/ceju.2015.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Behzadi P., Urbán E., Matuz M., Benkő R., Gajdács M. The role of gram-negative bacteria in urinary tract infections: Current concepts and therapeutic options. Adv. Microbiol. Infect. Dis. Public Health. 2020;15:35–69. doi: 10.1007/5584_2020_566. [DOI] [PubMed] [Google Scholar]
  • 108.Behzadi P., Behzadi E. Uropathogenic Escherichia coli: An ideal resource for DNA microarray probe designing; Proceedings of the International Conference on Bioinformatics and Biomedical Engineering; Granada, Spain. 26–28 April 2017; pp. 12–19. [Google Scholar]
  • 109.Kalivoda E.J., Stella N.A., O'Dee D.M., Nau G.J., Shanks R.M. The cyclic AMP-dependent catabolite repression system of Serratia marcescens mediates biofilm formation through regulation of type 1 fimbriae. Appl. Environ. Microbiol. 2008;74:3461–3470. doi: 10.1128/AEM.02733-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Liu C., Sun D., Zhu J., Liu J., Liu W. The regulation of bacterial biofilm formation by cAMP-CRP: A mini-review. Front. Microbiol. 2020;11:802. doi: 10.3389/fmicb.2020.00802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Labbate M., Zhu H., Thung L., Bandara R., Larsen M.R., Willcox M.D., Givskov M., Rice S.A., Kjelleberg S. Quorum-sensing regulation of adhesion in Serratia marcescens MG1 is surface dependent. J. Bacteriol. 2007;189:2702–2711. doi: 10.1128/JB.01582-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Shanks R.M., Stella N.A., Kalivoda E.J., Doe M.R., O'Dee D.M., Lathrop K.L., Guo F.L., Nau G.J. A Serratia marcescens OxyR homolog mediates surface attachment and biofilm formation. J. Bacteriol. 2007;189:7262–7272. doi: 10.1128/JB.00859-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu. Rev. Biochem. 2006;75:39–68. doi: 10.1146/annurev.biochem.75.103004.142545. [DOI] [PubMed] [Google Scholar]
  • 114.Anderson M.T., Mitchell L.A., Zhao L., Mobley H.L. Capsule production and glucose metabolism dictate fitness during Serratia marcescens bacteremia. MBio. 2017;8:e00740-17. doi: 10.1128/mBio.00740-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Aucken H.M., Wilkinson S.G., Pitt T.L. Re-evaluation of the serotypes of Serratia marcescens and separation into two schemes based on lipopolysaccharide (O) and capsular polysaccharide (K) antigens. Microbiology. 1998;144:639–653. doi: 10.1099/00221287-144-3-639. [DOI] [PubMed] [Google Scholar]
  • 116.Aucken H.M., Wilkinson S.G., Pitt T.L. Identification of capsular antigens in Serratia marcescens. J. Clin. Microbiol. 1997;35:59–63. doi: 10.1128/jcm.35.1.59-63.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Weakland D.R., Smith S.N., Bell B., Tripathi A., Mobley H.L. The Serratia marcescens siderophore serratiochelin is necessary for full virulence during bloodstream infection. Infect. Immun. 2020;88:e00117-20. doi: 10.1128/IAI.00117-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Rahn A., Beis K., Naismith J.H., Whitfield C. A novel outer membrane protein, Wzi, is involved in surface assembly of the Escherichia coli K30 group 1 capsule. J. Bacteriol. 2003;185:5882–5890. doi: 10.1128/JB.185.19.5882-5890.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Bushell S.R., Mainprize I.L., Wear M.A., Lou H., Whitfield C., Naismith J.H. Wzi is an outer membrane lectin that underpins group 1 capsule assembly in Escherichia coli. Structure. 2013;21:844–853. doi: 10.1016/j.str.2013.03.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Anderson M.T., Himpsl S.D., Mitchell L.A., Kingsley L.G., Snider E.P., Mobley H.L. Identification of distinct capsule types associated with Serratia marcescens infection isolates. PLoS Pathog. 2022;18:e1010423. doi: 10.1371/journal.ppat.1010423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Sun J., Rutherford S.T., Silhavy T.J., Huang K.C. Physical properties of the bacterial outer membrane. Nat. Rev. Microbiol. 2022;20:236–248. doi: 10.1038/s41579-021-00638-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Silhavy T.J., Kahne D., Walker S. The bacterial cell envelope. Cold Spring Harb. Perspect. Biol. 2010;2:a000414. doi: 10.1101/cshperspect.a000414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Cho S.H., Szewczyk J., Pesavento C., Zietek M., Banzhaf M., Roszczenko P., Asmar A., Laloux G., Hov A.K., Leverrier P., et al. Detecting envelope stress by monitoring β-barrel assembly. Cell. 2014;159:1652–1664. doi: 10.1016/j.cell.2014.11.045. [DOI] [PubMed] [Google Scholar]
  • 124.Konovalova A., Perlman D.H., Cowles C.E., Silhavy T.J. Transmembrane domain of surface-exposed outer membrane lipoprotein RcsF is threaded through the lumen of β-barrel proteins. Proc. Natl. Acad. Sci. USA. 2014;111:E4350–E4358. doi: 10.1073/pnas.1417138111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Belas R. Biofilms, flagella, and mechanosensing of surfaces by bacteria. Trends Microbiol. 2014;22:517–527. doi: 10.1016/j.tim.2014.05.002. [DOI] [PubMed] [Google Scholar]
  • 126.Konovalova A., Mitchell A.M., Silhavy T.J. A lipoprotein/β-barrel complex monitors lipopolysaccharide integrity transducing information across the outer membrane. elife. 2016;5:e15276. doi: 10.7554/eLife.15276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Kaparakis-Liaskos M., Ferrero R.L. Immune modulation by bacterial outer membrane vesicles. Nat. Rev. Immunol. 2015;15:375–387. doi: 10.1038/nri3837. [DOI] [PubMed] [Google Scholar]
  • 128.Kuehn M.J., Kesty N.C. Bacterial outer membrane vesicles and the host–pathogen interaction. Genes. Dev. 2005;19:2645–2655. doi: 10.1101/gad.1299905. [DOI] [PubMed] [Google Scholar]
  • 129.Rana D.S., Sharma V., Sheerswal A. Understanding host-pathogen interactions in urinary tract infections and advancements in diagnostic methods. Urol. Sci. 2025;36:61–75. doi: 10.1097/us9.0000000000000075. [DOI] [Google Scholar]
  • 130.Behzadi P., Kim C.-H., Pawlak E.A., Algammal A. The innate and adaptive immune system in human urinary system. Front. Immunol. 2023;14:1294869. doi: 10.3389/fimmu.2023.1294869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Sarshar M., Behzadi P., Scribano D., Palamara A.T., Ambrosi C. Acinetobacter baumannii: An ancient commensal with weapons of a pathogen. Pathogens. 2021;10:387. doi: 10.3390/pathogens10040387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Giordano N.P., Cian M.B., Dalebroux Z.D. Outer membrane lipid secretion and the innate immune response to gram-negative bacteria. Infect. Immun. 2020;88:e00920-19. doi: 10.1128/IAI.00920-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Nudleman E., Wall D., Kaiser D. Cell-to-cell transfer of bacterial outer membrane lipoproteins. Science. 2005;309:125–127. doi: 10.1126/science.1112440. [DOI] [PubMed] [Google Scholar]
  • 134.Kulp A., Kuehn M.J. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu. Rev. Microbiol. 2010;64:163–184. doi: 10.1146/annurev.micro.091208.073413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Behzadi P., Ambrosi C., Scribano D., Zanetti S., Sarshar M., Gajdács M., Donadu M.G. Current perspectives on Pseudomonas aeruginosa: Epidemiology, virulence and contemporary strategies to combat multidrug-resistant (MDR) pathogens. Front. Microbiol. 2022;13:975616. doi: 10.3389/fmicb.2022.975616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Zhou G., Wang Q., Wang Y., Wen X., Peng H., Peng R., Shi Q., Xie X., Li L. Outer membrane porins contribute to antimicrobial resistance in gram-negative bacteria. Microorganisms. 2023;11:1690. doi: 10.3390/microorganisms11071690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Henderson J.C., Zimmerman S.M., Crofts A.A., Boll J.M., Kuhns L.G., Herrera C.M., Trent M.S. The power of asymmetry: Architecture and assembly of the Gram-negative outer membrane lipid bilayer. Annu. Rev. Microbiol. 2016;701:255–278. doi: 10.1146/annurev-micro-102215-095308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138.Rollauer S.E., Sooreshjani M.A., Noinaj N., Buchanan S.K. Outer membrane protein biogenesis in Gram-negative bacteria. Philos. Trans. R. Soc. B Biol. Sci. 2015;370:20150023. doi: 10.1098/rstb.2015.0023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139.Davin-Regli A., Pagès J.M., Vergalli J. The contribution of porins to enterobacterial drug resistance. J. Antimicrob. Chemother. 2024;79:2460–2470. doi: 10.1093/jac/dkae265. [DOI] [PubMed] [Google Scholar]
  • 140.Choi U., Lee C.R. Distinct roles of outer membrane porins in antibiotic resistance and membrane integrity in Escherichia coli. Front. Microbiol. 2019;10:953. doi: 10.3389/fmicb.2019.00953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.O’Shea R., Moser H.E. Physicochemical properties of antibacterial compounds: Implications for drug discovery. J. Med. Chem. 2008;51:2871–2878. doi: 10.1021/jm700967e. [DOI] [PubMed] [Google Scholar]
  • 142.Rodrigues I.C., Rodrigues S.C., Duarte F.V., Costa P.M., Costa P.M. The role of outer membrane proteins in UPEC antimicrobial resistance: A systematic review. Membranes. 2022;12:981. doi: 10.3390/membranes12100981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143.Hutsul J.-A., Worobec E. Molecular characterization of a 40 kDa OmpC-like porin from Serratia marcescens. Microbiology. 1994;140:379–387. doi: 10.1099/13500872-140-2-379. [DOI] [PubMed] [Google Scholar]
  • 144.Diamandas A. Serratia marcescens: Outer Membrane Porins and Comparative Genomics. The University of Manitoba; Winnipeg, MB, Canada: 2019. [Google Scholar]
  • 145.Vergalli J., Bodrenko I.V., Masi M., Moynié L., Acosta-Gutiérrez S., Naismith J.H., Davin-Regli A., Ceccarelli M., van Den Berg B., Winterhalter M., et al. Porins and small-molecule translocation across the outer membrane of Gram-negative bacteria. Nat. Rev. Microbiol. 2020;18:164–176. doi: 10.1038/s41579-019-0294-2. [DOI] [PubMed] [Google Scholar]
  • 146.Darby E.M., Trampari E., Siasat P., Gaya M.S., Alav I., Webber M.A., Blair J.M. Molecular mechanisms of antibiotic resistance revisited. Nat. Rev. Microbiol. 2023;21:280–295. doi: 10.1038/s41579-022-00820-y. [DOI] [PubMed] [Google Scholar]
  • 147.Ferrand A., Vergalli J., Pagès J.M., Davin-Regli A. An intertwined network of regulation controls membrane permeability including drug influx and efflux in Enterobacteriaceae. Microorganisms. 2020;8:833. doi: 10.3390/microorganisms8060833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.Chekabab S.M., Harel J., Dozois C.M. Interplay between genetic regulation of phosphate homeostasis and bacterial virulence. Virulence. 2014;5:786–793. doi: 10.4161/viru.29307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149.Begic S., Worobec E.A. Regulation of Serratia marcescens ompF and ompC porin genes in response to osmotic stress, salicylate, temperature and pH. Microbiology. 2006;152:485–491. doi: 10.1099/mic.0.28428-0. [DOI] [PubMed] [Google Scholar]
  • 150.Benz R., Schmid A., Hancock R. Ion selectivity of gram-negative bacterial porins. J. Bacteriol. 1985;162:722–727. doi: 10.1128/jb.162.2.722-727.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 151.Hagge S.O., De Cock H., Gutsmann T., Beckers F., Seydel U., Wiese A. Pore formation and function of phosphoporin PhoE of Escherichia coli are determined by the core sugar moiety of lipopolysaccharide. J. Biol. Chem. 2002;277:34247–34253. doi: 10.1074/jbc.M201950200. [DOI] [PubMed] [Google Scholar]
  • 152.van den Berg B. Structural basis for outer membrane sugar uptake in pseudomonads. J. Biol. Chem. 2012;287:41044–41052. doi: 10.1074/jbc.M112.408518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153.Van Gelder P., Dumas F., Bartoldus I., Saint N., Prilipov A., Winterhalter M., Wang Y., Philippsen A., Rosenbusch J.R.P., Schirmer T. Sugar transport through maltoporin of Escherichia coli: Role of the greasy slide. J. Bacteriol. 2002;184:2994–2999. doi: 10.1128/JB.184.11.2994-2999.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154.Manrique P.D., López C.A., Gnanakaran S., Rybenkov V.V., Zgurskaya H.I. New understanding of multidrug efflux and permeation in antibiotic resistance, persistence, and heteroresistance. Ann. N. Y. Acad. Sci. 2023;1519:46–62. doi: 10.1111/nyas.14921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155.Acosta-Gutiérrez S., Ferrara L., Pathania M., Masi M., Wang J., Bodrenko I., Zahn M., Winterhalter M., Stavenger R.A., Pagès J.M., et al. Getting drugs into Gram-negative bacteria: Rational rules for permeation through general porins. ACS Infect. Dis. 2018;4:1487–1498. doi: 10.1021/acsinfecdis.8b00108. [DOI] [PubMed] [Google Scholar]
  • 156.Delcour A.H. Outer membrane permeability and antibiotic resistance. Biochim. Biophys. Acta (BBA)—Proteins Proteom. 2009;1794:808–816. doi: 10.1016/j.bbapap.2008.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157.Nikaido H., Rosenberg E., Foulds J. Porin channels in Escherichia coli: Studies with beta-lactams in intact cells. J. Bacteriol. 1983;153:232–240. doi: 10.1128/jb.153.1.232-240.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158.Lou H., Chen M., Black S.S., Bushell S.R., Ceccarelli M., Mach T., Beis K., Low A.S., Bamford V.A., Booth I.R. Altered antibiotic transport in OmpC mutants isolated from a series of clinical strains of multi-drug resistant E. coli. PLoS ONE. 2011;6:e25825. doi: 10.1371/journal.pone.0025825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.Kojima S., Nikaido H. High salt concentrations increase permeability through OmpC channels of Escherichia coli. J. Biol. Chem. 2014;289:26464–26473. doi: 10.1074/jbc.M114.585869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160.Sato M., Machida K., Arikado E., Saito H., Kakegawa T., Kobayashi H. Expression of outer membrane proteins in Escherichia coli growing at acid pH. Appl. Environ. Microbiol. 2000;66:943–947. doi: 10.1128/AEM.66.3.943-947.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 161.Li X.-Z., Plésiat P., Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 2015;28:337–418. doi: 10.1128/CMR.00117-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 162.Samsudin F., Ortiz-Suarez M.L., Piggot T.J., Bond P.J., Khalid S. OmpA: A flexible clamp for bacterial cell wall attachment. Structure. 2016;24:2227–2235. doi: 10.1016/j.str.2016.10.009. [DOI] [PubMed] [Google Scholar]
  • 163.Pratt L.A., Hsing W., Gibson K.E., Silhavy T.J. From acids to osmZ: Multiple factors influence synthesis of the OmpF and OmpC porins in Escherichia coli. Mol. Microbiol. 1996;20:911–917. doi: 10.1111/j.1365-2958.1996.tb02532.x. [DOI] [PubMed] [Google Scholar]
  • 164.Kaeriyama M., Machida K., Kitakaze A., Wang H., Lao Q., Fukamachi T., Saito H., Kobayashi H. OmpC and OmpF are required for growth under hyperosmotic stress above pH 8 in Escherichia coli. Lett. Appl. Microbiol. 2006;42:195–201. doi: 10.1111/j.1472-765X.2006.01845.x. [DOI] [PubMed] [Google Scholar]
  • 165.Wang Y., Wang L., Sun Y., Chen Y., Zhu L., Guo L., Luo B., Wang H. Disrupted OmpC causes osmosis sensitivity of Escherichia coli in alkaline medium. J. Genet. Genom. 2007;34:1131–1138. doi: 10.1016/S1673-8527(07)60129-5. [DOI] [PubMed] [Google Scholar]
  • 166.Chong Z.S., Woo W.F., Chng S.S. Osmoporin OmpC forms a complex with MlaA to maintain outer membrane lipid asymmetry in Escherichia coli. Mol. Microbiol. 2015;98:1133–1146. doi: 10.1111/mmi.13202. [DOI] [PubMed] [Google Scholar]
  • 167.Choi U., Lee C.-R. Antimicrobial agents that inhibit the outer membrane assembly machines of gram-negative bacteria. J. Microbiol. Biotechnol. 2019;29:1–10. doi: 10.4014/jmb.1804.03051. [DOI] [PubMed] [Google Scholar]
  • 168.Sutterlin H.A., Shi H., May K.L., Miguel A., Khare S., Huang K.C., Silhavy T.J. Disruption of lipid homeostasis in the Gram-negative cell envelope activates a novel cell death pathway. Proc. Natl. Acad. Sci. USA. 2016;113:E1565–E1574. doi: 10.1073/pnas.1601375113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169.Mecsas J., Welch R., Erickson J.W., Gross C.A. Identification and characterization of an outer membrane protein, OmpX, in Escherichia coli that is homologous to a family of outer membrane proteins including Ail of Yersinia enterocolitica. J. Bacteriol. 1995;177:799–804. doi: 10.1128/jb.177.3.799-804.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170.Tuttobene M.R., Bruna R.E., Molino M.V., García Véscovi E. PrtA-mediated flagellar turnover is essential for robust biofilm development in Serratia marcescens. Appl. Environ. Microbiol. 2025;91:e01261-25. doi: 10.1128/aem.01261-25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 171.Guasch J.F., Ferrer S., Enfedaque J., Viejo M.B., Regue M. A 17 kDa outer-membrane protein (Omp4) from Serratia marcescens confers partial resistance to bacteriocin 28b when expressed in Escherichia coli. Microbiology. 1995;141:2535–2542. doi: 10.1099/13500872-141-10-2535. [DOI] [PubMed] [Google Scholar]
  • 172.Hong H., Patel D.R., Tamm L.K., van den Berg B. The outer membrane protein OmpW forms an eight-stranded β-barrel with a hydrophobic channel. J. Biol. Chem. 2006;281:7568–7577. doi: 10.1074/jbc.M512365200. [DOI] [PubMed] [Google Scholar]
  • 173.Albrecht R., Zeth K., Söding J., Lupas A., Linke D. Expression, crystallization and preliminary X-ray crystallographic studies of the outer membrane protein OmpW from Escherichia coli. Struct. Biol. Cryst. Commun. 2006;62:415–418. doi: 10.1107/S1744309106010190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174.McClean S. Eight stranded β-barrel and related outer membrane proteins: Role in bacterial pathogenesis. Protein Pept. Lett. 2012;19:1013–1025. doi: 10.2174/092986612802762688. [DOI] [PubMed] [Google Scholar]
  • 175.Singh R., Shasany A., Aggarwal A., Sinha S., Sisodia B., Khanuja S., Misra R. Low molecular weight proteins of outer membrane of Salmonella typhimurium are immunogenic in Salmonella induced reactive arthritis revealed by proteomics. Clin. Exp. Immunol. 2007;148:486–493. doi: 10.1111/j.1365-2249.2007.03362.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176.Nandi B., Nandy R.K., Sarkar A., Ghose A.C. Structural features, properties and regulation of the outer-membrane protein W (OmpW) of Vibrio cholerae. Microbiology. 2005;151:2975–2986. doi: 10.1099/mic.0.27995-0. [DOI] [PubMed] [Google Scholar]
  • 177.Touw D.S., Patel D.R., van den Berg B. The crystal structure of OprG from Pseudomonas aeruginosa, a potential channel for transport of hydrophobic molecules across the outer membrane. PLoS ONE. 2010;5:e15016. doi: 10.1371/journal.pone.0015016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 178.Ashorn S., Raukola H., Välineva T., Ashorn M., Wei B., Braun J., Rantala I., Kaukinen K., Luukkaala T., Collin P. Elevated serum anti-Saccharomyces cerevisiae, anti-I2 and anti-OmpW antibody levels in patients with suspicion of celiac disease. J. Clin. Immunol. 2008;28:486–494. doi: 10.1007/s10875-008-9200-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 179.Ashorn S., Välineva T., Kaukinen K., Ashorn M., Braun J., Raukola H., Rantala I., Collin P., Mäki M., Luukkaala T. Serological responses to microbial antigens in celiac disease patients during a gluten-free diet. J. Clin. Immunol. 2009;29:190–195. doi: 10.1007/s10875-008-9255-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 180.Iltanen S., Tervo L., Halttunen T., Wei B., Braun J., Rantala I., Honkanen T., Kronenberg M., Cheroutre H., Turovskaya O. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm. Bowel Dis. 2006;12:389–394. doi: 10.1097/01.MIB.0000218765.84087.42. [DOI] [PubMed] [Google Scholar]
  • 181.Wei B., Dalwadi H., Gordon L.K., Landers C., Bruckner D., Targan S.R., Braun J. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect. Immun. 2001;69:6044–6054. doi: 10.1128/IAI.69.10.6044-6054.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182.Behzadi P., Behzadi E., Ranjbar R. The incidence and prevalence of Crohn’s disease in global scale. SOJ Immunol. 2015;3:1–6. doi: 10.15226/soji/3/2/00125. [DOI] [Google Scholar]
  • 183.Dodero V.I., Morré S.A., Behzadi P. Gut microbiota and immunity in health and disease: Dysbiosis and eubiosis’s effects on the human body. Front. Immunol. 2024;15:1536258. doi: 10.3389/fimmu.2024.1536258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184.Behzadi P., Dodero V.I., Golubnitschaja O. All Around Suboptimal Health: Advanced Approaches by Predictive, Preventive and Personalised Medicine for Healthy Populations. Springer; Berlin/Heidelberg, Germany: 2024. Systemic inflammation as the health-related communication tool between the human host and gut microbiota in the framework of predictive, preventive, and personalized medicine; pp. 203–241. [Google Scholar]
  • 185.Behzadi P., García-Perdomo H.A., Karpiński T.M. Toll-like receptors: General molecular and structural biology. J. Immunol. Res. 2021;2021:9914854. doi: 10.1155/2021/9914854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 186.Mukherjee S., Patra R., Behzadi P., Masotti A., Paolini A., Sarshar M. Toll-like receptor-guided therapeutic intervention of human cancers: Molecular and immunological perspectives. Front. Immunol. 2023;14:1244345. doi: 10.3389/fimmu.2023.1244345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 187.Behzadi P., Behzadi E., Ranjbar R. IL-12 family cytokines: General characteristics, pathogenic microorganisms, receptors, and signalling pathways. Acta Microbiol. Immunol. Hung. 2016;63:1–25. doi: 10.1556/030.63.2016.1.1. [DOI] [PubMed] [Google Scholar]
  • 188.Behzadi P., Sameer A.S., Nissar S., Banday M.Z., Gajdács M., García-Perdomo H.A., Akhtar K., Pinheiro M., Magnusson P., Sarshar M. The Interleukin-1 (IL-1) superfamily cytokines and their single nucleotide polymorphisms (SNPs) J. Immunol. Res. 2022;2022:2054431. doi: 10.1155/2022/2054431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 189.Chen L., Zhang L., Hua H., Liu L., Mao Y., Wang R. Interactions between toll-like receptors signaling pathway and gut microbiota in host homeostasis. Immun. Inflamm. Dis. 2024;12:e1356. doi: 10.1002/iid3.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 190.Behzadi P., Chandran D., Chakraborty C., Bhattacharya M., Saikumar G., Dhama K., Chakraborty A., Mukherjee S., Sarshar M. The dual role of toll-like receptors in COVID-19: Balancing protective immunity and Immunopathogenesis. Int. J. Biol. Macromol. 2024;284:137836. doi: 10.1016/j.ijbiomac.2024.137836. [DOI] [PubMed] [Google Scholar]
  • 191.Tursi A., Elisei W., Picchio M. Incidence and prevalence of inflammatory bowel diseases in gastroenterology primary care setting. Eur. J. Intern. Med. 2013;24:852–856. doi: 10.1016/j.ejim.2013.06.005. [DOI] [PubMed] [Google Scholar]
  • 192.Xiao M., Lai Y., Sun J., Chen G., Yan A. Transcriptional regulation of the outer membrane porin gene ompW reveals its physiological role during the transition from the aerobic to the anaerobic lifestyle of Escherichia coli. Front. Microbiol. 2016;7:799. doi: 10.3389/fmicb.2016.00799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 193.Silk E., Harding K., Mahler M., Fineran P.C., Meaden S. Abiotic environmental conditions determine phage resistance outcomes in a salt-marsh bacterium. Philos. Trans. R. Soc. B Biol. Sci. 2025;380:20240071. doi: 10.1098/rstb.2024.0071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 194.Mahler M., Malone L.M., van den Berg D.F., Smith L.M., Brouns S.J., Fineran P.C. An OmpW-dependent T4-like phage infects Serratia sp. ATCC 39006. Microb. Genom. 2023;9:000968. doi: 10.1099/mgen.0.000968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 195.Garcia Gonzalez J., Hernandez F.J. Nuclease activity: An exploitable biomarker in bacterial infections. Expert Rev. Mol. Diagn. 2022;22:265–294. doi: 10.1080/14737159.2022.2049249. [DOI] [PubMed] [Google Scholar]
  • 196.Sharma P., Garg N., Sharma A., Capalash N., Singh R. Nucleases of bacterial pathogens as virulence factors, therapeutic targets and diagnostic markers. Int. J. Med. Microbiol. 2019;309:151354. doi: 10.1016/j.ijmm.2019.151354. [DOI] [PubMed] [Google Scholar]
  • 197.González G.M., Andrade A., Villanueva-Lozano H., Campos-Cortés C.L., Becerril-García M.A., Montoya A.M., Sánchez-González A., Bonifaz A., Franco-Cendejas R., López-Jácome L.E. Comparative analysis of virulence profiles of Serratia marcescens isolated from diverse clinical origins in Mexican patients. Surg. Infect. 2020;21:608–612. doi: 10.1089/sur.2020.029. [DOI] [PubMed] [Google Scholar]
  • 198.Marty K.B., Williams C.L., Guynn L.J., Benedik M.J., Blanke S.R. Characterization of a cytotoxic factor in culture filtrates of Serratia marcescens. Infect. Immun. 2002;70:1121–1128. doi: 10.1128/IAI.70.3.1121-1128.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 199.Matsumoto K. Role of bacterial proteases in pseudomonal and serratial keratitis. Biol. Chem. 2004;385:1007. doi: 10.1515/BC.2004.131. [DOI] [PubMed] [Google Scholar]
  • 200.Kida Y., Inoue H., Shimizu T., Kuwano K. Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2. Infect. Immun. 2007;75:164–174. doi: 10.1128/IAI.01239-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 201.Hertle R. The family of Serratia type pore forming toxins. Curr. Protein Pept. Sci. 2005;6:313–325. doi: 10.2174/1389203054546370. [DOI] [PubMed] [Google Scholar]
  • 202.Hertle R., Schwarz H. Serratia marcescens internalization and replication in human bladder epithelial cells. BMC Infect. Dis. 2004;4:16. doi: 10.1186/1471-2334-4-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 203.Lin C.-S., Horng J.-T., Yang C.-H., Tsai Y.-H., Su L.-H., Wei C.-F., Chen C.-C., Hsieh S.-C., Lu C.-C., Lai H.-C. RssAB-FlhDC-ShlBA as a major pathogenesis pathway in Serratia marcescens. Infect. Immun. 2010;78:4870–4881. doi: 10.1128/IAI.00661-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 204.González-Juarbe N., Mares C.A., Hinojosa C.A., Medina J.L., Cantwell A., Dube P.H., Orihuela C.J., Bergman M.A. Requirement for Serratia marcescens cytolysin in a murine model of hemorrhagic pneumonia. Infect. Immun. 2015;83:614–624. doi: 10.1128/IAI.01822-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 205.Lin J., Yu Y., Zhao K., Zhao J., Rensing C., Chen J., Jia X. PtrA regulates prodigiosin synthesis and biological functions in Serratia marcescens FZSF02. Front. Microbiol. 2023;14:1240102. doi: 10.3389/fmicb.2023.1240102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 206.Pramanik A., Könninger U., Selvam A., Braun V. Secretion and activation of the Serratia marcescens hemolysin by structurally defined ShlB mutants. Int. J. Med. Microbiol. 2014;304:351–359. doi: 10.1016/j.ijmm.2013.11.021. [DOI] [PubMed] [Google Scholar]
  • 207.Koyun M.T., Sirin S., Aslim B., Taner G., Dolanbay S.N. Characterization of prodigiosin pigment by Serratia marcescens and the evaluation of its bioactivities. Toxicol. In Vitro. 2022;82:105368. doi: 10.1016/j.tiv.2022.105368. [DOI] [PubMed] [Google Scholar]
  • 208.Yip C.-H., Yarkoni O., Ajioka J., Wan K.-L., Nathan S. Recent advancements in high-level synthesis of the promising clinical drug, prodigiosin. Appl. Microbiol. Biotechnol. 2019;103:1667–1680. doi: 10.1007/s00253-018-09611-z. [DOI] [PubMed] [Google Scholar]
  • 209.Darshan N., Manonmani H. Prodigiosin and its potential applications. J. Food Sci. Technol. 2015;52:5393–5407. doi: 10.1007/s13197-015-1740-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 210.Islan G.A., Rodenak-Kladniew B., Noacco N., Duran N., Castro G.R. Prodigiosin: A promising biomolecule with many potential biomedical applications. Bioengineered. 2022;13:14227–14258. doi: 10.1080/21655979.2022.2084498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 211.Balasubramaniam B., Alexpandi R., Darjily D.R. Exploration of the optimized parameters for bioactive prodigiosin mass production and its biomedical applications in vitro as well as in silico. Biocatal. Agric. Biotechnol. 2019;22:101385. doi: 10.1016/j.bcab.2019.101385. [DOI] [Google Scholar]
  • 212.Jia X., Liu F., Zhao K., Lin J., Fang Y., Cai S., Lin C., Zhang H., Chen L., Chen J. Identification of essential genes associated with prodigiosin production in Serratia marcescens FZSF02. Front. Microbiol. 2021;12:705853. doi: 10.3389/fmicb.2021.705853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 213.Williamson N.R., Fineran P.C., Leeper F.J., Salmond G.P. The biosynthesis and regulation of bacterial prodiginines. Nat. Rev. Microbiol. 2006;4:887–899. doi: 10.1038/nrmicro1531. [DOI] [PubMed] [Google Scholar]
  • 214.Horng Y.T., Deng S.C., Daykin M., Soo P.C., Wei J.R., Luh K.T., Ho S.W., Swift S., Lai H.C., Williams P. The LuxR family protein SpnR functions as a negative regulator of N-acylhomoserine lactone-dependent quorum sensing in Serratia marcescens. Mol. Microbiol. 2002;45:1655–1671. doi: 10.1046/j.1365-2958.2002.03117.x. [DOI] [PubMed] [Google Scholar]
  • 215.Stella N.A., Lahr R.M., Brothers K.M., Kalivoda E.J., Hunt K.M., Kwak D.H., Liu X., Shanks R.M. Serratia marcescens cyclic AMP receptor protein controls transcription of EepR, a novel regulator of antimicrobial secondary metabolites. J. Bacteriol. 2015;197:2468–2478. doi: 10.1128/JB.00136-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 216.Fineran P.C., Slater H., Everson L., Hughes K., Salmond G.P. Biosynthesis of tripyrrole and β-lactam secondary metabolites in Serratia: Integration of quorum sensing with multiple new regulatory components in the control of prodigiosin and carbapenem antibiotic production. Mol. Microbiol. 2005;56:1495–1517. doi: 10.1111/j.1365-2958.2005.04660.x. [DOI] [PubMed] [Google Scholar]
  • 217.Gristwood T., Fineran P.C., Everson L., Williamson N.R., Salmond G.P. The PhoBR two-component system regulates antibiotic biosynthesis in Serratia in response to phosphate. BMC Microbiol. 2009;9:112. doi: 10.1186/1471-2180-9-112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 218.Fineran P.C., Everson L., Slater H., Salmond G.P. A GntR family transcriptional regulator (PigT) controls gluconate-mediated repression and defines a new, independent pathway for regulation of the tripyrrole antibiotic, prodigiosin, in Serratia. Microbiology. 2005;151:3833–3845. doi: 10.1099/mic.0.28251-0. [DOI] [PubMed] [Google Scholar]
  • 219.Gristwood T., McNeil M.B., Clulow J.S., Salmond G.P., Fineran P.C. PigS and PigP regulate prodigiosin biosynthesis in Serratia via differential control of divergent operons, which include predicted transporters of sulfur-containing molecules. J. Bacteriol. 2011;193:1076–1085. doi: 10.1128/JB.00352-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 220.Fineran P.C., Williamson N.R., Lilley K.S., Salmond G.P. Virulence and prodigiosin antibiotic biosynthesis in Serratia are regulated pleiotropically by the GGDEF/EAL domain protein, PigX. J. Bacteriol. 2007;189:7653–7662. doi: 10.1128/JB.00671-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 221.Tanikawa T., Nakagawa Y., Matsuyama T. Transcriptional downregulator hexS controlling prodigiosin and serrawettin W1 biosynthesis in Serratia marcescens. Microbiol. Immunol. 2006;50:587–596. doi: 10.1111/j.1348-0421.2006.tb03833.x. [DOI] [PubMed] [Google Scholar]
  • 222.Xu Z., Wang Y., Chater K.F., Ou H.-Y., Xu H.H., Deng Z., Tao M. Large-scale transposition mutagenesis of Streptomyces coelicolor identifies hundreds of genes influencing antibiotic biosynthesis. Appl. Environ. Microbiol. 2017;83:e02889-16. doi: 10.1128/AEM.02889-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 223.Sun Y., Wang L., Pan X., Osire T., Fang H., Zhang H., Yang S.-T., Yang T., Rao Z. Improved prodigiosin production by relieving CpxR temperature-sensitive inhibition. Front. Bioeng. Biotechnol. 2020;8:344. doi: 10.3389/fbioe.2020.00344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 224.Green E.R., Mecsas J. Bacterial secretion systems: An overview. Microbiol. Spectr. 2016;4:VMBF-0012-2015. doi: 10.1128/microbiolspec.VMBF-0012-2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 225.Natale P., Brüser T., Driessen A.J. Sec-and Tat-mediated protein secretion across the bacterial cytoplasmic membrane—Distinct translocases and mechanisms. Biochim. Biophys. Acta (BBA)—Biomembr. 2008;1778:1735–1756. doi: 10.1016/j.bbamem.2007.07.015. [DOI] [PubMed] [Google Scholar]
  • 226.Papanikou E., Karamanou S., Economou A. Bacterial protein secretion through the translocase nanomachine. Nat. Rev. Microbiol. 2007;5:839–851. doi: 10.1038/nrmicro1771. [DOI] [PubMed] [Google Scholar]
  • 227.Robinson C., Bolhuis A. Tat-dependent protein targeting in prokaryotes and chloroplasts. Biochim. Biophys. Acta (BBA)—Mol. Cell Res. 2004;1694:135–147. doi: 10.1016/j.bbamcr.2004.03.010. [DOI] [PubMed] [Google Scholar]
  • 228.Berks B.C., Palmer T., Sargent F. Protein targeting by the bacterial twin-arginine translocation (Tat) pathway. Curr. Opin. Microbiol. 2005;8:174–181. doi: 10.1016/j.mib.2005.02.010. [DOI] [PubMed] [Google Scholar]
  • 229.Sargent F., Stanley N.R., Berks B.C., Palmer T. Sec-independent protein translocation in Escherichia coli: A distinct and pivotal role for the TatB protein. J. Biol. Chem. 1999;274:36073–36082. doi: 10.1074/jbc.274.51.36073. [DOI] [PubMed] [Google Scholar]
  • 230.Pop O., Martin U., Abel C., Müller J.P. The twin-arginine signal peptide of PhoD and the TatAd/Cd proteins of Bacillus subtilis form an autonomous Tat translocation system. J. Biol. Chem. 2002;277:3268–3273. doi: 10.1074/jbc.M110829200. [DOI] [PubMed] [Google Scholar]
  • 231.Müller M. Twin-arginine-specific protein export in Escherichia coli. Res. Microbiol. 2005;156:131–136. doi: 10.1016/j.resmic.2004.09.016. [DOI] [PubMed] [Google Scholar]
  • 232.Palmer T., Berks B.C. The twin-arginine translocation (Tat) protein export pathway. Nat. Rev. Microbiol. 2012;10:483–496. doi: 10.1038/nrmicro2814. [DOI] [PubMed] [Google Scholar]
  • 233.Costa T.R., Felisberto-Rodrigues C., Meir A., Prevost M.S., Redzej A., Trokter M., Waksman G. Secretion systems in Gram-negative bacteria: Structural and mechanistic insights. Nat. Rev. Microbiol. 2015;13:343–359. doi: 10.1038/nrmicro3456. [DOI] [PubMed] [Google Scholar]
  • 234.Gerlach R.G., Hensel M. Protein secretion systems and adhesins: The molecular armory of Gram-negative pathogens. Int. J. Med. Microbiol. 2007;297:401–415. doi: 10.1016/j.ijmm.2007.03.017. [DOI] [PubMed] [Google Scholar]
  • 235.Lycklama a Nijeholt J.A., Driessen A.J. The bacterial Sec-translocase: Structure and mechanism. Philos. Trans. R. Soc. B Biol. Sci. 2012;367:1016–1028. doi: 10.1098/rstb.2011.0201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 236.Rego A.T., Chandran V., Waksman G. Two-step and one-step secretion mechanisms in Gram-negative bacteria: Contrasting the type IV secretion system and the chaperone-usher pathway of pilus biogenesis. Biochem. J. 2010;425:475–488. doi: 10.1042/BJ20091518. [DOI] [PubMed] [Google Scholar]
  • 237.Kanonenberg K., Schwarz C.K., Schmitt L. Type I secretion systems—A story of appendices. Res. Microbiol. 2013;164:596–604. doi: 10.1016/j.resmic.2013.03.011. [DOI] [PubMed] [Google Scholar]
  • 238.Piddock L.J. Multidrug-resistance efflux pumps? not just for resistance. Nat. Rev. Microbiol. 2006;4:629–636. doi: 10.1038/nrmicro1464. [DOI] [PubMed] [Google Scholar]
  • 239.Kadaba N.S., Kaiser J.T., Johnson E., Lee A., Rees D.C. The high-affinity E. coli methionine ABC transporter: Structure and allosteric regulation. Science. 2008;321:250–253. doi: 10.1126/science.1157987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 240.Shintre C.A., Pike A.C., Li Q., Kim J.-I., Barr A.J., Goubin S., Shrestha L., Yang J., Berridge G., Ross J. Structures of ABCB10, a human ATP-binding cassette transporter in apo-and nucleotide-bound states. Proc. Natl. Acad. Sci. USA. 2013;110:9710–9715. doi: 10.1073/pnas.1217042110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 241.Maphosa S., Moleleki L.N., Motaung T.E. Bacterial secretion system functions: Evidence of interactions and downstream implications. Microbiology. 2023;169:001326. doi: 10.1099/mic.0.001326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 242.Kanonenberg K., Spitz O., Erenburg I.N., Beer T., Schmitt L. Type I secretion system—It takes three and a substrate. FEMS Microbiol. Lett. 2018;365:fny094. doi: 10.1093/femsle/fny094. [DOI] [PubMed] [Google Scholar]
  • 243.Letoffe S., Delepelaire P., Wandersman C. Protein secretion in gram-negative bacteria: Assembly of the three components of ABC protein-mediated exporters is ordered and promoted by substrate binding. EMBO J. 1996;15:5804–5811. doi: 10.1002/j.1460-2075.1996.tb00967.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 244.Riedel K., Ohnesorg T., Krogfelt K.A., Hansen T.S., Omori K., Givskov M., Eberl L. N-acyl-L-homoserine lactone-mediated regulation of the lip secretion system in Serratia liquefaciens MG1. J. Bacteriol. 2001;183:1805–1809. doi: 10.1128/JB.183.5.1805-1809.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 245.Pena R.T., Blasco L., Ambroa A., González-Pedrajo B., Fernández-García L., López M., Bleriot I., Bou G., García-Contreras R., Wood T.K. Relationship between quorum sensing and secretion systems. Front. Microbiol. 2019;10:1100. doi: 10.3389/fmicb.2019.01100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 246.Rice S., Koh K., Queck S., Labbate M., Lam K., Kjelleberg S. Biofilm formation and sloughing in Serratia marcescens are controlled by quorum sensing and nutrient cues. J. Bacteriol. 2005;187:3477–3485. doi: 10.1128/JB.187.10.3477-3485.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 247.Korotkov K.V., Sandkvist M., Hol W.G. The type II secretion system: Biogenesis, molecular architecture and mechanism. Nat. Rev. Microbiol. 2012;10:336–351. doi: 10.1038/nrmicro2762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 248.Voulhoux R., Ball G., Ize B., Vasil M.L., Lazdunski A., Wu L.F., Filloux A. Involvement of the twin-arginine translocation system in protein secretion via the type II pathway. EMBO J. 2001;20:6735–6741. doi: 10.1093/emboj/20.23.6735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 249.Sauvonnet N., Vignon G., Pugsley A.P., Gounon P. Pilus formation and protein secretion by the same machinery in Escherichia coli. EMBO J. 2000;19:2221–2228. doi: 10.1093/emboj/19.10.2221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 250.Sandkvist M. Type II secretion and pathogenesis. Infect. Immun. 2001;69:3523–3535. doi: 10.1128/IAI.69.6.3523-3535.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 251.Cianciotto N.P. Type II secretion: A protein secretion system for all seasons. Trends Microbiol. 2005;13:581–588. doi: 10.1016/j.tim.2005.09.005. [DOI] [PubMed] [Google Scholar]
  • 252.Büttner D. Protein export according to schedule: Architecture, assembly, and regulation of type III secretion systems from plant-and animal-pathogenic bacteria. Microbiol. Mol. Biol. Rev. 2012;76:262–310. doi: 10.1128/MMBR.05017-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 253.Young B.M., Young G.M. YplA is exported by the Ysc, Ysa, and flagellar type III secretion systems of Yersinia enterocolitica. J. Bacteriol. 2002;184:1324–1334. doi: 10.1128/JB.184.5.1324-1334.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 254.Young G.M., Schmiel D.H., Miller V.L. A new pathway for the secretion of virulence factors by bacteria: The flagellar export apparatus functions as a protein-secretion system. Proc. Natl. Acad. Sci. USA. 1999;96:6456–6461. doi: 10.1073/pnas.96.11.6456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 255.Jin Q., He S.-Y. Role of the Hrp pilus in type III protein secretion in Pseudomonas syringae. Science. 2001;294:2556–2558. doi: 10.1126/science.1066397. [DOI] [PubMed] [Google Scholar]
  • 256.Bhatty M., Gomez J.A.L., Christie P.J. The expanding bacterial type IV secretion lexicon. Res. Microbiol. 2013;164:620–639. doi: 10.1016/j.resmic.2013.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 257.Ranjbar R., Behzadi P., Farshad S. Advances in diagnosis and treatment of Helicobacter pylori infection. Acta Microbiol. Immunol. Hung. 2017;64:273–292. doi: 10.1556/030.64.2017.008. [DOI] [PubMed] [Google Scholar]
  • 258.Zhang W., Rong C., Chen C., Gao G.F. Type-IVC secretion system: A novel subclass of type IV secretion system (T4SS) common existing in gram-positive genus Streptococcus. PLoS ONE. 2012;7:e46390. doi: 10.1371/journal.pone.0046390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 259.Roberts A.P., Mullany P. A modular master on the move: The Tn916 family of mobile genetic elements. Trends Microbiol. 2009;17:251–258. doi: 10.1016/j.tim.2009.03.002. [DOI] [PubMed] [Google Scholar]
  • 260.Clewell D.B., Flannagan S.E., Jaworski D.D. Unconstrained bacterial promiscuity: The Tn916–Tn1545 family of conjugative transposons. Trends Microbiol. 1995;3:229–236. doi: 10.1016/S0966-842X(00)88930-1. [DOI] [PubMed] [Google Scholar]
  • 261.Soge O.O., Beck N.K., White T.M., No D.B., Roberts M.C. A novel transposon, Tn 6009, composed of a Tn 916 element linked with a Staphylococcus aureus mer operon. J. Antimicrob. Chemother. 2008;62:674–680. doi: 10.1093/jac/dkn255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 262.Roberts A.P., Mullany P. Tn 916-like genetic elements: A diverse group of modular mobile elements conferring antibiotic resistance. FEMS Microbiol. Rev. 2011;35:856–871. doi: 10.1111/j.1574-6976.2011.00283.x. [DOI] [PubMed] [Google Scholar]
  • 263.Purtschert-Montenegro G., Cárcamo-Oyarce G., Pinto-Carbó M., Agnoli K., Bailly A., Eberl L. Pseudomonas putida mediates bacterial killing, biofilm invasion and biocontrol with a type IVB secretion system. Nat. Microbiol. 2022;7:1547–1557. doi: 10.1038/s41564-022-01209-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 264.Sheedlo M.J., Ohi M.D., Lacy D.B., Cover T.L. Molecular architecture of bacterial type IV secretion systems. PLoS Pathog. 2022;18:e1010720. doi: 10.1371/journal.ppat.1010720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 265.Leo J.C., Grin I., Linke D. Type V secretion: Mechanism (s) of autotransport through the bacterial outer membrane. Philos. Trans. R. Soc. B Biol. Sci. 2012;367:1088–1101. doi: 10.1098/rstb.2011.0208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 266.Jose J., Jähnig F., Meyer T.F. Common structural features of IgA1 protease-like outer membrane protein autotransporters. Mol. Microbiol. 1995;18:378–380. doi: 10.1111/j.1365-2958.1995.mmi_18020378.x. [DOI] [PubMed] [Google Scholar]
  • 267.Fan E., Chauhan N., Udatha D.G., Leo J.C., Linke D. Type V secretion systems in bacteria. Virulence Mech. Bact. Pathog. 2016;4:305–335. doi: 10.1128/microbiolspec.VMBF-0009-2015. [DOI] [PubMed] [Google Scholar]
  • 268.Meuskens I., Saragliadis A., Leo J.C., Linke D. Type V secretion systems: An overview of passenger domain functions. Front. Microbiol. 2019;10:1163. doi: 10.3389/fmicb.2019.01163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 269.Grijpstra J., Arenas J., Rutten L., Tommassen J. Autotransporter secretion: Varying on a theme. Res. Microbiol. 2013;164:562–582. doi: 10.1016/j.resmic.2013.03.010. [DOI] [PubMed] [Google Scholar]
  • 270.Coppens F., Castaldo G., Debraekeleer A., Subedi S., Moonens K., Lo A., Remaut H. Hop-family Helicobacter outer membrane adhesins form a novel class of Type 5-like secretion proteins with an interrupted β-barrel domain. Mol. Microbiol. 2018;110:33–46. doi: 10.1111/mmi.14075. [DOI] [PubMed] [Google Scholar]
  • 271.Yen Y.T., Kostakioti M., Henderson I.R., Stathopoulos C. Common themes and variations in serine protease autotransporters. Trends Microbiol. 2008;16:370–379. doi: 10.1016/j.tim.2008.05.003. [DOI] [PubMed] [Google Scholar]
  • 272.Ruiz-Perez F., Nataro J.P. Bacterial serine proteases secreted by the autotransporter pathway: Classification, specificity, and role in virulence. Cell. Mol. Life Sci. 2014;71:745–770. doi: 10.1007/s00018-013-1355-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 273.Braun V., Ondraczek R., Hobbie S. Activation and secretion of Serratia hemolysin. Zentralblatt Bakteriol. 1993;278:306–315. doi: 10.1016/S0934-8840(11)80847-9. [DOI] [PubMed] [Google Scholar]
  • 274.St Geme J., 3rd The HMW1 adhesin of nontypeable Haemophilus influenzae recognizes sialylated glycoprotein receptors on cultured human epithelial cells. Infect. Immun. 1994;62:3881–3889. doi: 10.1128/iai.62.9.3881-3889.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 275.Ohnishi Y., Beppu T., Horinouchi S. Two genes encoding serine protease homologues in Serratia marcescens and characterization of their products in Escherichia coli. J. Biochem. 1997;121:902–913. doi: 10.1093/oxfordjournals.jbchem.a021672. [DOI] [PubMed] [Google Scholar]
  • 276.Kida Y., Higashimoto Y., Inoue H., Shimizu T., Kuwano K. A novel secreted protease from Pseudomonas aeruginosa activates NF-κB through protease-activated receptors. Cell. Microbiol. 2008;10:1491–1504. doi: 10.1111/j.1462-5822.2008.01142.x. [DOI] [PubMed] [Google Scholar]
  • 277.Riedel K., Talker-Huiber D., Givskov M., Schwab H., Eberl L. Identification and characterization of a GDSL esterase gene located proximal to the swr quorum-sensing system of Serratia liquefaciens MG1. Appl. Environ. Microbiol. 2003;69:3901–3910. doi: 10.1128/AEM.69.7.3901-3910.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 278.Jiang L., Yi W., Zhao Y., Zhu N., Zhao D., Peng Z., Song L., Dong T., Jiang X., Liu D. Comprehensive genomic analysis of type VI secretion system diversity and associated proteins in Serratia. Microb. Genom. 2025;11:001424. doi: 10.1099/mgen.0.001424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 279.Reglinski M., Hurst Q.W., Williams D.J., Gierlinski M., Şahin A.T., Mathers K., Ostrowski A., Bergkessel M., Zachariae U., Pitt S.J. A widely-occurring family of pore-forming effectors broadens the impact of the Serratia Type VI secretion system. EMBO J. 2025;44:6892. doi: 10.1038/s44318-025-00587-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 280.Smith W.P., Vettiger A., Winter J., Ryser T., Comstock L.E., Basler M., Foster K.R. The evolution of the type VI secretion system as a disintegration weapon. PLoS Biol. 2020;18:e3000720. doi: 10.1371/journal.pbio.3000720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 281.Buttner D., He S.Y. Type III protein secretion in plant pathogenic bacteria. Plant Physiol. 2009;150:1656–1664. doi: 10.1104/pp.109.139089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 282.Coulthurst S. The Type VI secretion system: A versatile bacterial weapon. Microbiology. 2019;165:503–515. doi: 10.1099/mic.0.000789. [DOI] [PubMed] [Google Scholar]
  • 283.Lien Y.-W., Lai E.-M. Type VI secretion effectors: Methodologies and biology. Front. Cell. Infect. Microbiol. 2017;7:254. doi: 10.3389/fcimb.2017.00254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 284.Teschler J.K., Jiménez-Siebert E., Jeckel H., Singh P.K., Park J.H., Pukatzki S., Nadell C.D., Drescher K., Yildiz F.H. VxrB influences antagonism within biofilms by controlling competition through extracellular matrix production and type 6 secretion. MBio. 2022;13:e01885-22. doi: 10.1128/mbio.01885-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 285.Luo J., Chu X., Jie J., Sun Y., Guan Q., Li D., Luo Z.-Q., Song L. Acinetobacter baumannii kills fungi via a type VI DNase effector. MBio. 2023;14:e03420-22. doi: 10.1128/mbio.03420-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 286.Cummins T., Songra S., Garrett S.R., Blower T.R., Mariano G. Multi-conflict islands are a widespread trend within Serratia spp. Cell Rep. 2024;43:115055. doi: 10.1016/j.celrep.2024.115055. [DOI] [PubMed] [Google Scholar]
  • 287.Gupta G., Chauhan P.S., Jha P.N., Verma R.K., Singh S., Yadav V.K., Sahoo D.K., Patel A. Secretory molecules from secretion systems fine-tune the host-beneficial bacteria (PGPRs) interaction. Front. Microbiol. 2024;15:1355750. doi: 10.3389/fmicb.2024.1355750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 288.Liu Y., Shu X., Chen L., Zhang H., Feng H., Sun X., Xiong Q., Li G., Xun W., Xu Z. Plant commensal type VII secretion system causes iron leakage from roots to promote colonization. Nat. Microbiol. 2023;8:1434–1449. doi: 10.1038/s41564-023-01402-1. [DOI] [PubMed] [Google Scholar]
  • 289.Spencer B.L., Doran K.S. Evolving understanding of the type VII secretion system in Gram-positive bacteria. PLoS Pathog. 2022;18:e1010680. doi: 10.1371/journal.ppat.1010680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 290.Unnikrishnan M., Constantinidou C., Palmer T., Pallen M.J. The enigmatic Esx proteins: Looking beyond mycobacteria. Trends Microbiol. 2017;25:192–204. doi: 10.1016/j.tim.2016.11.004. [DOI] [PubMed] [Google Scholar]
  • 291.Barnhart M.M., Chapman M.R. Curli biogenesis and function. Annu. Rev. Microbiol. 2006;60:131–147. doi: 10.1146/annurev.micro.60.080805.142106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 292.Hammar M., Arnqvist A., Bian Z., Olsén A., Normark S. Expression of two csg operons is required for production of fibronectin-and congo red-binding curli polymers in Escherichia coli K-12. Mol. Microbiol. 1995;18:661–670. doi: 10.1111/j.1365-2958.1995.mmi_18040661.x. [DOI] [PubMed] [Google Scholar]
  • 293.Van Gerven N., Klein R.D., Hultgren S.J., Remaut H. Bacterial amyloid formation: Structural insights into curli biogensis. Trends Microbiol. 2015;23:693–706. doi: 10.1016/j.tim.2015.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 294.Lasica A.M., Ksiazek M., Madej M., Potempa J. The type IX secretion system (T9SS): Highlights and recent insights into its structure and function. Front. Cell. Infect. Microbiol. 2017;7:215. doi: 10.3389/fcimb.2017.00215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 295.Gorasia D.G., Veith P.D., Reynolds E.C. The type IX secretion system: Advances in structure, function and organisation. Microorganisms. 2020;8:1173. doi: 10.3390/microorganisms8081173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 296.Veith P.D., Glew M.D., Gorasia D.G., Reynolds E.C. Type IX secretion: The generation of bacterial cell surface coatings involved in virulence, gliding motility and the degradation of complex biopolymers. Mol. Microbiol. 2017;106:35–53. doi: 10.1111/mmi.13752. [DOI] [PubMed] [Google Scholar]
  • 297.Chowdhury M., Stansfeld P.J., Sargent F. A lysis less ordinary: The bacterial Type 10 Secretion System. Adv. Microb. Physiol. 2025;86:175–198. doi: 10.1016/bs.ampbs.2025.02.002. [DOI] [PubMed] [Google Scholar]
  • 298.Hamilton J.J., Marlow V.L., Owen R.A., Costa M.d.A.A., Guo M., Buchanan G., Chandra G., Trost M., Coulthurst S.J., Palmer T. A holin and an endopeptidase are essential for chitinolytic protein secretion in Serratia marcescens. J. Cell Biol. 2014;207:615–626. doi: 10.1083/jcb.201404127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 299.Palmer T., Finney A.J., Saha C.K., Atkinson G.C., Sargent F. A holin/peptidoglycan hydrolase-dependent protein secretion system. Mol. Microbiol. 2021;115:345–355. doi: 10.1111/mmi.14599. [DOI] [PubMed] [Google Scholar]
  • 300.Geiger T., Lara-Tejero M., Xiong Y., Galan J.E. Mechanisms of substrate recognition by a typhoid toxin secretion-associated muramidase. Elife. 2020;9:e53473. doi: 10.7554/eLife.53473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 301.Grossman A.S., Escobar C.A., Mans E.J., Mucci N.C., Mauer T.J., Jones K.A., Moore C.C., Abraham P.E., Hettich R.L., Schneider L. A surface exposed, two-domain lipoprotein cargo of a type XI secretion system promotes colonization of host intestinal epithelia expressing glycans. Front. Microbiol. 2022;13:800366. doi: 10.3389/fmicb.2022.800366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 302.Grossman A.S., Mauer T.J., Forest K.T., Goodrich-Blair H. A widespread bacterial secretion system with diverse substrates. MBio. 2021;12:e01956-21. doi: 10.1128/mBio.01956-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 303.Hooda Y., Lai C.C., Moraes T.F. Identification of a large family of Slam-dependent surface lipoproteins in Gram-negative bacteria. Front. Cell. Infect. Microbiol. 2017;7:207. doi: 10.3389/fcimb.2017.00207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 304.Bhasin A., Chaston J.M., Goodrich-Blair H. Mutational analyses reveal overall topology and functional regions of NilB, a bacterial outer membrane protein required for host association in a model of animal-microbe mutualism. J. Bacteriol. 2012;194:1763–1776. doi: 10.1128/JB.06711-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 305.Wandersman C., Stojiljkovic I. Bacterial heme sources: The role of heme, hemoprotein receptors and hemophores. Curr. Opin. Microbiol. 2000;3:215–220. doi: 10.1016/S1369-5274(00)00078-3. [DOI] [PubMed] [Google Scholar]
  • 306.Page M.G. The role of iron and siderophores in infection, and the development of siderophore antibiotics. Clin. Infect. Dis. 2019;69:S529–S537. doi: 10.1093/cid/ciz825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 307.Benevides-Matos N., Biville F. The Hem and Has haem uptake systems in Serratia marcescens. Microbiology. 2010;156:1749–1757. doi: 10.1099/mic.0.034405-0. [DOI] [PubMed] [Google Scholar]
  • 308.Richard K.L., Kelley B.R., Johnson J.G. Heme uptake and utilization by gram-negative bacterial pathogens. Front. Cell. Infect. Microbiol. 2019;9:81. doi: 10.3389/fcimb.2019.00081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 309.Yukl E.T., Jepkorir G., Alontaga A.Y., Pautsch L., Rodriguez J.C., Rivera M., Moënne-Loccoz P. Kinetic and spectroscopic studies of hemin acquisition in the hemophore HasAp from Pseudomonas aeruginosa. Biochemistry. 2010;49:6646–6654. doi: 10.1021/bi100692f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 310.Kumar R., Qi Y., Matsumura H., Lovell S., Yao H., Battaile K.P., Im W., Moënne-Loccoz P., Rivera M. Replacing arginine 33 for alanine in the hemophore HasA from Pseudomonas aeruginosa causes closure of the H32 loop in the apo-protein. Biochemistry. 2016;55:2622–2631. doi: 10.1021/acs.biochem.6b00239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 311.Dent A.T., Mouriño S., Huang W., Wilks A. Post-transcriptional regulation of the Pseudomonas aeruginosa heme assimilation system (Has) fine-tunes extracellular heme sensing. J. Biol. Chem. 2019;294:2771–5555. doi: 10.1074/jbc.RA118.006185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 312.Izadi N., Henry Y., Haladjian J., Goldberg M.E., Wandersman C., Delepierre M., Lecroisey A. Purification and characterization of an extracellular heme-binding protein, HasA, involved in heme iron acquisition. Biochemistry. 1997;36:7050–7057. doi: 10.1021/bi962577s. [DOI] [PubMed] [Google Scholar]
  • 313.Izadi-Pruneyre N., Huché F., Lukat-Rodgers G.S., Lecroisey A., Gilli R., Rodgers K.R., Wandersman C., Delepelaire P. The heme transfer from the soluble HasA hemophore to its membrane-bound receptor HasR is driven by protein-protein interaction from a high to a lower affinity binding site. J. Biol. Chem. 2006;281:25541–25550. doi: 10.1074/jbc.M603698200. [DOI] [PubMed] [Google Scholar]
  • 314.Paquelin A., Ghigo J.M., Bertin S., Wandersman C. Characterization of HasB, a Serratia marcescens TonB-like protein specifically involved in the haemophore-dependent haem acquisition system. Mol. Microbiol. 2001;42:995–1005. doi: 10.1046/j.1365-2958.2001.02628.x. [DOI] [PubMed] [Google Scholar]
  • 315.Amorim G.C.d., Prochnicka-Chalufour A., Delepelaire P., Lefevre J., Simenel C., Wandersman C., Delepierre M., Izadi-Pruneyre N. The structure of HasB reveals a new class of TonB protein fold. PLoS ONE. 2013;8:e58964. doi: 10.1371/journal.pone.0058964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 316.Benevides-Matos N., Wandersman C., Biville F. HasB, the Serratia marcescens TonB paralog, is specific to HasR. J. Bacteriol. 2008;190:21–27. doi: 10.1128/JB.01389-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 317.Biou V., Adaixo R.J.D., Chami M., Coureux P.-D., Laurent B., Enguéné V.Y.N., de Amorim G.C., Izadi-Pruneyre N., Malosse C., Chamot-Rooke J. Structural and molecular determinants for the interaction of ExbB from Serratia marcescens and HasB, a TonB paralog. Commun. Biol. 2022;5:355. doi: 10.1038/s42003-022-03306-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 318.Seyedsayamdost M.R., Cleto S., Carr G., Vlamakis H., João Vieira M., Kolter R., Clardy J. Mixing and matching siderophore clusters: Structure and biosynthesis of serratiochelins from Serratia sp. V4. J. Am. Chem. Soc. 2012;134:13550–13553. doi: 10.1021/ja304941d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 319.Zhang G., Wang X., Zhang X., Ye L., Ke L., Fan S., Hong X., Li G., Yang B., Luo L. Catechol Siderophores from a Mangrove-Derived Bacteria Serratia marcescens F2-2 and Their Cytotoxic Activity. Mar. Drugs. 2025;23:241. doi: 10.3390/md23060241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 320.Eze P.M., Simons V.E., Frank M., van Geelen L., Abba C.C., Ebada S.S., Esimone C.O., Okoye F.B., Proksch P., Kalscheuer R. Serratiochelin D, a new siderophore from Serratia marcescens. Phytochem. Lett. 2023;57:22–25. doi: 10.1016/j.phytol.2023.07.008. [DOI] [Google Scholar]
  • 321.Ehlert G., Taraz K., Budzikiewicz H. Serratiochelin, a new catecholate siderophore from Serratia marcescens. Z. Naturforschung C. 1994;49:11–17. doi: 10.1515/znc-1994-1-203. [DOI] [Google Scholar]
  • 322.Pacheco A.R., Sperandio V. Inter-kingdom signaling: Chemical language between bacteria and host. Curr. Opin. Microbiol. 2009;12:192–198. doi: 10.1016/j.mib.2009.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 323.Kumaravel A., Sathyamoorthi S. Harnessing Quorum Quenching for Disease Management. Academic Press; Cambridge, MA, USA: 2026. Quorum sensing and quorum quenching: A brief review; pp. 3–19. [DOI] [Google Scholar]
  • 324.Fan Q., Zuo J., Wang H., Grenier D., Yi L., Wang Y. Contribution of quorum sensing to virulence and antibiotic resistance in zoonotic bacteria. Biotechnol. Adv. 2022;59:107965. doi: 10.1016/j.biotechadv.2022.107965. [DOI] [PubMed] [Google Scholar]
  • 325.Juszczuk-Kubiak E. Molecular aspects of the functioning of pathogenic bacteria biofilm based on quorum sensing (QS) signal-response system and innovative non-antibiotic strategies for their elimination. Int. J. Mol. Sci. 2024;25:2655. doi: 10.3390/ijms25052655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 326.Sharma A., Singh P., Sarmah B.K., Nandi S.P. Quorum sensing: Its role in microbial social networking. Res. Microbiol. 2020;171:159–164. doi: 10.1016/j.resmic.2020.06.003. [DOI] [PubMed] [Google Scholar]
  • 327.Breijyeh Z., Jubeh B., Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules. 2020;25:1340. doi: 10.3390/molecules25061340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 328.Wei J.-R., Tsai Y.-H., Horng Y.-T., Soo P.-C., Hsieh S.-C., Hsueh P.-R., Horng J.-T., Williams P., Lai H.-C. A mobile quorum-sensing system in Serratia marcescens. J. Bacteriol. 2006;188:1518–1525. doi: 10.1128/JB.188.4.1518-1525.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 329.Eberl L., Winson M.K., Sternberg C., Stewart G.S., Christiansen G., Chhabra S.R., Bycroft B., Williams P., Molin S., Givskov M. Involvement of N-acyl-l-homoserine lactone autoinducers in controlling the multicellular behaviour of Serratia liquefaciens. Mol. Microbiol. 1996;20:127–136. doi: 10.1111/j.1365-2958.1996.tb02495.x. [DOI] [PubMed] [Google Scholar]
  • 330.Thomson N., Crow M., McGowan S., Cox A., Salmond G. Biosynthesis of carbapenem antibiotic and prodigiosin pigment in Serratia is under quorum sensing control. Mol. Microbiol. 2000;36:539–556. doi: 10.1046/j.1365-2958.2000.01872.x. [DOI] [PubMed] [Google Scholar]
  • 331.Christensen A.B., Riedel K., Eberl L., Flodgaard L.R., Molin S., Gram L., Givskov M. Quorum-sensing-directed protein expression in Serratia proteamaculans B5a. Microbiology. 2003;149:471–483. doi: 10.1099/mic.0.25575-0. [DOI] [PubMed] [Google Scholar]
  • 332.Liu F., Zhao Q., Jia Z., Zhang S., Wang J., Song S., Jia Y. N-3-oxo-octanoyl homoserine lactone primes plant resistance against necrotrophic pathogen Pectobacterium carotovorum by coordinating jasmonic acid and auxin-signaling pathways. Front. Plant Sci. 2022;13:886268. doi: 10.3389/fpls.2022.886268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 333.Coulthurst S.J., Williamson N.R., Harris A.K., Spring D.R., Salmond G.P. Metabolic and regulatory engineering of Serratia marcescens: Mimicking phage-mediated horizontal acquisition of antibiotic biosynthesis and quorum-sensing capacities. Microbiology. 2006;152:1899–1911. doi: 10.1099/mic.0.28803-0. [DOI] [PubMed] [Google Scholar]
  • 334.Zhou J.-W., Ruan L.-Y., Chen H.-J., Luo H.-Z., Jiang H., Wang J.-S., Jia A.-Q. Inhibition of quorum sensing and virulence in Serratia marcescens by hordenine. J. Agric. Food Chem. 2019;67:784–795. doi: 10.1021/acs.jafc.8b05922. [DOI] [PubMed] [Google Scholar]
  • 335.Qi Y., Ji P., Yin K., Zheng Y., Niu J., Jia A., Zhou J., Li J. Phloretin inhibits quorum sensing and biofilm formation in Serratia marcescens. Molecules. 2023;28:8067. doi: 10.3390/molecules28248067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 336.Khanna A., Khanna M., Aggarwal A. Serratia marcescens—A rare opportunistic nosocomial pathogen and measures to limit its spread in hospitalized patients. J. Clin. Diagn. Res. JCDR. 2012;7:243. doi: 10.7860/JCDR/2013/5010.2737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 337.Shrestha L., Fan H.-M., Tao H.-R., Huang J.-D. Recent strategies to combat biofilms using antimicrobial agents and therapeutic approaches. Pathogens. 2022;11:292. doi: 10.3390/pathogens11030292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 338.Pandey P., Rao L., Shekhar B.R., Das D.K., Vavilala S.L. Molecular insights into flavone-mediated quorum sensing interference: A novel strategy against Serratia marcescens biofilm-induced antibiotic resistance. Chem. Biol. Interact. 2024;396:111027. doi: 10.1016/j.cbi.2024.111027. [DOI] [PubMed] [Google Scholar]
  • 339.Petakh P., Behzadi P., Oksenych V., Kamyshnyi O. Current treatment options for leptospirosis: A mini-review. Front. Microbiol. 2024;15:1403765. doi: 10.3389/fmicb.2024.1403765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 340.Petakh P., Duve K., Oksenych V., Behzadi P., Kamyshnyi O. Molecular mechanisms and therapeutic possibilities of short-chain fatty acids in posttraumatic stress disorder patients: A mini-review. Front. Neurosci. 2024;18:1394953. doi: 10.3389/fnins.2024.1394953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 341.Ceresa C., Fracchia L., Sansotera A.C., De Rienzo M.A.D., Banat I.M. Harnessing the potential of biosurfactants for biomedical and pharmaceutical applications. Pharmaceutics. 2023;15:2156. doi: 10.3390/pharmaceutics15082156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 342.Kumar R., Das A.J. Rhamnolipid Biosurfactant: Recent Trends in Production and Application. Springer; Berlin/Heidelberg, Germany: 2018. Quorum sensing: Its role in Rhamnolipid production; pp. 125–135. [Google Scholar]
  • 343.Abisado R.G., Benomar S., Klaus J.R., Dandekar A.A., Chandler J.R. Bacterial quorum sensing and microbial community interactions. MBio. 2018;9:e02331-17. doi: 10.1128/mBio.02331-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 344.Mangwani N., Kumari S., Das S. Bacterial biofilms and quorum sensing: Fidelity in bioremediation technology. Biotechnol. Genet. Eng. Rev. 2016;32:43–73. doi: 10.1080/02648725.2016.1196554. [DOI] [PubMed] [Google Scholar]
  • 345.Desai V., Sahana M., Mayegowda S.B., Gadilingappa M.N., Nagshetty K. Harnessing Quorum Quenching for Disease Management. Elsevier; Amsterdam, The Netherlands: 2026. Harnessing quorum sensing for disease management; pp. 137–151. [Google Scholar]
  • 346.Jiang Q., Chen J., Yang C., Yin Y., Yao K. Quorum sensing: A prospective therapeutic target for bacterial diseases. BioMed Res. Int. 2019;2019:2015978. doi: 10.1155/2019/2015978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 347.Zhao X., Yu Z., Ding T. Quorum-sensing regulation of antimicrobial resistance in bacteria. Microorganisms. 2020;8:425. doi: 10.3390/microorganisms8030425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 348.Kumavath R., Gupta P., Tatta E.R., Mohan M.S., Salim S.A., Busi S. Unraveling the role of mobile genetic elements in antibiotic resistance transmission and defense strategies in bacteria. Front. Syst. Biol. 2025;5:1557413. doi: 10.3389/fsysb.2025.1557413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 349.Haudiquet M., de Sousa J.M., Touchon M., Rocha E.P. Selfish, promiscuous and sometimes useful: How mobile genetic elements drive horizontal gene transfer in microbial populations. Philos. Trans. R. Soc. B. 2022;377:20210234. doi: 10.1098/rstb.2021.0234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 350.Smillie C., Garcillán-Barcia M.P., Francia M.V., Rocha E.P., de la Cruz F. Mobility of plasmids. Microbiol. Mol. Biol. Rev. 2010;74:434–452. doi: 10.1128/MMBR.00020-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 351.Rodríguez-Rubio L., Serna C., Ares-Arroyo M., Matamoros B.R., Delgado-Blas J.F., Montero N., Bernabe-Balas C., Wedel E.F., Mendez I.S., Muniesa M. Extensive antimicrobial resistance mobilization via multicopy plasmid encapsidation mediated by temperate phages. J. Antimicrob. Chemother. 2020;75:3173–3180. doi: 10.1093/jac/dkaa311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 352.Ramsay J.P., Firth N. Diverse mobilization strategies facilitate transfer of non-conjugative mobile genetic elements. Curr. Opin. Microbiol. 2017;38:1–9. doi: 10.1016/j.mib.2017.03.003. [DOI] [PubMed] [Google Scholar]
  • 353.Oliveira P.H., Touchon M., Cury J., Rocha E.P. The chromosomal organization of horizontal gene transfer in bacteria. Nat. Commun. 2017;8:841. doi: 10.1038/s41467-017-00808-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 354.Brown-Jaque M., Calero-Cáceres W., Muniesa M. Transfer of antibiotic-resistance genes via phage-related mobile elements. Plasmid. 2015;79:1–7. doi: 10.1016/j.plasmid.2015.01.001. [DOI] [PubMed] [Google Scholar]
  • 355.Liu G., Thomsen L.E., Olsen J.E. Antimicrobial-induced horizontal transfer of antimicrobial resistance genes in bacteria: A mini-review. J. Antimicrob. Chemother. 2022;77:556–567. doi: 10.1093/jac/dkab450. [DOI] [PubMed] [Google Scholar]
  • 356.Velazquez-Meza M.E., Galarde-López M., Carrillo-Quiróz B., Alpuche-Aranda C.M. Antimicrobial resistance: One health approach. Vet. World. 2022;15:743. doi: 10.14202/vetworld.2022.743-749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 357.Endale H., Mathewos M., Abdeta D. Potential causes of spread of antimicrobial resistance and preventive measures in one health perspective—A review. Infect. Drug Resist. 2023;16:7515–7545. doi: 10.2147/IDR.S428837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 358.Andersson D.I., Hughes D. Antibiotic resistance and its cost: Is it possible to reverse resistance? Nat. Rev. Microbiol. 2010;8:260–271. doi: 10.1038/nrmicro2319. [DOI] [PubMed] [Google Scholar]
  • 359.McArthur A.G., Wright G.D. Bioinformatics of antimicrobial resistance in the age of molecular epidemiology. Curr. Opin. Microbiol. 2015;27:45–50. doi: 10.1016/j.mib.2015.07.004. [DOI] [PubMed] [Google Scholar]
  • 360.Wyrsch E.R., Roy Chowdhury P., Chapman T.A., Charles I.G., Hammond J.M., Djordjevic S.P. Genomic microbial epidemiology is needed to comprehend the global problem of antibiotic resistance and to improve pathogen diagnosis. Front. Microbiol. 2016;7:843. doi: 10.3389/fmicb.2016.00843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 361.Bertelli C., Greub G. Rapid bacterial genome sequencing: Methods and applications in clinical microbiology. Clin. Microbiol. Infect. 2013;19:803–813. doi: 10.1111/1469-0691.12217. [DOI] [PubMed] [Google Scholar]
  • 362.Marquez B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie. 2005;87:1137–1147. doi: 10.1016/j.biochi.2005.04.012. [DOI] [PubMed] [Google Scholar]
  • 363.Blair J.M., Bavro V.N., Ricci V., Modi N., Cacciotto P., Kleinekathöfer U., Ruggerone P., Vargiu A.V., Baylay A.J., Smith H.E. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity. Proc. Natl. Acad. Sci. USA. 2015;112:3511–3516. doi: 10.1073/pnas.1419939112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 364.Blanco P., Hernando-Amado S., Reales-Calderon J.A., Corona F., Lira F., Alcalde-Rico M., Bernardini A., Sanchez M.B., Martinez J.L. Bacterial multidrug efflux pumps: Much more than antibiotic resistance determinants. Microorganisms. 2016;4:14. doi: 10.3390/microorganisms4010014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 365.Hernando-Amado S., Blanco P., Alcalde-Rico M., Corona F., Reales-Calderon J.A., Sanchez M.B., Martinez J.L. Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials. Drug Resist. Updates. 2016;28:13–27. doi: 10.1016/j.drup.2016.06.007. [DOI] [PubMed] [Google Scholar]
  • 366.Gaurav A., Bakht P., Saini M., Pandey S., Pathania R. Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. Microbiology. 2023;169:001333. doi: 10.1099/mic.0.001333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 367.Shirshikova T.V., Sierra-Bakhshi C.G., Kamaletdinova L.K., Matrosova L.E., Khabipova N.N., Evtugyn V.G., Khilyas I.V., Danilova I.V., Mardanova A.M., Sharipova M.R. The ABC-type efflux pump MacAB is involved in protection of Serratia marcescens against aminoglycoside antibiotics, polymyxins, and oxidative stress. Msphere. 2021;6:e00033-21. doi: 10.1128/mSphere.00033-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 368.Ruiz C., Levy S.B. Regulation of acrAB expression by cellular metabolites in Escherichia coli. J. Antimicrob. Chemother. 2014;69:390–399. doi: 10.1093/jac/dkt352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 369.Alav I., Sutton J.M., Rahman K.M. Role of bacterial efflux pumps in biofilm formation. J. Antimicrob. Chemother. 2018;73:2003–2020. doi: 10.1093/jac/dky042. [DOI] [PubMed] [Google Scholar]
  • 370.Seukep A.J., Mbuntcha H.G., Kuete V., Chu Y., Fan E., Guo M.-Q. What approaches to thwart bacterial efflux pumps-mediated resistance? Antibiotics. 2022;11:1287. doi: 10.3390/antibiotics11101287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 371.Henderson P.J., Maher C., Elbourne L.D., Eijkelkamp B.A., Paulsen I.T., Hassan K.A. Physiological functions of bacterial “multidrug” efflux pumps. Chem. Rev. 2021;121:5417–5478. doi: 10.1021/acs.chemrev.0c01226. [DOI] [PubMed] [Google Scholar]
  • 372.Jack D.L., Yang N.M., Saier M.H. The drug/metabolite transporter superfamily. Eur. J. Biochem. 2001;268:3620–3639. doi: 10.1046/j.1432-1327.2001.02265.x. [DOI] [PubMed] [Google Scholar]
  • 373.Paulsen I.T., Skurray R.A., Tam R., Saier M.H., Turner R.J., Weiner J.H., Goldberg E.B., Grinius L.L. The SMR family: A novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Mol. Microbiol. 1996;19:1167–1175. doi: 10.1111/j.1365-2958.1996.tb02462.x. [DOI] [PubMed] [Google Scholar]
  • 374.Bay D.C., Rommens K.L., Turner R.J. Small multidrug resistance proteins: A multidrug transporter family that continues to grow. Biochim. Biophys. Acta (BBA)—Biomembr. 2008;1778:1814–1838. doi: 10.1016/j.bbamem.2007.08.015. [DOI] [PubMed] [Google Scholar]
  • 375.Winstone T.L., Duncalf K.A., Turner R.J. Optimization of expression and the purification by organic extraction of the integral membrane protein EmrE. Protein Expr. Purif. 2002;26:111–121. doi: 10.1016/S1046-5928(02)00525-9. [DOI] [PubMed] [Google Scholar]
  • 376.Elbourne L.D., Tetu S.G., Hassan K.A., Paulsen I.T. TransportDB 2.0: A database for exploring membrane transporters in sequenced genomes from all domains of life. Nucleic Acids Res. 2017;45:D320–D324. doi: 10.1093/nar/gkw1068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 377.Ren Q., Chen K., Paulsen I.T. TransportDB: A comprehensive database resource for cytoplasmic membrane transport systems and outer membrane channels. Nucleic Acids Res. 2007;35:D274–D279. doi: 10.1093/nar/gkl925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 378.Saier M.H., Reddy V.S., Tsu B.V., Ahmed M.S., Li C., Moreno-Hagelsieb G. The transporter classification database (TCDB): Recent advances. Nucleic Acids Res. 2016;44:D372–D379. doi: 10.1093/nar/gkv1103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 379.Matsuo T., Chen J., Minato Y., Ogawa W., Mizushima T., Kuroda T., Tsuchiya T. SmdAB, a heterodimeric ABC-type multidrug efflux pump, in Serratia marcescens. J. Bacteriol. 2008;190:648–654. doi: 10.1128/JB.01513-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 380.Chen J., Kuroda T., Huda M.N., Mizushima T., Tsuchiya T. An RND-type multidrug efflux pump SdeXY from Serratia marcescens. J. Antimicrob. Chemother. 2003;52:176–179. doi: 10.1093/jac/dkg308. [DOI] [PubMed] [Google Scholar]
  • 381.Kumar A., Worobec E.A. Cloning, sequencing, and characterization of the SdeAB multidrug efflux pump of Serratia marcescens. Antimicrob. Agents Chemother. 2005;49:1495–1501. doi: 10.1128/AAC.49.4.1495-1501.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 382.Hornsey M., Ellington M.J., Doumith M., Hudson S., Livermore D.M., Woodford N. Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome. J. Antimicrob. Chemother. 2010;65:479–482. doi: 10.1093/jac/dkp475. [DOI] [PubMed] [Google Scholar]
  • 383.Begic S., Worobec E.A. The role of the Serratia marcescens SdeAB multidrug efflux pump and TolC homologue in fluoroquinolone resistance studied via gene-knockout mutagenesis. Microbiology. 2008;154:454–461. doi: 10.1099/mic.0.2007/012427-0. [DOI] [PubMed] [Google Scholar]
  • 384.Toba S., Minato Y., Kondo Y., Hoshikawa K., Minagawa S., Komaki S., Kumagai T., Matoba Y., Morita D., Ogawa W. Comprehensive analysis of resistance-nodulation-cell division superfamily (RND) efflux pumps from Serratia marcescens, Db10. Sci. Rep. 2019;9:4854. doi: 10.1038/s41598-019-41237-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 385.Minato Y., Shahcheraghi F., Ogawa W., Kuroda T., Tsuchiya T. Functional gene cloning and characterization of the SsmE multidrug efflux pump from Serratia marcescens. Biol. Pharm. Bull. 2008;31:516–519. doi: 10.1248/bpb.31.516. [DOI] [PubMed] [Google Scholar]
  • 386.Tal N., Schuldiner S. A coordinated network of transporters with overlapping specificities provides a robust survival strategy. Proc. Natl. Acad. Sci. USA. 2009;106:9051–9056. doi: 10.1073/pnas.0902400106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 387.Gadea R., Fuentes M.Á.F., Pulido R.P., Gálvez A., Ortega E. Effects of exposure to quaternary-ammonium-based biocides on antimicrobial susceptibility and tolerance to physical stresses in bacteria from organic foods. Food Microbiol. 2017;63:58–71. doi: 10.1016/j.fm.2016.10.037. [DOI] [PubMed] [Google Scholar]
  • 388.Shahcheraghi F., Minato Y., Chen J., Mizushima T., Ogawa W., Kuroda T., Tsuchiya T. Molecular cloning and characterization of a multidrug efflux pump, SmfY, from Serratia marcescens. Biol. Pharm. Bull. 2007;30:798–800. doi: 10.1248/bpb.30.798. [DOI] [PubMed] [Google Scholar]
  • 389.Thompson S.A., Maani E.V., Lindell A.H., King C.J., McArthur J.V. Novel tetracycline resistance determinant isolated from an environmental strain of Serratia marcescens. Appl. Environ. Microbiol. 2007;73:2199–2206. doi: 10.1128/AEM.02511-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 390.Neuberger A., Du D., Luisi B.F. Structure and mechanism of bacterial tripartite efflux pumps. Res. Microbiol. 2018;169:401–413. doi: 10.1016/j.resmic.2018.05.003. [DOI] [PubMed] [Google Scholar]
  • 391.Wand M.E., Jamshidi S., Bock L.J., Rahman K.M., Sutton J.M. SmvA is an important efflux pump for cationic biocides in Klebsiella pneumoniae and other Enterobacteriaceae. Sci. Rep. 2019;9:1344. doi: 10.1038/s41598-018-37730-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 392.Srinivasan V.B., Rajamohan G. Genome analysis of urease positive Serratia marcescens, co-producing SRT-2 and AAC (6′)-Ic with multidrug efflux pumps for antimicrobial resistance. Genomics. 2019;111:653–660. doi: 10.1016/j.ygeno.2018.04.001. [DOI] [PubMed] [Google Scholar]
  • 393.Lazarus J.E., Warr A.R., Westervelt K.A., Hooper D.C., Waldor M.K. A genome-scale antibiotic screen in Serratia marcescens identifies YdgH as a conserved modifier of cephalosporin and detergent susceptibility. Antimicrob. Agents Chemother. 2021;65:e0078621. doi: 10.1128/AAC.00786-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 394.Naas T., Oueslati S., Bonnin R.A., Dabos M.L., Zavala A., Dortet L., Retailleau P., Iorga B.I. Beta-lactamase database (BLDB)–structure and function. J. Enzym. Inhib. Med. Chem. 2017;32:917–919. doi: 10.1080/14756366.2017.1344235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 395.Overmeyer A.J., Prentice E., Brink A., Lennard K., Moodley C. The genomic characterization of carbapenem-resistant Serratia marcescens at a tertiary hospital in South Africa. JAC-Antimicrob. Resist. 2023;5:dlad089. doi: 10.1093/jacamr/dlad089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 396.Naas T., Vandel L., Sougakoff W., Livermore D.M., Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob. Agents Chemother. 1994;38:1262–1270. doi: 10.1128/AAC.38.6.1262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 397.Ramirez M.S., Tolmasky M.E. Aminoglycoside modifying enzymes. Drug Resist. Updates. 2010;13:151–171. doi: 10.1016/j.drup.2010.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 398.Kohlmann R., Bähr T., Gatermann S.G. Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase. J. Antimicrob. Chemother. 2018;73:1530–1536. doi: 10.1093/jac/dky084. [DOI] [PubMed] [Google Scholar]
  • 399.Suh B., Bae I.K., Kim J., Jeong S.H., Yong D., Lee K. Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC β-lactamase overproduction and outer membrane protein loss. Antimicrob. Agents Chemother. 2010;54:5057–5061. doi: 10.1128/AAC.00768-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 400.Tamma P.D., Girdwood S.C., Gopaul R., Tekle T., Roberts A.A., Harris A.D., Cosgrove S.E., Carroll K.C. The use of cefepime for treating AmpC β-lactamase–producing Enterobacteriaceae. Clin. Infect. Dis. 2013;57:781–788. doi: 10.1093/cid/cit395. [DOI] [PubMed] [Google Scholar]
  • 401.Ferreira R.L., Rezende G.S., Damas M.S., Oliveira-Silva M., Pitondo-Silva A., Brito M.C., Leonardecz E., Góes F.R., Campanini E.B., Malavazi I., et al. Characterization of KPC-producing Serratia marcescens in an intensive care unit of a Brazilian tertiary hospital. Front. Microbiol. 2020;11:956. doi: 10.3389/fmicb.2020.00956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 402.Hooper D.C., Jacoby G.A. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. Cold. Spring Harb. Perspect. Med. 2016;6:a025320. doi: 10.1101/cshperspect.a025320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 403.Kim E.S., Jeong J.Y., Jun J.B., Choi S.H., Lee S.O., Kim M.N., Woo J.H., Kim Y.S. Prevalence of aac (6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. Antimicrob. Agents Chemother. 2009;53:2643–2645. doi: 10.1128/AAC.01534-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 404.Velkov T., Roberts K.D., Thompson P.E., Li J. Polymyxins: A new hope in combating Gram-negative superbugs? Future Med. Chem. 2016;8:1017–1025. doi: 10.4155/fmc-2016-0091. [DOI] [PubMed] [Google Scholar]
  • 405.Lin Q.Y., Tsai Y.-L., Liu M.-C., Lin W.-C., Hsueh P.-R., Liaw S.-J. Serratia marcescens arn, a PhoP-regulated locus necessary for polymyxin B resistance. Antimicrob. Agents Chemother. 2014;58:5181–5190. doi: 10.1128/AAC.00013-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 406.Olaitan A.O., Morand S., Rolain J.-M. Mechanisms of polymyxin resistance: Acquired and intrinsic resistance in bacteria. Front. Microbiol. 2014;5:643. doi: 10.3389/fmicb.2014.00643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 407.Gunn J.S., Lim K.B., Krueger J., Kim K., Guo L., Hackett M., Miller S.I. PmrA–PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol. Microbiol. 1998;27:1171–1182. doi: 10.1046/j.1365-2958.1998.00757.x. [DOI] [PubMed] [Google Scholar]
  • 408.Potrykus J., Wegrzyn G. Chloramphenicol-sensitive Escherichia coli strain expressing the chloramphenicol acetyltransferase (cat) gene. Antimicrob. Agents Chemother. 2001;45:3610–3612. doi: 10.1128/AAC.45.12.3610-3612.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 409.Schwarz S., Kehrenberg C., Doublet B., Cloeckaert A. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol. Rev. 2004;28:519–542. doi: 10.1016/j.femsre.2004.04.001. [DOI] [PubMed] [Google Scholar]
  • 410.Yang Y.J., Wu P.J., Livermore D.M. Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob. Agents Chemother. 1990;34:755–758. doi: 10.1128/AAC.34.5.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 411.Şimşek M. Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger. J. Clin. Pract. 2019;22:125–130. doi: 10.4103/njcp.njcp_362_18. [DOI] [PubMed] [Google Scholar]
  • 412.Dabos L., Patino-Navarrete R., Nastro M., Famiglietti A., Glaser P., Rodriguez C.H., Naas T. SME-4-producing Serratia marcescens from Argentina belonging to clade 2 of the S. marcescens phylogeny. J. Antimicrob. Chemother. 2019;74:1836–1841. doi: 10.1093/jac/dkz115. [DOI] [PubMed] [Google Scholar]
  • 413.Hernández-García M., Pérez-Viso B., Navarro-San Francisco C., Baquero F., Morosini M.I., Ruiz-Garbajosa P., Cantón R. Intestinal co-colonization with different carbapenemase-producing Enterobacterales isolates is not a rare event in an OXA-48 endemic area. EClinicalMedicine. 2019;15:72–79. doi: 10.1016/j.eclinm.2019.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 414.Arana D.M., Saez D., García-Hierro P., Bautista V., Fernández-Romero S., De La Cal M.A., Alós J.I., Oteo J. Concurrent interspecies and clonal dissemination of OXA-48 carbapenemase. Clin. Microbiol. Infect. 2015;21:148.e1–148.e4. doi: 10.1016/j.cmi.2014.07.008. [DOI] [PubMed] [Google Scholar]
  • 415.Bolourchi N., Goodarzi N.N., Giske C.G., Nematzadeh S., Jouriani F.H., Solgi H., Badmasti F. Comprehensive pan-genomic, resistome and virulome analysis of clinical OXA-48 producing carbapenem-resistant Serratia marcescens strains. Gene. 2022;822:146355. doi: 10.1016/j.gene.2022.146355. [DOI] [PubMed] [Google Scholar]
  • 416.Iovene M.R., Pota V., Galdiero M., Corvino G., Di Lella F.M., Stelitano D., Passavanti M.B., Pace M.C., Alfieri A., Di Franco S. First Italian outbreak of VIM-producing Serratia marcescens in an adult polyvalent intensive care unit, August–October 2018: A case report and literature review. World J. Clin. Cases. 2019;7:3535. doi: 10.12998/wjcc.v7.i21.3535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 417.Firmo E.F., Beltrão E.M.B., da Silva F.R.F., Alves L.C., Brayner F.A., Veras D.L., Lopes A.C.S. Association of blaNDM-1 with blaKPC-2 and aminoglycoside-modifying enzyme genes among Klebsiella pneumoniae, Proteus mirabilis and Serratia marcescens clinical isolates in Brazil. J. Glob. Antimicrob. Resist. 2020;21:255–261. doi: 10.1016/j.jgar.2019.08.026. [DOI] [PubMed] [Google Scholar]
  • 418.Douka E., Perivolioti E., Kraniotaki E., Fountoulis K., Economidou F., Tsakris A., Skoutelis A., Routsi C. Emergence of a pandrug-resistant VIM-1-producing Providencia stuartii clonal strain causing an outbreak in a Greek intensive care unit. Int. J. Antimicrob. Agents. 2015;45:533–536. doi: 10.1016/j.ijantimicag.2014.12.030. [DOI] [PubMed] [Google Scholar]
  • 419.Sabtcheva S., Stoikov I., Ivanov I.N., Donchev D., Lesseva M., Georgieva S., Teneva D., Dobreva E., Christova I. Genomic characterization of carbapenemase-producing Enterobacter hormaechei, Serratia marcescens, Citrobacter freundii, Providencia stuartii, and Morganella morganii clinical isolates from Bulgaria. Antibiotics. 2024;13:455. doi: 10.3390/antibiotics13050455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 420.Gajdács M., Urbán E. Resistance trends and epidemiology of citrobacter-enterobacter-serratia in urinary tract infections of inpatients and outpatients (RECESUTI): A 10-year survey. Medicina. 2019;55:285. doi: 10.3390/medicina55060285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 421.Choi S.H., Kim Y.S., Chung J.W., Kim T.H., Choo E.J., Kim M.N., Kim B.N., Kim N.J., Woo J.H., Ryu J. Serratia bacteremia in a large university hospital: Trends in antibiotic resistance during 10 years and implications for antibiotic use. Infect. Control Hosp. Epidemiol. 2002;23:740–747. doi: 10.1086/502004. [DOI] [PubMed] [Google Scholar]
  • 422.Laupland K.B., Parkins M.D., Gregson D.B., Church D.L., Ross T., Pitout J.D. Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region. Eur. J. Clin. Microbiol. Infect. Dis. 2008;27:89–95. doi: 10.1007/s10096-007-0400-7. [DOI] [PubMed] [Google Scholar]
  • 423.Barabás E., Maier A., Maier I., Cighir T., Mártha O. Multidrug-resistant Serratia marcescens strain isolated in a urology unit-case report. Acta Microbiol. Immunol. Hung. 2015;62:5–6. [Google Scholar]
  • 424.Gupta N.H.S., Moulton-Meissner H.A., Stevens K.M., McIntyre M.G., Jensen B., Kuhar D.T., Noble-Wang J.A., Schnatz R.G., Becker S.C., Kastango E.S. Outbreak of Serratia marcescens bloodstream infections in patients receiving parenteral nutrition prepared by a compounding pharmacy. Clin. Infect. Dis. 2014;59:1–8. doi: 10.1093/cid/ciu218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 425.Rodríguez-Baño J.G.-G.B., Machuca I., Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Rev. 2018;31:10–128. doi: 10.1128/CMR.00079-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 426.Moy S., Sharma R. Treatment Outcomes in Infections Caused by “SPICE” (Serratia, Pseudomonas, Indole-positive Proteus, Citrobacter, and Enterobacter) Organisms: Carbapenem versus Noncarbapenem Regimens. Clin. Ther. 2017;39:170–176. doi: 10.1016/j.clinthera.2016.11.025. [DOI] [PubMed] [Google Scholar]
  • 427.Codjoe F.S., Donkor E.S. Carbapenem resistance: A review. Med. Sci. 2018;6:1. doi: 10.3390/medsci6010001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 428.Abraham O. Appropriate therapy for carbapenem-resistant Enterobacteriaceae (CRE) Int. J. Infect. Dis. 2016;45:5. doi: 10.1016/j.ijid.2016.02.038. [DOI] [Google Scholar]
  • 429.Gajdács M. The concept of an ideal antibiotic: Implications for drug design. Molecules. 2019;24:892. doi: 10.3390/molecules24050892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 430.Al-Zarouni M., Senok A., Al-Zarooni N., Al-Nassay F., Panigrahi D. Extended-spectrum β-lactamase-producing Enterobacteriaceae: In vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline. Med. Princ. Pract. 2012;21:543–547. doi: 10.1159/000339200. [DOI] [PubMed] [Google Scholar]
  • 431.Miao M., Wen H., Xu P., Niu S., Lv J., Xie X., Mediavilla J.R., Tang Y.-W., Kreiswirth B.N., Zhang X. Genetic diversity of carbapenem-resistant Enterobacteriaceae (CRE) clinical isolates from a tertiary hospital in Eastern China. Front. Microbiol. 2019;9:3341. doi: 10.3389/fmicb.2018.03341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 432.Nordmann P., Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin. Microbiol. Infect. 2014;20:821–830. doi: 10.1111/1469-0691.12719. [DOI] [PubMed] [Google Scholar]
  • 433.Bush K., Jacoby G.A. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 2010;54:969–976. doi: 10.1128/AAC.01009-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 434.Bush K., Fisher J.F. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu. Rev. Microbiol. 2011;65:455–478. doi: 10.1146/annurev-micro-090110-102911. [DOI] [PubMed] [Google Scholar]
  • 435.Logan L.K., Weinstein R.A. The epidemiology of carbapenem-resistant Enterobacteriaceae: The impact and evolution of a global menace. J. Infect. Dis. 2017;215:S28–S36. doi: 10.1093/infdis/jiw282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 436.Sheinman M., Arkhipova K., Arndt P.F., Dutilh B.E., Hermsen R., Massip F. Identical sequences found in distant genomes reveal frequent horizontal transfer across the bacterial domain. Elife. 2021;10:e62719. doi: 10.7554/eLife.62719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 437.Zhu W., Chen X., Shen H., Wei M., Gu L., Liu Q. Genomic evolution, antimicrobial resistance, and dissemination of global Serratia spp. unveil increasing species diversity and carbapenemae-resistance: A retrospective and genomic epidemiology study. Curr. Res. Microb. Sci. 2025;9:100456. doi: 10.1016/j.crmicr.2025.100456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 438.Li Y., Sun X., Dong N., Wang Z., Li R. Global distribution and genomic characteristics of carbapenemase-producing Escherichia coli among humans, 2005–2023. Drug Resist. Updates. 2024;72:101031. doi: 10.1016/j.drup.2023.101031. [DOI] [PubMed] [Google Scholar]
  • 439.Nordmann P., Naas T., Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 2011;17:1791. doi: 10.3201/eid1710.110655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 440.Prado G., Mendes E.T., Martins R.C., Perdigao-Neto L.V., Freire M.P., Marchi A.P., Cortes M.F., de Castro Lima V.A., Rossi F., Guimarães T., et al. Phenotypic and genotypic characteristics of a carbapenem-resistant Serratia marcescens cohort and outbreak: Describing an opportunistic pathogen. Int. J. Antimicrob. Agents. 2022;59:106463. doi: 10.1016/j.ijantimicag.2021.106463. [DOI] [PubMed] [Google Scholar]
  • 441.Cai J.C., Zhou H.W., Zhang R., Chen G.X. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli isolates possessing the plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrob. Agents Chemother. 2008;52:2014–2018. doi: 10.1128/AAC.01539-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 442.Xu Q., Fu Y., Zhao F., Jiang Y., Yu Y. Molecular characterization of carbapenem-resistant Serratia marcescens clinical isolates in a tertiary hospital in Hangzhou, China. Infect. Drug Resist. 2020;13:999–1008. doi: 10.2147/IDR.S243197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 443.Tsakris A., Voulgari E., Poulou A., Kimouli M., Pournaras S., Ranellou K., Kosmopoulou O., Petropoulou D. In vivo acquisition of a plasmid-mediated bla KPC-2 gene among clonal isolates of Serratia marcescens. J. Clin. Microbiol. 2010;48:2546–2549. doi: 10.1128/JCM.00264-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 444.Gona F., Caio C., Iannolo G., Monaco F., Di Mento G., Cuscino N., Fontana I., Panarello G., Maugeri G., Mezzatesta M.L., et al. Detection of the IncX3 plasmid carrying bla KPC-3 in a Serratia marcescens strain isolated from a kidney–liver transplanted patient. J. Med. Microbiol. 2017;66:1454–1456. doi: 10.1099/jmm.0.000592. [DOI] [PubMed] [Google Scholar]
  • 445.Jimenez A., Abbo L.M., Martinez O., Shukla B., Sposato K., Iovleva A., Fowler E.L., McElheny C.L., Doi Y. KPC-3–Producing Serratia marcescens Outbreak between acute and long-term care facilities, Florida, USA. Emerg. Infect. Dis. 2020;26:2746–2750. doi: 10.3201/eid2611.202203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 446.Chen L., Ai W., Zhou Y., Wu C., Guo Y., Wu X., Wang B., Rao L., Xu Y., Zhang J., et al. Outbreak of IncX8 plasmid-Mediated KPC-3-Producing Enterobacterales infection, China. Emerg. Infect. Dis. 2022;28:1421–1430. doi: 10.3201/eid2807.212181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 447.Wang X.X.W., Li L., Jing M., Sun M., Chang Y., Qu Y., Jiang Y., Xu Q. Analysis of the molecular characteristics of a blaKPC-2-harbouring untypeable plasmid in Serratia marcescens. Int. Microbiol. 2022;25:237–244. doi: 10.1007/s10123-021-00172-2. [DOI] [PubMed] [Google Scholar]
  • 448.Pérez-Viso B., Hernández-García M., Ponce-Alonso M., Morosini M.I., Ruiz-Garbajosa P., Del Campo R., Cantón R. Characterization of carbapenemase-producing Serratia marcescens and whole-genome sequencing for plasmid typing in a hospital in Madrid, Spain (2016–18) J. Antimicrob. Chemother. 2021;76:110–116. doi: 10.1093/jac/dkaa398. [DOI] [PubMed] [Google Scholar]
  • 449.Nastro M., Monge R., Zintgraff J., Vaulet L., Boutureira M., Famiglietti A., Rodriguez C. First nosocomial outbreak of VIM-16-producing Serratia marcescens in Argentina. Clin. Microbiol. Infect. 2013;19:617–619. doi: 10.1111/j.1469-0691.2012.03978.x. [DOI] [PubMed] [Google Scholar]
  • 450.Tóth Á., Makai A., Jánvári L., Damjanova I., Gajdács M., Urbán E. Characterization of a rare blaVIM-4 metallo-β-lactamase-producing Serratia marcescens clinical isolate in Hungary. Heliyon. 2020;6:e04231. doi: 10.1016/j.heliyon.2020.e04231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 451.Osano E., Arakawa Y., Wacharotayankun R., Ohta M., Horii T., Ito H., Yoshimura F., Kato N. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob. Agents Chemother. 1994;38:71–78. doi: 10.1128/AAC.38.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 452.Watanabe M., Iyobe S., Inoue M., Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1991;35:147–151. doi: 10.1128/AAC.35.1.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 453.Lauretti L., Riccio M.L., Mazzariol A., Cornaglia G., Amicosante G., Fontana R., Rossolini G.M. Cloning and characterization of bla VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 1999;43:1584–1590. doi: 10.1128/AAC.43.7.1584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 454.Zhong Y., Liu W., Yuan P., Yang L., Xu Z., Chen D. Occurrence of Serratia marcescens Carrying bla IMP-26 and mcr-9 in Southern China: New Insights in the Evolution of Megaplasmid IMP-26. Antibiotics. 2022;11:869. doi: 10.3390/antibiotics11070869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 455.Wang S., Zhou K., Xiao S., Xie L., Gu F., Li X., Ni Y., Sun J., Han L. A Multidrug Resistance Plasmid pIMP26, Carrying bla IMP-26, fosA5, bla DHA-1, and qnrB 4 in Enterobacter cloacae. Sci. Rep. 2019;9:10212. doi: 10.1038/s41598-019-46777-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 456.Gou J.-J., Liu N., Guo L.-H., Xu H., Lv T., Yu X., Chen Y.-B., Guo X.-B., Rao Y.-T., Zheng B.-W. Carbapenem-resistant Enterobacter hormaechei ST1103 with IMP-26 carbapenemase and ESBL gene blaSHV-178. Infect. Drug Resist. 2020;13:597–605. doi: 10.2147/IDR.S232514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 457.Harmer C.J., Hall R.M. IS 26 and the IS 26 family: Versatile resistance gene movers and genome reorganizers. Microbiol. Mol. Biol. Rev. 2024;88:e00119-22. doi: 10.1128/mmbr.00119-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 458.Furlan J.P.R., Zarrilli R., Daoud Z., He F., Ruan Z. Global dissemination and evolution of epidemic multidrug-resistant Gram-negative bacterial pathogens: Surveillance, diagnosis and treatment, volume III. Front. Microbiol. 2025;16:1583112. doi: 10.3389/fmicb.2025.1583112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 459.Huang X., Shen S., Shi Q., Ding L., Wu S., Han R., Zhou X., Yu H., Hu F. First Report of bla IMP–4 and bla SRT–2 Coproducing Serratia marcescens Clinical Isolate in China. Front. Microbiol. 2021;12:743312. doi: 10.3389/fmicb.2021.743312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 460.Ghaith D.M., Mahmoud Zafer M., Ismail D.K., Al-Agamy M.H., Bohol M.F.F., Al-Qahtani A., Al-Ahdal M.N., Elnagdy S.M., Mostafa I.Y. First reported nosocomial outbreak of Serratia marcescens harboring blaIMP-4 and blaVIM-2 in a neonatal intensive care unit in Cairo, Egypt. Infect. Drug Resist. 2018;11:2211–2217. doi: 10.2147/IDR.S174869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 461.Roberts L.W., Catchpoole E., Jennison A.V., Bergh H., Hume A., Heney C., George N., Paterson D.L., Schembri M.A., Beatson S.A. Genomic analysis of carbapenemase-producing Enterobacteriaceae in Queensland reveals widespread transmission of bla IMP-4 on an IncHI2 plasmid. Microb. Genom. 2020;6:e000321. doi: 10.1099/mgen.0.000321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 462.Albiger B., Glasner C., Struelens M., Grundmann H., Monnet D. European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: Assessment by national experts from 38 countries, May 2015. Euro Surveill. 2015;20:30062. doi: 10.2807/1560-7917.ES.2015.20.45.30062. [DOI] [PubMed] [Google Scholar]
  • 463.Mathers A.J., Peirano G., Pitout J.D. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin. Microbiol. Rev. 2015;28:565–591. doi: 10.1128/CMR.00116-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 464.Poirel L., Dortet L., Bernabeu S., Nordmann P. Genetic features of bla NDM-1-positive Enterobacteriaceae. Antimicrob. Agents Chemother. 2011;55:5403–5407. doi: 10.1128/AAC.00585-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 465.Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob. Agents Chemother. 2009;53:2227–2238. doi: 10.1128/AAC.01707-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 466.Kopotsa K., Osei Sekyere J., Mbelle N.M. Plasmid evolution in carbapenemase-producing Enterobacteriaceae: A review. Ann. N. Y. Acad. Sci. 2019;1457:61–91. doi: 10.1111/nyas.14223. [DOI] [PubMed] [Google Scholar]
  • 467.Carattoli A., Seiffert S.N., Schwendener S., Perreten V., Endimiani A. Differentiation of IncL and IncM plasmids associated with the spread of clinically relevant antimicrobial resistance. PLoS ONE. 2015;10:e0123063. doi: 10.1371/journal.pone.0123063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 468.Blackwell G.A., Doughty E.L., Moran R.A. Evolution and dissemination of L and M plasmid lineages carrying antibiotic resistance genes in diverse Gram-negative bacteria. Plasmid. 2021;113:102528. doi: 10.1016/j.plasmid.2020.102528. [DOI] [PubMed] [Google Scholar]
  • 469.Wein T., Dagan T. Plasmid evolution. Curr. Biol. 2020;30:R1158–R1163. doi: 10.1016/j.cub.2020.07.003. [DOI] [PubMed] [Google Scholar]
  • 470.Porse A., Schønning K., Munck C., Sommer M.O. Survival and evolution of a large multidrug resistance plasmid in new clinical bacterial hosts. Mol. Biol. Evol. 2016;33:2860–2873. doi: 10.1093/molbev/msw163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 471.Mauffrey F., Bertelli C., Greub G., Grandbastien B., Senn L., Blanc D.S. Plasmid diversity of Serratia marcescens and Klebsiella pneumoniae isolates involved in two carbapenem-resistant Enterobacteriaceae outbreaks in a Swiss hospital. Microbiol. Spectr. 2025;13:e03284-24. doi: 10.1128/spectrum.03284-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 472.El Khoury M., Salloum T., Al Kodsi I., Jisr T., El Chaar M., Tokajian S., in Lebanon C.G.D. Whole-genome sequence analysis of carbapenem-resistant Enterobacteriaceae recovered from hospitalized patients. J. Glob. Antimicrob. Resist. 2023;34:150–160. doi: 10.1016/j.jgar.2023.07.004. [DOI] [PubMed] [Google Scholar]
  • 473.Xu T., Song J., Liu J., Huang L., Li Z., Zhou K. First report of multidrug-resistant carbapenemase-producing Aeromonas caviae co-harboring mcr-3.43 and mcr-7.2. Microbiol. Spectr. 2024;12:e03685-23. doi: 10.1128/spectrum.03685-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 474.Liu X., Liu Z., Yu K., Huang Z., Gao H., Bai X., Sun Z., Wei Q., Wang D. Global genomic epidemiology and plasmid-mediated dissemination of blaKPC and blaNDM in the Serratia marcescens complex. Curr. Res. Microb. Sci. 2025;9:100436. doi: 10.1016/j.crmicr.2025.100436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 475.Xu Q., Zheng B., Li K., Shen P., Xiao Y. A preliminary exploration on the mechanism of the carbapenem-resistance transformation of Serratia marcescens in vivo. BMC Genom. 2024;25:2. doi: 10.1186/s12864-023-09904-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 476.Zheng Y., Jing Y., Zhang Y., Zhang J., Ye J., Chen H., Jin Y., He J., Zhang Y., Luo X. Evolutionary genomics of KPC-2-producing Serratia marcescens and characterization of a novel blaKPC− 2-harboring plasmid. BMC Microbiol. 2025;26:80. doi: 10.1186/s12866-025-04617-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 477.Wang Y., Zhang H., Liu Y., Wang Y. Genomic Insights into Plasmid Mediated Dissemination of bla KPC-2 and bla CTX-M-14 in a Fecal ST595 Serratia Marcescens Isolate. Infect. Drug Resist. 2025;18:5523–5527. doi: 10.2147/IDR.S548908. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No new data were created or analysed in this study. Data sharing is not applicable to this article.


Articles from Antibiotics are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES